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Prostate cancer is the most common malignancy and the second leading cause of death in 
American men. Primary prostate cancer is often hormone-dependent and relies on signaling 
through the androgen receptor (AR); therefore, the majority of patients are responsive to 
front-line treatment with androgen-deprivation therapy. However, some cases progress to 
an incurable stage of the disease known as castration-resistant prostate cancer (CRPC), 
which still relies on AR signaling.  
 
Substantial efforts have been undertaken to study sustained AR signaling in CRPC. The 
mechanisms identified include AR amplifications, AR splice variants, alterations in 
cofactor recruitment, and ligand-independent activation via crosstalk with signal 
transduction pathways. However, few studies have investigated the roles of non-coding 
RNAs (ncRNAs) in AR signaling axis. Noncoding RNAs are a class of transcripts with 
diverse and largely uncharacterized biological functions. Through crosstalk with 
chromatin, DNA, RNA, and proteins, ncRNAs function via chromatin remodeling as well 




To discover long non-coding RNAs (lncRNAs) with therapeutic or diagnostic potential in 
prostate cancer, we have performed a comprehensive RNA-seq profile investigation of 
cancer-associated, AR-regulated lncRNAs from prostate cancer cell lines and patient tissue 
samples. Through this analysis, we identified ARLNC1 (AR-regulated long noncoding 
RNA 1), an important lncRNA that is significantly enriched in prostate lineage and 
associates with prostate cancer progression. 
 
ARLNC1 is directly induced by the AR protein and modulates AR signaling. ARLNC1 
knockdown suppresses AR expression, AR-responsive genes, and prostate cancer growth 
in vitro and in vivo. Further dissection of ARLNC1 cellular mechanism showed that the 
lncRNA stabilized the AR transcript via RNA-RNA interaction. This positive feedback 
loop, where AR transcriptionally regulates ARLNC1 and ARLNC1 regulates its master 
regulator (AR) post-transcriptionally, suggests that lncRNAs can serve as novel regulatory 
nodes on AR signaling pathway.  
 
Because modulation of ARLNC1 expression levels resulted in a striking proliferation 
phenotype, it is hypothesized that ARLNC1 inhibition could be used therapeutically for 
the treatment of prostate cancer. Supporting this hypothesis, antisense oligonucleotides 
(ASOs) targeting ARLNC1 inhibited prostate cancer cell growth in vitro and in vivo. The 
fact that ARLNC1 acts upstream of AR signaling presents the possibility that targeting 
ARLNC1 may afford an additional option to patients that have de novo or acquired 




In addition, we evaluated the clinical relevance of ARLNC1 as a diagnostic biomarker. 
Among the prostate samples, ARLNC1 expression was significantly higher in localized 
and metastatic prostate cancers than in benign tissues, as assessed by RNA-seq and RNA 
in situ hybridization. Moreover, there exists an association of ARLNC1 levels with 
accentuated AR signaling and luminal epithelial differentiation in patient tumors, both of 
which are important clinical considerations for anti-androgen treatment.  
 
Finally, we characterized expression patterns of another type of non-coding RNA, circular 
RNA (circRNA). A set of circRNAs were identified as candidate biomarkers for prostate 
cancer. They have higher stability compared to linear transcripts. We further validated the 
existence of a novel class of circular transcripts, termed read-through circRNAs, that 
involve exons originating from different genes. Additionally, circRNAs can be detected in 
patient urine samples and may be developed into non-invasive biomarkers. 
 
Taken together, this work defines essential roles for ARLNC1 in prostate cancer 
progression, uncovers novel aspects of AR signaling and lncRNA biology, and underscores 









Introduction: Non-coding RNAs and prostate cancer biology 
 
Prostate cancer 
Prostate cancer statistics 
Prostate cancer is the most commonly diagnosed cancer in American men, accounting for 
nearly 1 case in 5 new cancer diagnoses. It is estimated that 174,650 new cases will be 
diagnosed in 2019[1]. Compared with other types of cancer, prostate cancer has the 
highest 5-year relative survival rates, which is 98%. The survival rate differs significantly 
across cancer stages. Localized and regional prostate cancer has nearly a 100% 5-year 
survival rate, while distant metastasis has a poor survival rate of 30%. As such, it is 
vitally important to discriminate dormant prostate cancer from aggressive disease, and to 
understand the molecular pathogenesis of metastatic prostate cancer. The mortality of 
prostate cancer has dropped steeply by ~50% from 1993 to 2016[1]. These reductions 
result from efforts to detect the disease at early stages and advances in treatments[2, 3]. 
Despite the substantial drop in mortality, prostate cancer is still the second leading cause 






The biggest risk factor for developing prostate cancer is age. Risk for prostate cancer 
increases with age, especially after age 50. More than 80% of prostate cancers are 
diagnosed in men beyond 65 years old, and less than 2% of cases are diagnosed in men 
under the age of 40 (SEER Cancer Statistics Review 1975-2015). Ethnicity is another risk 
factor. Compared to Caucasian men, African-American men are 76% more likely to 
acquire prostate cancer, and more than twice as likely to die from the disease[4]. 
Meanwhile, Hispanic or Asian men have a lower risk of developing and dying from the 
disease. There is also inherited risk for prostate cancer, due to a combination of shared 
genes (such as germline mutations on BRCA2) and shared environmental or lifestyle 
factors. Hereditary prostate cancer accounts for 5 to 10 percent of all prostate cancer 
diagnoses. A man with a close relative diagnosed with prostate cancer (especially at an 
early age) is approximately twice as likely to develop prostate cancer compared to a man 
with no family history of the disease[5-7].  
 
Understanding prostate cancer genome 
The majority of patients with primary prostate cancer can be cured, while some men 
develop metastatic disease and receive primary Androgen Deprivation Therapy (ADT). 
However, nearly all men with metastatic disease eventually develop resistance to primary 
ADT, reaching a disease state named metastatic castration-resistant prostate cancer 




abiraterone acetate[8, 9] and enzalutamide[10, 11]. However, mCRPC patients will 
eventually develop resistance to these drugs as well (Figure 1.1).  
 
Advances of large-scale sequencing have largely reshaped our understanding of cancer. 
Pan-cancer genomic analysis uncovered the causative roles of driving mutations/copy 
number variations/gene fusion or rearrangement in tumorigenesis[12, 13]. In the past five 
years, a significant part of the sequencing efforts has shifted from profiling primary 
cancers to metastatic disease. This is because advanced cancers are more likely to be 
lethal, and the clinical genomics of advanced disease produce altered patterns compared 
to that of primary cancer[14].  
 
In primary prostate cancer, past studies have identified recurrent mutations, gene 
rearrangements, deletions of tumor suppressive genes, and amplifications of oncogenes 
[15-22]. Frequent point mutations were observed in TP53 and SPOP, while low levels of 
mutations occurred on FOXA1, ASHXL, MLL2, and BRAF. E26 transformation-specific 
[23] fusions, which originate from the 5’ regions of an androgen-responsive gene plus a 
member of the ETS transcription factor family, can be detected in half of prostate cancer 
cases. Tumor suppressive genes PTEN, TP53, and RB1 are commonly deleted, while 
oncogenes like MYC and PIK3CA are amplified. Despite the comprehensive 






Recent studies on individuals affected with mCRPC uncovered novel alterations that are 
enriched in mCRPC, and highlighted clinically actionable molecular alterations in 
specific pathways (Figure 1.2)[24]. Most of genetic alterations identified from primary 
prostate cancer also exist in mCRPC, including deletions of TP53, PTEN, RB1, and 
CHD1, as well as amplifications of AR, PIK3CA, PIK3CB, and CCND1.  
 
Of note, a few genes were selectively mutated at a higher rate in mCRPC: TP53, AR, 
KMT2D, APC, BRCA2, and GNAS. Interestingly, the androgen receptor (AR) and GNAS 
were exclusively mutated in mCRPC[24]. This study highlighted the aberrations in the 
AR signaling pathway in mCRPC[24]: A total of 71.3% of all cases studied harbored 
alterations in the AR pathway. The majority (63%) of them directly affects AR (by 
mutations or amplifications), while the rest of the cases have aberrations of the AR-
cofactors FOXA1, NCOR1/2, and ZBTB16. Additional deregulated pathways enriched in 
mCRPC include PI3K pathway, Wnt pathway, Cell-cycle pathway, and DNA repair 
pathway.  
 
Central role of Androgen Receptor signaling in prostate cancer 
Androgen Receptor signaling plays a pivotal role in the development of normal prostate 
and prostate cancer[25]. It is physiologically regulated by hypothalamic-pituitary-
testicular axis, adrenal gland steroidogenesis, and prostate cell intrinsic factors (Figure 
1.3)[25]. The androgen receptor belongs to the steroid hormone group of nuclear 




expression of specific genes. At AR-responsive elements, AR recruits coactivator 
complexes that open chromatin structure and recruit RNA polymerase II to initiate 
transcription[26]. Additionally, AR can act through binding to other transcription 
factors[27] or alternative steroid receptors[28]. In the normal prostate, AR mediates 
differentiation of luminal epithelial cells and regulates genes that are essential for prostate 
function. In prostate cancer, sustained AR signaling modulates cell cycle regulation, 
survival signaling, and contribute to cell growth[29].  
 
As such, androgen signaling blockade by inhibiting androgen production or components 
in AR signaling axis largely inhibits prostate cancer growth. Androgen deprivation 
therapy (ADT) is initially highly effective for treatment of locally advanced or metastatic 
disease. However, the clinical course is uniformly marked by progression to the 
metastatic castration resistant disease state (mCRPC), where residual androgens that 
remain after castration and AR itself continue to be crucial for the progression to CRPC 
and its continued growth. This sustained AR signaling is achieved through mechanisms 
of AR mutations [24, 30], AR amplifications[24], AR splice variants[31-33], somatically 
acquired enhancer of AR[34], alterations in cofactor recruitment[23, 35], and ligand-
independent activation via cross-talk with signal transduction pathways[36, 37]. These 
findings highlight the rationale of the search for alternative nodes on AR signaling axis to 
block AR signaling.  
 




Overview of non-coding RNA species 
RNA molecules were initially identified as a node in the “central dogma”, that carries 
genetic information from DNA to the functional product of genetic information, 
protein[38, 39]. For many years, the only reported “non-coding” forms of RNA were 
ribosomal RNAs, which are components of the ribosome, and tRNAs, which are 
translators of codon sequences[40].  
 
Two decades ago, pioneering works in C. elegans (lin-4 and let-7) demonstrated for the 
first time that some small RNAs, though without protein-coding potential, are functional 
regulators for development[41, 42]. Since then, advances in next-generation sequencing 
have enabled the comprehensive identification and annotation of non-coding RNAs 
(ncRNAs) from various normal and cancer tissues[43-46]. Aside from the ~2% protein-
coding genes within human genome, non-coding RNAs constitute ~60% of total 
transcriptional output[44, 45, 47]. Increasing evidence has demonstrated that ncRNAs 
serve as regulators for a multitude of cellular processes and pathways under 
developmental and pathological contexts.  
 
Non-coding RNAs can be classified by size into three classes[48]: (a) Short ncRNAs with 
18-31 nucleotides in length (e.g. microRNAs and PIWI-interacting RNAs), (b) mid-size 
ncRNAs with 20~200 nucleotides (e.g. small nucleolar RNAs and tRNA derivatives), and 
(c) long non-coding RNAs with >200 nucleotides (e.g. long intergenic long non-coding 





microRNAs in cancer transcriptome 
The most extensively studied type of ncRNAs are miRNAs. They are 18 to 24 
nucleotides in length, and regulate target gene expression by mRNA degradation or 
translational repression. Primary miRNAs are initially transcribed by RNA Polymerase II 
(Pol II), then sequentially processed by Dgcr8/Drosha (microprocessor complex) and 
Dicer (riboendonuclease) to yield mature miRNA duplexes[42, 49-51]. Following the 
formation of the RNA-induced silencing complex (RISC), miRNAs recognize the 3’ 
untranslated regions (3’ UTR) on mRNA targets via imperfect base pairing, mediating 
post-transcriptional repression. The functional relevance of miRNAs in cancer was first 
suggested by the frequent genomic deletion or amplification observed at genomic sites 
coding for miRNAs in certain types of cancer[52, 53]. Since then, deregulation of 
miRNAs and miRNAs possessing oncogenic or tumor-suppressive functions have been 
reported[54-60]. miRNA-mediated feedback or feedforward loops play an integral role in 
gene regulatory networks[61-66].  
 
Long non-coding RNA in cancer transcriptome 
Long non-coding RNAs are capped, spliced, polyadenylated RNA transcripts ranging 
from 200 to several kilobases in length[67]. Transcriptional start sites (TSSs) of lncRNAs 
are enriched for histone 3 lysine 4 trimethylation (H3K4me3) and Pol II binding sites, 
both of which are markers for active promoters. The catalog of lncRNAs has grown 




methods for transcriptome assembly and lncRNA annotation[44-46]. Relative locations 
of lncRNAs in the genome can be within intergenic regions, antisense of protein-coding 
gene regions[68], active enhancers[69], or promoter regions[70].  
 
In order to comprehensively profile human lncRNAs in the context of normal tissues and 
cancers, our group performed ab initio analysis on 7,256 RNA-sequencing libraries 
derived from normal tissues, primary cancers, metastasis diseases, and cell lines[46]. A 
total of 58,648 lncRNAs were identified in the human transcriptome. Several features of 
lncRNAs were discovered that are in accord with other published studies: (1) LncRNAs 
outnumber protein-coding genes, but with a much lower average expression level. With 
RNA-sequencing analysis, RPKM values of protein coding genes are more than 10 fold 
as high as that of the majority of lncRNAs. (2) Overall, the conservation scores of 
lncRNAs are not as high as protein-coding genes, although they are higher than random 
control regions[71]. However, there does exist a small set of intergenic lncRNAs 
harboring ultraconserved DNA elements that are more than 200nt in length with nearly 
perfect sequence identity across multiple organisms. These highly conserved lncRNAs 
are of great research interest and may contribute to development and oncogenic 
processes[72]. Some lncRNAs overlap with disease-associated SNPs identified from 
Genome-wide association (GWAS) studies[73, 74]. This regional proximity suggests 
possible regulation of SNPs on allele-specific gene expression at certain genomic hotspot 
regions critical to cancer progression. (4) Differential expression analysis has uncovered 




lncRNAs demonstrated unique signatures for each cancer type. These lncRNAs can be 
further evaluated as potential pathological biomolecules. 
 
Circular RNAs in cancer transcriptome 
Circular RNAs are a group of single-stranded RNA molecules produced from pre-
mRNAs through the back-splicing process. They form covalently closed circles and thus 
have different chemical-physical features compared to linear RNA transcripts (for 
instance, resistant to exoribonuclease digestion). Only a handful of circRNAs have been 
studied in cancer. They have implicated roles in tumorigenesis, epithelial-mesenchymal 
transition, and gene regulation[75-82]. Studies in colorectal cancer unraveled the 
sponging effect of circular RNA ciRS-7 on the tumor suppressor miR-7[82]. Cancer-
associated chromosomal translocations may generate fusion-circRNAs with oncogenic 
potential, as exemplified by the f-circM9-accelerated tumorigenesis in MLL-AF9 driven 
acute myeloid leukemia models [83].  
 
Expression of some circular RNAs are tissue-specific, and can be found in cells, 
exosomes, cell-free saliva, and plasma. The spatial-temporal specific expression pattern, 
plus the existence in cell-free context, make circular RNAs potential biomarkers in 
cancer. It is thus worth investigating which circular RNAs are specifically enriched in 
cancers originating from varied lineages, and which are detectable in cell-free specimens.  
 




Non-coding RNAs as potential biomarkers 
Cancer genome and transcriptome analyses have revealed an extensive landscape of 
alterations in the non-coding genome. Regardless of the functional relevance of these 
alterations, characterization of the expression of alterations can significantly contribute to 
the development of biomarkers. Compared to normal physiological states, recurrent 
somatic mutations, copy-number variations, and epigenetic alterations in cancer have 
defined non-coding RNA expression profiles unique to pathological states. These 
findings highlight the opportunities for exploration of non-coding RNAs as biomarkers.  
  
Through the differential expression analysis of RNA-Seq from normal samples and tumor 
samples from the same tissue, researchers have identified lncRNA biomarkers that can 
stratify normal tissues from cancers tissues (eg. PCAT1, CCAT2, HOTAIR, PCA3, 
lncRNA-AA174084). Through surveying clinically-relevant cancer subtypes with 
differing degrees of aggression, biomarkers indicating a higher grade of cancer were 
developed (eg SCHALP1). Through comparison of specimens from patients with a 
spectrum of survival rates and drug responsive rates, biomarkers with potential to predict 
therapeutic responses were identified (HOTAIR). Reported lncRNAs with diagnostic or 
prognostic potential are summarized in Table 1.1.  
 
Non-coding RNAs as therapeutic targets 
The last two decades have witnessed rapid advances in targeted therapies for 




leukemia, or vemurafenib treatment for BRAF(V600E) melanoma have verified the 
rationale of targeted therapies, which function by directly targeting the existing driver 
mutations in certain subtypes of cancer. This principle can be further developed and 
applied in the search of therapeutic options targeting non-coding RNAs.  
 
Compared to the development of chemical compounds inhibiting protein targets, the 
targeting strategy for non-coding RNAs is more straight-forward. Clinical-grade 
antisense oligonucleotides have been developed to inhibit RNAs directly in vivo. ASOs 
bind with RNA targets by base-pair matching, resulting in the mRNA degradation, 
translational arrest, splicing modulation, or inhibition of RNA-binding proteins[84]. As 
of 2019, the FDA has approved the use of several antisense drugs: fomivirsen as a 
treatment for cytomegalovirus retinitis, mipomersen for homozygous familial 
hypercholesterolemia, eteplirsen for Duchenne muscular dystrophy, and nusinersen for 
spinal muscular atrophy. These practices open a new door for therapeutic management of 
diseases where non-coding RNAs are key drivers to disease initiation or progression.  
 
By contributing to nearly 60% of transcriptional output, non-coding RNAs offer great 
opportunities for the exploration of therapeutic targets in cancer. The critical problem lies 
in the identification of non-coding RNAs with bona fide oncogenic effects. Furthermore, 
the clinical benefits of non-coding RNA that exhibit tissue- and/or cancer-restricted 
expression pattern are large. Targeting these ncRNAs should eschew potential off-target 




lncRNAs with clear mechanism of oncogenic functions have been reported in the 
literature. Functions of two example oncogenic lncRNAs, THOR and SAMMSON, will be 
discussed in the next section.  
 
Functions and mechanisms of non-coding RNAs in cancer 
As discussed above, most lncRNAs are expressed at relatively low levels compared to 
protein-coding genes. It remains a debatable question what percentage of lncRNAs are 
solely by-product of genome openness and regulation, and what percentage has bona-fide 
functional roles. The well-established hallmarks of cancer contain six aspects, which 
includes sustaining proliferative signaling, evading growth suppressors, resisting cell 
death, activating invasion and metastasis, enabling replicative immortality, and inducing 
angiogenesis[85]. LncRNAs have been reported to contribute to each of these aspects, 
mainly through modulating critical pathways involved in cancer initiation and 
progression (Figure 1.4).   
 
Functional mechanisms of lncRNAs can be categorized by the molecular complexes that 
interact with them (Figure 1.5). The first group of lncRNAs interacts with the chromatin 
complex and directly regulates gene transcription and chromatin openness. The second 
group of lncRNAs interacts with RNAs or miRNAs and mediates post-transcriptional 
regulation of RNA transcripts. The third group of lncRNAs directly interacts with 
proteins and affects protein abundance or localization. Detailed mechanisms of lncRNAs 





The interaction of lncRNAs with the chromatin complex 
LncRNAs can form architectures with chromatin complexes and mediate epigenetic 
changes by altering DNA methylation, histone modifications, and chromatin structures. 
These lncRNAs can either work in cis, which regulate histone modifications or chromatin 
structures and thus affect transcription of neighboring genes, or they can work in trans by 
recruiting or scaffolding histone modification complexes to genomically distant genes. 
The effect of these lncRNAs could either be localized to specific gene regions (for 
instance, LUNAR1, ANRIL), or cover large chromosomal regions (for instance, Xist, H19, 
Kcnq1ot1, Airn, Snprn, etc). The proposed functioning models of imprinting lncRNAs, 




Genomic imprinting introduces parent-dependent epigenetic marking, thus ensuring the 
expression of genes in a parent-of-origin manner. This lncRNA-mediated allelic 
regulation affects ~5%-10% of genes in the mammalian genome[86]. LncRNAs 
coordinate in cis with chromatin-modifying complexes, which in turn, silence or activate 
genes within clusters regulated by alleles. Roles of imprinting RNAs are directly defined 
by endogenous genetic manipulation (truncating lncRNA by insertion of polyadenylation 
signals). Well characterized clusters of imprinted genes include Igf2/H19, Igf2r/Airn, 





Two types of mechanisms have been proposed regarding how imprinting is initiated by 
lncRNAs in cis[86]: (1) imprinting RNAs can function through the act of transcription 
(not through the transcript itself). The sense-antisense overlap transcription between 
lncRNA and adjacent imprinted genes results in transcriptional interference at mRNA 
promoter or enhancers, thus attenuating transcription from adjacent mRNA. One example 
supporting this model is imprinting cluster Igf2r/Airn. Even after Airn was truncated, 
silencing of Igf2r could still be achieved as long as Airn transcription overlaps with Igf2r 
promoter[89, 90]. (2) Many imprinting RNAs act through the transcripts themselves. By 
coating the local chromosomal structure by RNA clouds at the site of transcription, 
imprinting RNAs recruit repressive chromatin modifiers, thus confirming a repressive 
chromatin compartment[91-94]. The earliest evidence of this mechanism was acquired 
from Xist, which mediates X-chromosome inactivation via Polycomb proteins[95-98]. It 
is of note that the aforementioned two types of mechanisms can be employed by the same 
imprinting cluster under different spatiotemporal contexts. For example, in placenta, the 
aforementioned example Airn is required for allele-specific silencing of Slc22a3 through 
interacting with H3K9 histone methyltransferase G9a at Slc22a3 promoter regions[91]. 
 
Enhancer lncRNAs 
Enhancer RNAs are lncRNAs transcribed by Pol II from enhancer regions[69]. The 
universal existence of enhancer lncRNAs in many different cell lines and species 




function[69]. Among the limited enhancer RNAs studied with clear functions, two types 
of mechanisms have been reported. One type includes lncRNA recruitment of the 
WDR5-containing methyltransferase complex, resulting in methylation of the histone H3 
on lysine 4 (H3K4me), which is a canonical chromatin signature for enhancers. lncRNAs 
bind to a specific pocket structure on WDR5 protein, through which the MLL complex is 
guided to specific stretches of DNA and confirm active chromatin [99]. Example 
enhancer lncRNAs in this group include NeST activation of Interferon-v Locus[100] and 
HOTTIP[101, 102]. The functioning mechanism of HOTTIP is described below.  
 
HOTTIP supports active chromatin confirmation by recruiting histone methyltransferase 
at HOX gene locus. HOX genes are evolutionally highly conserved and encode 
homeodomain-containing transcription factors[103]. They control critical processes in 
early development, ranging from cell identity establishment, tissue pattern development, 
to organogenesis[104, 105]. Malfunction of HOX genes result in epigenetic 
dysregulation, thus causing onset of malignancy. There are four clusters of HOX genes in 
human (A, B, C, D), located on different chromosomes. Within each cluster, HOX genes 
are “spatial collinearly” arranged on the chromosome according to their expression 
pattern along the anterior-posterior axis[106, 107].  
 
In 2011, The Chang Group identified for the first time that lncRNA contribute to HOX 
gene locus regulation[102]. HOTTIP is transcribed from the 5’ tip of the HOXA locus, 




WDR5, and targets the SET-domain containing WDR5/MLL complexes across HOXA, 
thus inducing H3K4 trimethylation and gene activation. Pro-oncogenic roles of HOTTIP 
have been observed in blood, prostate, lung, pancreatic, and many other cancers[108-
110].  
 
The other type of enhancer lncRNA involves modification of chromatin structures 
through lncRNA-mediated stabilization of Mediator complexes and RNA PolII at 
enhancer elements. Some studies termed lncRNAs that facilitate enhancer-promoter 
interaction as ncRNA-activating (ncRNA-a). ncRNA-a is able to induce long-range 
transcriptional activation through DNA-looping and association with the Mediator 
complex. Examples of these lncRNAs and their targets include ncRNA-a7 vs. SNA1 and 
AURKA, ncRNA-a7 vs. AURKA, ncRNA-a3 vs. TAL1, and LUNAR vs. IGF1R.[111-113]  
The functioning mechanism of one lncRNA in this group, LUNAR1, is described below. 
 
LUNAR1 configures chromatin structure through Mediator Complex. This lncRNA is 
regulated by NOTCH, and is essential for human T-cell acute lymphoblastic leukemia (T-
ALL) growth in vitro and in vivo. Genome-wide chromosome conformation capture (Hi-
C, a method to examine high-order chromatin structure) demonstrated that LUNAR1, 
together with neighboring gene IGF1R, locates in the same 500 kb topologically 
associating domain[114]. Expression of LUNAR1 is driven by a highly active enhancer 





Interestingly, the phenotypic effect and gene expression profile change caused by 
LUNAR1 loss largely resembles those observed when the IGF1R gene is silenced[113]. 
Chromosome conformation capture (3C) experiments have demonstrated that a chromatin 
loop places the enhancer region on IGF1R and the promoter region on LUNAR1 in close 
physical proximity, leading to the formation of a DNA loop. Depletion of LUNAR1 
lncRNA by shRNA leads to a decreased occupancy of the Mediator complex (MED1 and 
MED2) and RNA Pol II occupancy at the IGF1R enhancer region, as well as significant 
loss of RNA Pol II binding to the IGF1R promoter region. These observations support a 
model where LUNAR1 lncRNA enhances IGF1R mRNA expression and maintains IGF1 
signaling through cis-activation of chromatin high-order conformation[113].  
 
Other lncRNAs that bind with chromatin in cis or in trans 
Apart from imprinting lncRNAs and enhancer lncRNAs, there exist lncRNAs that 
function through chromatin, either in cis or in trans, thus repressing or enhancing target 
gene expression. lncRNAs in this group can bind to multi-layered components in the 
chromosomal structure, thus mediating DNA methylation, histone methylation, and 
chromatin looping. Molecules involved in this process include DNA methyltransferase 
(DNMTs) and demethylase (TET), histone methyltransferase or demethylase (Polycomb 
complex, MLL complex, LSD1/CoREST/REST Complex), as well as CTCF/cohesion 
and Mediator Complex[68, 116-121]. One lncRNA, ANRIL, that affects histone 





ANRIL is a lncRNA located antisense to INK4b-ARF-INK4a gene cluster on 
chromosome 9p21.The INK4b-ARF-INKa locus encodes for tumor suppressor genes that 
play widespread and independent roles in tumor suppression[122]. Recurrent events of 
deletions, mutations, and aberrant epigenetic inactivation of this locus have been 
observed across human cancer tissues and cell lines[123-125]. ANRIL expression is 
associated with SNPs on chromosome 9p21 and suggest susceptibility to several types of 
cancer[126, 127]. The epigenetic status of this locus is partially controlled by methylation 
of histone H3 at lysine 27 (H3K27me), which is exerted by the Polycomb group 
proteins[128].  
 
Elevated expression of ANRIL has been observed in cancers originated from a variety of 
tissues that include neoplastic epithelial tissues, oesophageal squamous cell carcinoma, 
and leukaemia leukocytes[126, 128, 129]. Through direct interaction with the CBX7 
protein (a component of PRC1 complex) or Suz12 protein (a component of PRC2 
complex), ANRIL recruits the PcG protein complex to the local chromosome, thus 
modulating chromatin structure and inducing stable transcription silencing of the tumor 
suppressor genes INK4B and INK4A.  
 
As lncRNA functions may be lineage-specific and pathological context-dependent, 
lncRNAs with established functions in cis may possess further functional roles in trans in 
different lineages. For example, in adult T-cell leukemia models, ANRIL engages EZH2 




cells. On the one hand, the ANRIL/EZH2 complex employs histone methyltransferase 
(HMT) activity to induce the H3K27 trimethylation to p21/CDKN1A promoter, thus 
inhibiting p21/CDKN1A transcription. On the other hand, ANRIL forms a ternary 
complex with EZH2 and p65, and activates the NF-kb pathway in ATL cells. This 
activation was independent of the HMT activity of EZH2[130].  
 
lncRNAs mediating post-transcriptional regulation of RNA 
Compared to the number of lncRNAs that interact with chromatin structures or the 
number of lncRNAs that bind proteins, a smaller amount of lncRNAs regulate mRNA at 
the post-transcriptional level, and can either increase or decrease the stability of mRNAs 
via RNA-binding proteins and miRNA species. Micro RNAs have been studied as key 
modulators of mRNA stability, while many lncRNAs have proposed roles of miRNA 
sponging.  
 
In some cases, lncRNAs act as microRNA decoys, causing sequestration of microRNAs, 
favoring expression of repressed target mRNAs[131]. For instance, lnc-MD1 “sponges” 
both miR-133 and miR-135 to stabilize MAML1 and MEF2C. Both of them are 
transcription factors that control muscle differentiation by activating muscle-specific 
gene expression[132]. lncRNA H19 “sponges” the let-7 family of microRNAs via 
canonical and non-canonical binding sites, thus playing a key role in cell differentiation 
and cancer metabolism[133]. lncRNA-ROR “sponges” miR-145 to stabilize ZEB2, thus 





In other cases, lncRNAs stabilize mRNA by competing with miRNAs for shared target 
mRNAs. For example, lncRNA BACE1-AS competes with miR-485-5p for binding to 
BACE1 mRNAs, leading to elevated expression level of BACE1, a critical enzyme in 
Alzheimer’s disease pathophysiology[72].  
 
lncRNAs interacting with proteins  
LncRNAs can bind with proteins and directly modulate protein functions. This is carried 
out by regulating protein stability, affecting protein binding with target macromolecules 
(DNA, RNA, or proteins), or dictating relative localization of proteins in cell 
compartments, etc. For instance, the modular domain in NEAT1 lncRNA recruits NONO 
dimers to initiate assembly of the paraspeckle structure[135]. p53-induced lincRNA-p21 
binds with hnRNP-K to modulate gene expression in the DNA damage response[119]. 
GAS5 lncRNA interacts with glucocorticoid receptor (GR) to prevent it from binding to 
the genomic glucocorticoid receptor elements, limiting the transcriptional induction of 
GR-responsive genes. Two lncRNAs functioning through protein binding partners are 
described in details below. 
 
THOR is an example lncRNAs that binds protein and modulates downstream protein 
functions[136]. THOR is expressed exclusively in the testis, and has elevated expression 
in a broad range of cancers[136]. This lncRNA is evolutionarily conserved, with 




tumor growth and invasiveness[136]. These functions are carried out by a conserved 
domain on THOR that interacts with the IGF2BP1 protein[136]. The IGF2BP1 protein 
possess many functions, including regulating the stability of a set of target mRNAs and 
modulating IGF2 signaling. THOR regulates these functions by stabilization between the 
IGF2BP1 protein and its target RNAs[136]. Loss of THOR decreases the stability of 
IGF2BP1 targeting mRNAs, as well as alters IGF2 signaling[136].  
 
SAMMSON is an example lncRNA that binds protein and modulates protein cellular 
localization[137]. This pro-oncogenic lncRNA is induced by lineage-specific 
transcription factor SOX10, with elevated expression levels in melanomas[137]. Loss of 
SAMMSON significantly decreases melanoma cell viability, whereas over-expression of 
SAMMSON increases clonogenic potential. These effects were achieved through a direct 
interaction with the p32 protein, a master regulator of mitochondrial homeostasis and 
metabolism[137]. Although SAMMSON silencing does not affect total p32 levels, it 
alters the cellular localization of p32, with a decrease in the mitochondrial fraction and an 
increase in nuclear fraction. Mitochondrial p32 plays a critical role in the maintenance of 
oxidative phosphorylation through mediating maturation of mitochondria 16S ribosomal 
RNA. SAMMSON-silencing causes p32 deficiency in mitochondria, and thus leads to 
reduced levels of mature 16S ribosomal RNA, as well as impaired enzymatic activity of 
respiratory complexes I and IV[137]. Through dictating protein localization in cell 
compartments, SAMMSON is able to potentiate mitochondria functions, and thus plays 





Outline of this study 
In this thesis, we aim to discover and characterize novel non-coding RNAs with 
therapeutic or diagnostic potential in prostate cancer. We begin by performing 
transcriptome analysis to identify long non-coding RNAs that are regulated by AR 
signaling and are associated with prostate cancer progression (Chapter 2). We then 
characterize a top lineage-specific lncRNA (ARLNC1) identified from this analysis, 
investigate its functional role, and evaluate its therapeutic potential in prostate cancer 
(Chapter 3). We further interrogate the involvement of ARLNC1 in the AR signaling 
regulation axis (Chapter 4). Next, we explore a novel class of non-coding RNA, circular 
RNAs, and evaluate their potential as biomarkers in cancer (Chapter 5). Finally, we 
explore and discuss future directions to study lncRNAs with functional roles and 







Figure 1.1 Phases in prostate cancer progression 
(Reproduced with permission from Watson, P.A., V.K. Arora, and C.L. Sawyers, Emerging 
mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev 
Cancer, 2015. 15(12): p. 701-11. License Number for Figure reprinting: 4592810956344) 
 
Increasing disease burden following primary prostate cancer therapy is indicated by rising 
prostate-specific antigen (PSA) levels and/or radiographic progression, and is treated with 
medical castration. The castration-resistant prostate cancer (CRPC) stage follows the failure of 
castration therapy. Treatment with next-generation androgen receptor (AR) inhibitors (for 
example, abiraterone or enzalutamide) is initiated during CRPC, but acquired (or inherent) 







Figure 1.2 Integrative landscape analysis of somatic and germline aberrations in metastatic 
CRPC 
(Reprinted with permission from Robinson, D., et al., Integrative clinical genomics of 
advanced prostate cancer. Cell, 2015. 161(5): p. 1215-1228. License Number for Figure 
reprinting: 4592810146567) 
 
Columns represent individual affected individuals, and rows represent specific genes grouped in 
pathways. Mutations per Mb are shown in the upper histogram, and incidence of aberrations in 
the cohort is in the right histogram. Copy number variations (CNVs) common to mCRPC are 
shown in in the lower matrix, with pink representing gain and light blue representing loss. Color 
legend of the aberrations represented including amplification, two copy loss, one copy loss, copy 
neutral loss of heterozygosity (LOH), splice site mutation, frameshift mutation, missense 
mutation, in-frame indel, and gene fusion. Cases with more aberration in a gene are represented 















Figure 1.3 AR signaling regulation 
(Reproduced with permission from Watson, P.A., V.K. Arora, and C.L. Sawyers, Emerging 
mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev 
Cancer, 2015. 15(12): p. 701-11. License Number for Figure reprinting: 4592810956344) 
 
(a) The hormones gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) bind 
to their cognate receptors, resulting in testosterone secretion from Leydig cells of the testes. 
Chronic use of GnRH agonists leads to downregulation of the GnRH receptor (GnRH‑R), 
whereas antagonists provide immediate GnRH‑R blockade. Both agents suppress LH production, 
which causes a decline in serum testosterone to castrate levels. The adrenal glands secrete the 
androgens dehydroepiandrosterone sulfate (DHEA-S; predominantly), DHEA and 
androstenedione (AD) into the circulation.  
(b) Adrenal androgen de novo steroidogenesis (enzymes in ovals). CYP17A1 (cytochrome P450 
family 17 subfamily A polypeptide 1 has 17α‑hydroxylation (red) and 17, 20‑lyase (blue) 
activities; both are inhibited by abiraterone. The dashed arrow indicates a weak effect.  
(c) Prostate conversion of adrenal androgens to dihydrotestosterone (DHT) is shown in the top 




conformational change that leads to nuclear translocation. DHT-bound AR homodimerizes and, 
with co-activators (CoAs) and RNA polymerase II (RNA Pol II) or co-repressors (not shown), 
binds to DNA at cis androgen response elements to activate or repress (not shown) AR target 
gene expression, respectively.Enzalutamide inhibits AR by competing with DHT for binding, 
blocking nuclear translocation, and blocking DNA and cofactor binding8. AKR1C3, aldo-keto 
reductase family 1 member C3; 3β-HSD, 3β‑hydroxysteroid dehydrogenase/Δ5‑4‑isomerase; 
17β‑HSD, 17β‑hydroxysteroid dehydrogenase; SRD5A, steroid 5α‑ reductase; STS, steryl-




















Figure 1.4 LncRNAs contribute to hallmarks of cancer 
(Reproduced with permission from Schmitt, A.M. and H.Y. Chang, Long Noncoding RNAs 
in Cancer Pathways. Cancer Cell, 2016. 29(4): p. 452-463. License Number for Figure 
reprinting: 4592800936029) 
 
lncRNAs contribute to each of the six hallmarks of cancer (diagram adapted from Hanahan and 
Weinberg, 2000[138]). Selected examples of lncRNAs and their molecular partners or genomic 
targets are shown for proliferation, growth suppression, motility, immortality, angiogenesis, and 










Figure 1.5 lncRNA mechanisms rely on interactions with cellular macromolecules 
(Reproduced with permission from Schmitt, A.M. and H.Y. Chang, Long Noncoding RNAs 
in Cancer Pathways. Cancer Cell, 2016. 29(4): p. 452-463. License Number for Figure 
reprinting: 4592800936029) 
 
(A) Chromatin-bound lncRNAs can regulate gene expression by controlling local chromatin 
architecture (above) or directing the recruitment of regulatory molecules to specific loci (below). 
(B) lncRNA interactions with multiple proteins can promote the assembly of protein complexes 
(above) or impair protein-protein interactions(below). 
(C) mRNA interactions with lncRNA can recruit protein machinery involved in multiple aspects 
of mRNA metabolism to affect splicing, mRNA stability, or translation (above) or sequester 














Table 1.1 lncRNAs with diagnostic or prognostic potential 
(Table adapted from Bhan, A., M. Soleimani, and S.S. Mandal, Long Noncoding RNA and 
Cancer: A New Paradigm. Cancer Res, 2017. 77(15): p. 3965-3981. License Number for 
reproduction: 4593960187578) 
 
Cancer LncRNA Biomarker Potential implications Site of detection 
Prostate cancer PCA3 Diagnosis; Prognosis Urine; Tumor 
  LincRNA-p21 Diagnosis; Stratification Urine 
  PCAT-18 Metastasis Plasma 
  MALAT1 Risk of tumorigenesis;  Urine; Plasma 
  PVT1 Aggressiveness Tumor 
  PCAT-14 Diagnosis Tumor, Urine 
  SCHLAP1 Aggressiveness Urine, Tumor 
  TRPM2 Early identification; aggressiveness Tumor 
Breast cancer ZFAS1 Diagnosis Tumor 
  HOTAIR Diagnosis Serum 
  RP11-445H22.4 Diagnosis Serum 
  HIF1A-AS2; AK124454 Recurrence Tumor 
Lung cancer MALAT1 Early detection; Risk of metastasis Whole blood; Tumor 
  SPRY4-IT1; ANRIL; NEAT1 Early detection Plasma 
  UCA1 Diagnosis Plasma; Tumor 
 GAS5 Diagnosis Plasma 






  FER1L4 Recurrence; Metastasis Plasma 








  uc001ncr; AX800134 
Detection (especially 
early-stage) Serum 






Risk of tumorigenesis, 
prognostic factor for 
recurrence and survival 
Plasma 
  XLOC014172; LOC149086 Risk of metastasis   
Bladder cancer UCA1 Diagnosis Urine 
  H19 Early recurrence Tumor 
  HOTAIR Overall survival Tumor 
Leukemia CRNDE 
Identification of 
subtypes of AML 
(acute myeloid 
leukemia) (M2 or M3) 
Bone marrow, Lymph 
nodes 






Early detection Serum 





Early screening Plasma 
Gastric cancer H19 Early screening Plasma 
  LINC00152 Detection; Invasion Gastric juice; Tumor 
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Transcriptome analysis identifies Androgen Receptor regulated long 
non-coding RNAs associated with prostate cancer progression1 
 
Abstract 
As the most commonly diagnosed non-cutaneous cancer in American men, prostate cancer 
causes approximately 30,000 deaths per year. The majority of these deaths are caused by 
metastatic disease, which is resistance to androgen-deprivation therapy. Thus, it is of 
critical importance to characterize molecular mechanisms of prostate cancer progression 
and resistance, and to develop novel therapeutic strategies. Sustained AR signaling has 
been frequently observed in castration-resistant prostate cancer (CRPC). However, nearly 
all previous studies focused on studying protein-coding genes in the AR signaling axis. 
 
Here, we study the long non-coding transcriptome regulated by AR in prostate cancer. We 
began by identifying lncRNAs that are directly regulated by AR using cell line models. We 
further constructed a bioinformatic pipeline to prioritize lncRNAs that have strong 
                                                          
1 This chapter was previously published as part of the following manuscript: Zhang, Y., et al., Analysis of 
the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer 
progression. Nat Genet, 2018. 50(6): p. 814-824. 
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association with cancer progression. In addition, we queried the prostate-lineage specificity 
of AR-regulated lncRNAs. The result demonstrated that there exists an abundant AR-
responsive non-coding transcriptome that are previously underappreciated. Top prostate 
lineage-specific, AR-regulated, cancer-associated lncRNAs are worth further 
investigation.  
   
Introduction 
Long noncoding RNAs (lncRNAs) are a class of transcripts with diverse and largely 
uncharacterized biological functions[1-3]. Through interactions with chromatin, DNA, 
RNA species and proteins, lncRNAs function via chromatin remodeling, transcriptional 
and post-transcriptional regulation[4-9]. High-throughput RNA sequencing (RNA-seq) has 
enabled the identification of lncRNAs with suggested oncogenic and tumor-suppressive 
roles, including involvement in the pathogenesis and progression of prostate cancer[7, 10-
12].  
 
Primary prostate cancer is often hormone dependent and relies on signaling through the 
AR; therefore, the majority of patients are responsive to front-line treatment with androgen-
deprivation therapy[13-15]. However, approximately 20% of cases progress to an incurable 
stage of the disease known as castration-resistant prostate cancer (CRPC), which still 
critically relies on AR signaling[16, 17], as evidenced by the clinical benefit afforded 
through the use of enzalutamide[18-21] or abiraterone[22-24]. Substantial efforts have 
been undertaken to identify mechanisms of sustained AR signaling in CRPC. AR 
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mutations, amplifications,  AR splice variants, and alternative activation pathways have 
been reported [25-33]. However, few studies have investigated the role of AR-regulated 
long non-coding RNAs. Therefore, we initiated a comprehensive RNA-seq profiling 
investigation of AR-regulated, cancer-associated lncRNAs from prostate cancer cell lines 
and patient tissue samples. 
 
Results 
Identification of AR-regulated lncRNAs in cell lines 
To nominate AR-regulated genes (ARGs), RNA-sequencing was performed on AR 
dependent VCaP and LNCaP prostate cancer cell lines that were stimulated with an AR 
ligand, dihydrotestosterone (DHT), for 6 hours or 24 hours (Figure 2.1A). A total of 1,702 
genes were identified to be concordantly induced or repressed in VCaP and LNCaP at both 
time points (Figure 2.1B-C). More than 500 of them are lncRNAs (Figure 2.1D, Table 
2.1). These data indicate that a large portion of the AR transcriptome remains 
uncharacterized.  
 
To differentiate between direct and indirect ARGs, previously published AR chromatin 
immunoprecipitation (ChIP)-Seq data from LNCaP and VCaP cells were analyzed to find 
AR-binding promoter regions [34]. As expected for direct AR targets, increased levels of 
AR binding at transcription start sites (TSSs) in both LNCaP and VCaP cells were observed 
(Figure 2.2B), and the binding sites revealed a de novo motif identical to the canonical AR 
response element (Figure 2.2D). Treatment of AR antagonist (enzalutamide) induced 
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reverse gene expression changes compared to DHT stimulation (Figure 2.2A). And the 
AR binding levels at promoter regions of ARGs decreased following enzalutamide 
treatment (Figure 2.2C).  A total of 987 genes were categorized as direct ARGs, including 
341 lncRNAs (lncARG).  
 
We further analyzed the histone modification status of these lncARGs by querying 
published ChIP-seq data of various histone modifidcations. we observed an enrichment of 
chromatin marks associated with ‘open’ chromatin (H3K27ac, H3K4me1), active 
promoters (H3K4me3), and active transcription (H3K36me3). All of these modifications, 
together with Pol II occupancy, are recognized as manifestations of active gene expression 
(Figure2.2E). 
 
Bromodomain and extra-terminal family proteins, such as BRD4, recognize acetylated 
histones and have been shown to promote AR transcriptional activity[34]. In accord with 
this, we observed the co-localization of BRD4 and AR protein at promoters of direct AR-
responsive genes. Furthermore, treatment with a bromodomain inhibitor (JQ1) resulted in 
loss of AR binding at promoter regions of AR-responsive genes (Figure 2.2C, E).  
 
Identification of AR-regulated lncRNAs from tissues 
We next sought to determine whether ARGs identified from cell lines were also targeted 
by AR in normal prostate tissues and primary tumors. We leveraged the data set from 
reference [35] and queried for the presence of AR peaks within ARG promoters (Figure 
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2.3A). Remarkably, the majority of ARG promoters were TSS-proximally bound by AR in 
both tissues and cell lines. Conversely, AR-independent genes were distal to AR-binding 
sites (Figure 2.3B-C). 
 
To confirm that the AR-regulated genes were also expressed in human prostate tissues, we 
interrogated RNA-Seq data from normal prostate, clinically localized prostate cancer (The 
Cancer Genome Atlas, TCGA)[36] and metastatic CRPC (Stand Up to Cancer-Prostate 
Cancer Foundation, SU2C-PCF)[31] (Fig. 2.4A). This revealed remarkable heterogeneity 
in the expression of ARGs during prostate cancer progression to metastatic disease. As 
expected, compared to protein-coding genes, non-coding ARGs were detected at lower 
overall levels, although ~10% of them showed robust expression of over 10 FPKM 
(fragments per kilobase of transcript per million mapped reads) on average across prostate 
cancer samples (Fig. 2.4B).  
 
Prioritization of AR-responsive lncRNAs associated with cancer progression 
We hypothesized that lncRNAs associated with prostate cancer progression and castration 
resistance should have differential expression levels between normal tissue and prostate 
cancer. Their expression is also expected to be AR-dependent and lineage-restricted if they 
are part of bona fide physiological feedback loops involved in AR signaling. Accordingly, 
a top-down strategy was developed to establish and prioritize clinically relevant, prostate 




First, we identified genes that were both directly regulated by AR in VCaP/LNCaP cell 
lines and upregulated in primary (Figure 2.5A-B) or metastatic prostate cancers (Figure 
2.5A-B) compared to normal prostate tissues. Importantly, this approach highlighted 
several novel lncARGs, including ARLNC1 (ENSG00000260896, PRCAT47), and 
validated previously identified lncARGs, such as CTBP1-AS[37]. Interestingly, ARLNC1 
was found to be one of the most differentially expressed AR-regulated genes in both 
localized and metastatic prostate cancers (Figure 2.5B, D). 
 
Next, we sought to establish the prostate lineage and cancer specificity of prostate cancer-
associated lncRNAs. We leveraged the MiTranscriptome assembly [10], an online 
resource, to interrogate lncRNA expression across a multitude of tissue and tumor types. 
We calculated sample set enrichment analysis (SSEA) scores, which indicate the strength 
of cancer and lineage association [10]. After applying an expression-level filter (10 FPKM 
at the 95th percentile), we identified 12 of the most prostate lineage- and prostate cancer-
specific lncRNAs (Figure 2.6A-C); 5 of these lncRNAs were regulated by AR. Across 




Previous study from our lab has identified 121 Prostate Cancer Associated Transcripts 
(PCATs), whose expression spectrums distinguished benign, localized, and metastatic 
stages of cancer. PCAT-1 shows tissue-specific expression and is a transcriptional repressor 
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implicated in a subset of prostate cancer patients[38]. SCHLAP1 is highly expressed in a 
subset of aggressive prostate cancers, and coordinates cancer cell invasion[7]. Lineage-
specific lncRNA PCAT14 predicts for prostate cancer aggressiveness and recurrence[12]. 
All of these studies initiated from differential expression analysis of prostate cancer 
samples, without focusing on critical cancer pathways. 
 
In this study, we focused on the non-coding transcriptome regulated by AR signaling, the 
pivotal pathway that mediates prostate cancer progression. We found that compared to 
protein-coding genes, fewer number of AR-responsive lncRNAs exist, with a lower 
average expression level. Some AR-responsive lncRNAs are specifically expressed in 
prostate-lineage, and demonstrate differential expression patterns across benign, localized, 
and metastatic cancer stages. It is thus worth investigating whether these lncRNAs 
contribute to prostate cancer progression, what are the transcriptional machineries that 
drive their expression, and whether these lncRNAs are involved in a feedback or 
feedforward loop regulating AR signaling. In the following Chapters, we investigate these 
questions on a prioritized prostate cancer-specific, AR-responsive lncRNA, ARLNC1.  
 
Materials and Methods 
Cell lines 
Cell lines were purchased from the American Type Culture Collection (ATCC) and 
maintained using standard media and conditions. All cell lines were genotyped by DNA 
fingerprinting analysis and tested for mycoplasma infection every two weeks. All cell lines 
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used in this study were mycoplasma-negative. For androgen stimulation experiments, 
VCaP and LNCaP cells were grown in charcoal-stripped serum containing media for 48 h 
and then stimulated with 10 nM DHT (Sigma-Aldrich) for 6 or 24 h. 
 
RNA-Sequencing 
Total RNA was extracted from LNCaP and VCaP cells following DHT treatment, using 
the miRNeasy kit (QIAGEN). RNA quality was assessed using the Agilent Bioanalyzer. 
Each sample was sequenced using the Illumina HiSeq 2000 (with a 100-nt read length) 
according to published protocols[38]. 
 
RNA-Seq data analysis to identify AR-regulated genes 
RNA-Seq data were analyzed as previously described[39]. Briefly, the strand-specific 
paired-end reads were inspected for sequencing and data quality (for example, insert size, 
sequencing adapter contamination, rRNA content, sequencing error rate). Libraries passing 
QC were trimmed of sequencing adapters and aligned to the human reference genome, 
GRCh38. Expression was quantified at the gene level using the ‘intersection non-empty’ 
mode[40] as implemented in featureCounts[41] using the Gencode v22[42] and/or 
MiTranscriptome assemblies[10]. All pairwise differential expression analyses were 
carried out using the voom–limma approach[43, 44] with all default parameters. Relative 
expression levels (FPKMs) were normalized for differences in sequencing depth using 





ARGs were identified from expression data for VCaP and LNCaP cells treated with DHT 
for 6 and 24 h using three linear models: separate models for each of the cell lines treating 
the two time points as biological replicates, and a merged model with all treated samples 
as replicates. ARGs were defined as genes that were significant (P value < 0.1 and absolute 
log fold-change > 2) in both separate models and/or the merged model. 
 
Identification of prostate cancer-associated protein-coding genes and lncRNAs 
Raw RNA-Seq data for primary and metastatic patients were obtained from the 
TCGA/PRAD and PCF/SU2C projects, respectively. External transcriptome samples were 
reanalyzed using in-house pipelines (see above) to facilitate direct comparisons of 
expression levels and identification of DEGs. Pan-cancer analyses based on the 
MiTranscriptome assembly[10] were leveraged as FPKMs and enrichment scores (SSEA) 
 were computed as part of that project.  
 
To visualize data, fold changes were computed relative to median expression levels 
estimated across the combined (normal, primary, metastatic) cohorts and subjected to 
unsupervised hierarchical clustering separately within each cohort. Tissue lineage[20] and 
prostate cancer-specific genes were identified using the SSEA method as previously 
described[10]. Briefly, the SSEA test was used to determine whether each gene was 
significantly associated with a set of samples (for example, prostate cancer), or cancer 
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progression in a given lineage (for example, prostate normal to prostate cancer). The genes 
were ranked according to their strength of association. 
 
ChIP–seq data analysis 
ChIP–seq data from published external and in-house datasets, GSE56288 and GSE55064, 
were reanalyzed using a standard pipeline. Briefly, groomed reads (vendor quality control, 
adaptor removal) were aligned to the GRCh38 reference genome using STAR settings that 
disable spliced alignment: outFilterMismatchNoverLmax: 0.05, outFilterMatchNmin: 16, 
outFilterScoreMinOverLread: 0, outFilterMatchNminOverLread: 0, alignIntronMax: 1. 
Improperly paired alignments and non-primary alignments were discarded. Peaks were 
called using MACS2 (callpeak --broad --qvalue 0.05 --broad-cutoff 0.05 and callpeak --
call-summits --qvalue 0.05)[46] and Q (-n 100000)[47]. ChIP enrichment plots were 
computed from alignment coverage files (BigWig[48]) as trimmed (trim = 0.05) smooth 
splines (spar = 0.05). The baseline (non-specific) ChIP signal was estimated from genomic 
windows furthest from the center of the queried region (peak summit, TSS) and subtracted 






Figure 2.1. AR regulated non-coding transcriptome in prostate cancer cells 
(A) A schematic illustration of the procedure used to discover AR-regulated genes (ARGs) in 
LNCaP and VCaP prostate cancer cell lines. 
(B) The androgen-regulated transcriptome of prostate cancer cells. The heat map represents the 
1,702 genes (including 547 lncRNAs) differentially regulated in LNCaP and VCaP cells following 
6 and 24 h of DHT treatment 
(C) Venn diagram indicating the overlap between AR-regulated genes in LNCaP and VCaP cells. 
(D) Bar plot depicting the distribution of gene biotypes (protein, lncRNA, and other) of all 





Figure 2.2 ARGs that are directly regulated by AR 
(A) Transcriptional response to DHT and enzalutamide treatment in VCaP cells, plotting AR-
regulated protein-coding genes (top) or AR-regulated lncRNAs (bottom). 
(B)Aggregate ChIP–seq enrichment profile depicting AR ChIP–seq signaling density on ARG 
promoters in LNCaP and VCaP cells. Data representative of two biological replicates are shown.  
(C) Aggregate ChIP–seq enrichment profile illustrating AR ChIP–seq signaling density on ARG 
promoters in LNCaP cells following DHT stimulation, AR antagonist (enzalutamide) treatment, or 
BRD4 inhibitor (JQ1) treatment. Data representative of two biologically replicated assays are 
shown. 
(D) Motif discovery analysis of the top 250 AR ChIP–seq peaks on AR promoters identifies a 
binding motif similar to the canonical AR response element. P value was calculated in the MEME 
suite. n = 2 independent AR ChIP–seq assays. 
(E) Aggregated ChIP–seq enrichment profiles depicting ChIP–seq signal density on direct ARG 




Figure 2.3 AR regulated genes in cell lines and clinical cancer samples 
(A) Pie chart showing the prostate cell line or tissue distribution of direct ARGs with AR binding 
at transcription start sites (TSSs) in ChIP–Seq. 
(B-C) Cumulative distribution plots of distances between the TSSs of genes and the nearest AR 
peak. B, AR binding near ARGs in benign prostate, prostate cancer tissues (PCa), and prostate cell 
lines. Approximately 50% (75%) of ARGs have an AR peak within 1 kb (10 kb) of the TSS. C, 
Comparison of distances between AR-binding sites for ARGs and genes not regulated by AR. 












Figure 2.4 LncRNA expression in prostate cancer tissues 
(A) The landscape of transcriptomic alterations of prostate cancer progression. The heat map 
depicts 1,155 protein-coding genes and 547 lncRNAs across benign prostate (normal, n = 52 
samples), localized prostate cancer (PCa, n = 500 samples) and metastatic prostate cancer (Mets, n 
= 100 samples) in TCGA prostate and SU2C-PCF RNA-seq data, with rows representing genes and 
columns representing patients. Patients were grouped by clinical stage, and genes were subjected 
to hierarchical clustering. Expression variability is quantified for each gene as a z-score relative to 
the mean expression in normal prostate samples.  
(B) A heat map representation of ranked median protein-coding gene and lncRNA expression levels 








Figure 2.5 Identification of AR-regulated, prostate cancer–associated genes 
(A/C) Identification of androgen-regulated transcripts elevated in prostate cancer progression. 
Scatterplots show the AR regulation and cancer association of the ARGs identified in Figure 
2.1(B). The y axis depicts the log2-transformed fold change in gene expression following DHT 
stimulation, and the x axis indicates the log2-transformed difference in gene expression level 
between benign prostate (n = 52 samples) and localized prostate cancer (n = 500 samples) (A) and 
between benign prostate (n = 52 samples) and metastatic prostate cancer (n = 100 samples) (C). 
Significant genes with log2 fold change > 1 were ranked according to combined P value (limma-
moderated t test). 
(B) The top ten AR-regulated, localized prostate cancer–associated genes identified in (A), after 
applying an expression filter of at least fourfold change (log2 (FC) = 2) upon DHT stimulation and 
at least 1 FPKM average expression in prostate cancer tissues. Genes are listed in the order of log2 
gene expression level difference between benign and localized prostate cancer tissues.  
54 
 
(D) The top ten AR regulated, metastatic prostate cancer–associated genes identified in (C), after 
applying an expression filter of at least four-fold change (log2 (FC) = 2) upon DHT stimulation 
and at least 1 FPKM average expression in prostate cancer tissues. Genes are listed in the order of 























Figure 2.6 AR-regulated lncRNAs with restricted expression in prostate lineage 
(A) Nomination of prostate cancer- and lineage-associated lncRNAs based on expression levels. 
The scatterplot shows the expression level, prostate tissue specificity and prostate cancer 
association of lncRNAs. The expression level is the FPKM value at the 95th percentile across 
TCGA prostate samples. Average cancer and lineage associations are represented by the percentile 
rank for each gene in SSEA (total n = 7,256 samples) 
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(B) The top 12 prostate tissue–specific, prostate cancer–associated lncRNAs identified in (A), after 
applying an expression filter of at least 10 FPKM in the prostate samples in the top 5% based on 
gene expression level. Genes are listed in the order of SSEA percentile (total n = 7,256 samples). 
(C) Schematic illustration of the procedure used to nominate prostate-lineage-specific, cancer-
























Table 2.1 AR-regulated long non-coding RNAs  
gene_id logFC AveExpr P.Value Name AR peak 
G000029 -1.40273 4.512501 0.086322 RP11-54O7.16 TRUE 
G000083 -0.93844 1.158834 0.09047   TRUE 
G000413 2.459051 -3.02711 0.218751   FALSE 
G000570 3.800678 -3.04578 0.503674 RP1-69M21.2,LOC101929181 FALSE 
G000954 -2.8858 -1.53426 0.061614   FALSE 
G000957 -3.28718 -3.10387 0.053328   FALSE 
G000961 -2.3384 -4.10562 0.475695 LOC339505 FALSE 
G000984 -2.06135 -2.16795 0.07318   TRUE 
G001032 -2.60188 -3.54856 0.091678   TRUE 
G001044 -1.85233 -2.28271 0.064382   FALSE 
G001284 -0.03819 -1.98824 0.968998   TRUE 
G001523 -2.07056 -2.70009 0.191786   FALSE 
G001610 1.019695 4.203816 0.069391 TRIM62,AX747064 FALSE 
G002113 -1.36784 -1.62679 0.130349   FALSE 
G002293 -1.2983 -0.97782 0.059388 RP11-296A18.5 FALSE 
G002951 -1.48863 -1.93426 0.069999   FALSE 
G002957 -2.88601 -3.6998 0.118898   FALSE 
G002979 2.291978 -4.23024 0.451315   TRUE 
G003105 2.206414 -2.03532 0.46127 AC104169.1 TRUE 
G003397 -2.59275 -2.23208 0.093728 PRCAT162 TRUE 
G003443 2.870749 -0.38506 0.441531 CAT81 TRUE 
G003511 -2.86857 -3.60086 0.041797   TRUE 
G003728 -2.25656 -1.79939 0.198171   FALSE 
G004008 -3.24034 -3.89471 0.037644 RP4-666F24.3 TRUE 
G004771 2.057032 2.691291 0.253539   TRUE 
G005055 0.938317 7.41409 0.056745 PEA15 TRUE 
G005339 -3.44333 -0.17244 0.216331   FALSE 
G005341 -2.17554 -4.10545 0.328533   FALSE 
G005401 0.382604 6.797597 0.824107 ATP1B1,RP5-1018K9.1 FALSE 
G005831 2.559296 -3.96092 0.355659 CAT142 TRUE 
G006356 2.384253 -2.80508 0.326401 BRCAT400 TRUE 
G006605 4.565885 -3.36451 0.33294   TRUE 
G006817 4.543252 0.16941 0.069695   TRUE 
G006819 6.186749 -0.34331 0.076236   TRUE 
G006954 -2.23559 -3.25508 0.333857 HLA-AS1,RP11-295M18.6 FALSE 
G007085 1.85509 -1.04499 0.055775   FALSE 
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G007098 -2.38812 -3.70988 0.114113 RP11-100E13.1 FALSE 
G007159 -1.99968 -1.98837 0.03704   FALSE 
G007163 -2.09422 -3.27298 0.062638   FALSE 
G007383 -2.96705 -3.30843 0.105423   FALSE 
G007610 -1.41944 -0.87436 0.086302 RP11-385F5.4 FALSE 
G008007 -2.27686 -1.12569 0.161393 RP11-809C18.4 TRUE 
G008037 5.790587 -2.77786 0.054362 HICLINC238 FALSE 
G008042 5.162066 -1.63039 0.267279 PRCAT131 TRUE 
G008058 3.21539 -1.70575 0.488045   TRUE 
G008061 2.060401 -0.24004 0.570387   TRUE 
G008276 -1.17264 3.449149 0.031712 ANKRD16 TRUE 
G008509 2.108577 -2.07119 0.268352 RP11-397C18.2 TRUE 
G008695 4.641644 -3.4018 0.213316   FALSE 
G008815 3.978471 -3.31978 0.130609 LINC00836 TRUE 
G009117 4.410848 -3.60583 0.17427 OVAT13 TRUE 
G009153 -0.68824 -2.76147 0.761584 PRCAT146 TRUE 
G009673 -2.27416 2.703485 0.043651 CAT1262 FALSE 
G009760 2.838842 -1.11348 0.091931 LINC00844 TRUE 
G009961 -0.96642 1.763986 0.08088 TET1,RP11-119F7.5 FALSE 
G010213 1.614178 7.878369 0.109639 VCL,RP11-178G16.5 TRUE 
G010922 -3.03621 -3.99695 0.09751   FALSE 
G011318 -3.18849 -4.94246 0.167603   FALSE 
G011552 3.791503 -1.79146 0.138597 HICLINC252,LINC00867 TRUE 
G011599 -2.04286 -1.40846 0.21971 CAT1308 TRUE 
G011673 -1.20567 2.059589 0.023432   TRUE 
G012015 -1.88167 -1.00968 0.311504 RP11-140A10.3 TRUE 
G012036 2.073307 -0.64926 0.561769 CAT1320 FALSE 
G012133 -2.19959 -2.99893 0.158982 RP11-326C3.7 FALSE 
G012156 -0.17914 0.022055 0.805833   TRUE 
G012515 -2.44759 -0.49534 0.106552 CTD-2516F10.4 TRUE 
G012518 -2.15444 -3.24177 0.056549 CAT1334 FALSE 
G012596 -2.34963 -2.81748 0.025585 RP11-540A21.2,LOC440028 TRUE 
G012600 -2.72678 -2.75043 0.107964 SBF2-AS1 FALSE 
G012645 -2.18801 0.195019 0.31606 PRCAT107 FALSE 
G012962 -2.70445 1.886309 0.039751 RP11-945A11.1 TRUE 
G012972 -2.09999 -3.60996 0.179782 RNU6-783P FALSE 
G013149 -0.58692 5.368326 0.096565 PIGCP1,CSTF3 FALSE 
G013177 -2.12665 -2.47174 0.101613 THCAT62 TRUE 
G013377 -1.86659 -3.08754 0.091945   FALSE 
G013394 0.5421 -2.14031 0.643857 CAT1352 FALSE 
G013729 2.539392 -1.78995 0.157474 RP11-872D17.4 TRUE 
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G013731 -2.15881 -3.39243 0.086878   FALSE 
G013895 -2.09179 -2.79967 0.136017   FALSE 
G014019 1.121222 0.722989 0.08334 RP11-727F15.9 FALSE 
G014366 -1.54226 2.600475 0.099778 CAT1378 TRUE 
G014393 3.8621 -2.52079 0.345474   TRUE 
G014395 3.510878 -2.53966 0.455489   TRUE 
G014426 5.539431 -2.97535 0.18408   TRUE 
G014440 2.115131 0.086668 0.061658   TRUE 
G014443 -1.3306 -0.7857 0.065621 RP11-554A11.9 FALSE 
G014526 2.94667 -3.72043 0.355806   TRUE 
G014752 2.49067 -4.80177 0.422102   TRUE 
G014814 1.174462 5.985298 0.11751 RP11-21L23.2,TSKU TRUE 
G014875 -1.53762 -1.31705 0.090784 KCTD21-AS1 FALSE 
G015185 6.297588 1.293683 0.094008   TRUE 
G015244 -2.06054 -2.94271 0.066042   FALSE 
G015250 1.117356 1.900357 0.083539 CAT1412 FALSE 
G015388 -1.64346 -1.26584 0.198222 CAT1418 FALSE 
G015569 -2.26587 -3.17946 0.036842   FALSE 
G015689 2.276888 -3.25057 0.166531   TRUE 
G015705 -2.19318 -4.02178 0.281674   FALSE 
G015801 -2.10643 -0.40878 0.247464   TRUE 
G016087 2.246145 -2.93804 0.19288   TRUE 
G016096 -1.955 -1.62232 0.075791 RP11-677M14.2 FALSE 
G016104 -1.21398 1.317699 0.066136   FALSE 
G016157 -2.75581 -1.14453 0.397584   TRUE 
G016301 2.354383 -3.21515 0.145715   TRUE 
G016346 -2.46747 0.864171 0.083108 BRCAT168 FALSE 
G016393 4.413411 1.144751 0.01745   FALSE 
G016394 5.944861 0.734599 0.036705   FALSE 
G016562 -2.39152 0.138731 0.014567 LSCAT213 TRUE 
G017565 -0.87589 1.147721 0.097781 DDX11-AS1 TRUE 
G017746 3.083808 -4.30591 0.467076 RP11-554L12.1 TRUE 
G017755 0.274128 6.02902 0.556552 KIF21A TRUE 
G017973 -3.2876 -3.92572 0.057536   FALSE 
G018118 -2.089 0.477997 0.008888 RP11-133N21.7 FALSE 
G018251 3.894872 -1.62045 0.215083 CAT1519 FALSE 
G018313 1.618524 9.212634 0.02132 KRT18 TRUE 
G018376 -1.86618 0.757625 0.416396 HOXC12 FALSE 
G018377 -2.5219 -2.47677 0.09772 HOTAIR FALSE 
G018403 -2.23539 -1.19372 0.386618 PRCAT266 TRUE 
G018424 -2.81916 -4.32886 0.182785 RP11-616L12.1 TRUE 
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G018646 -2.49969 -3.69424 0.132005 RP11-150C16.1 TRUE 
G019202 -2.83338 -4.36607 0.134294   FALSE 
G019273 -2.33538 2.333406 0.477252 CAT1556 TRUE 
G019355 2.712525 -2.9699 0.292885 THCAT348 TRUE 
G019413 -2.13267 -3.56224 0.087021 THCAT117 TRUE 
G019524 3.898204 -2.64033 0.097695 RP11-1060G2.1 TRUE 
G019603 -2.54518 -0.92217 0.023421   TRUE 
G019709 2.126962 -2.34201 0.174618   TRUE 
G019738 2.228846 -2.00067 0.316086   TRUE 
G020410 -2.50675 -1.59928 0.033233 RP11-340F14.5 TRUE 
G020732 -2.47975 -3.62988 0.389865 RP11-474D1.4 TRUE 
G021007 -1.40868 -0.27431 0.039187   TRUE 
G021008 -1.00041 2.048907 0.077388   FALSE 
G021168 -2.41102 -1.49025 0.276367 RP11-556N21.1 FALSE 
G021193 3.133273 -3.19062 0.201823   TRUE 
G021396 -2.25568 -3.45376 0.140427   FALSE 
G021791 2.545117 -1.23567 0.121584   TRUE 
G021795 -2.08065 -4.73708 0.461419 PNAT43 FALSE 
G022457 2.124815 -1.39562 0.602168   FALSE 
G022968 -0.13757 -0.86369 0.90107 CVAT23 FALSE 
G023010 3.433052 -2.38729 0.389409 PRCAT119 TRUE 
G023011 2.508325 2.481916 0.026529   FALSE 
G023160 1.218719 4.117183 0.092673 CAT1629 TRUE 
G023293 -1.67437 -1.94169 0.095162 LINC00443, CAT1630 FALSE 
G023299 -2.77178 -3.30031 0.220396   TRUE 
G023358 0.244029 -2.84844 0.918259   TRUE 
G023426 2.165865 0.632621 0.30537   TRUE 
G023500 -1.98748 -2.16237 0.275833 KHCAT425 FALSE 
G023634 3.033478 -4.16511 0.376117 CTD-2311B13.5 TRUE 
G023653 3.149136 -4.8208 0.252929 RP11-244H18.1 TRUE 
G024250 1.995911 -3.31086 0.411596   FALSE 
G024296 -1.28195 -0.18703 0.120839 RP11-356O9.2 TRUE 
G024330 1.100132 -2.91931 0.553886 RP11-545M17.1 FALSE 
G024513 1.318476 3.700693 0.02454 METAZOA_SRP TRUE 
G024748 -1.5747 0.018065 0.114371 KTN1-AS1 FALSE 
G024875 -2.22908 -1.92311 0.282515 CAT1672 FALSE 
G024927 7.287695 -1.0292 0.0697 CAT1675 TRUE 
G025353 -1.4429 -0.973 0.051318 CAT1690 FALSE 
G025411 -2.45281 -3.22515 0.097509 PNAT35 TRUE 
G025547 -1.51519 -2.83162 0.093512   TRUE 
G025778 -1.63215 -0.8919 0.072199 RP11-1078H9.5 FALSE 
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G025786 -1.66493 -1.88622 0.085561 THCAT584 FALSE 
G026094 1.197943 4.624136 0.034955 EML1,RNU1-47P FALSE 
G026238 -2.64345 -3.00103 0.224774   FALSE 
G026470 1.839078 2.537458 0.396469 LACAT82 TRUE 
G026630 3.464848 -1.11123 0.011904   TRUE 
G026637 3.802638 -3.28186 0.100706 RP11-73C9.1 TRUE 
G026770 -2.07999 -1.00441 0.303534   FALSE 
G026838 -1.71555 0.514114 0.031741 RP11-16E12.1 FALSE 
G027262 -0.80142 3.030266 0.093148   FALSE 
G027289 2.148715 -3.63384 0.395701 Y_RNA FALSE 
G027363 -1.6571 -2.49369 0.087245 CMAT29 FALSE 
G027732 -2.77653 0.806557 0.020331 RP11-82L7.4 TRUE 
G027831 -1.38642 -1.63598 0.076946   TRUE 
G028003 3.573007 -0.35107 0.107095 ITGA11,RP11-709B3.2 FALSE 
G028313 -1.62027 -1.91996 0.085827 DNM1P35 TRUE 
G028326 -1.67163 -0.89168 0.043935 RP11-593F23.1 FALSE 
G028517 -1.20337 2.402392 0.098477 CAT1779 TRUE 
G028795 -2.57497 -3.6042 0.135936 MEAT119 FALSE 
G028850 -1.60316 -2.32207 0.063746 PRC1-AS1 FALSE 
G029034 3.121861 -3.98315 0.207632   TRUE 
G029104 1.550068 6.509867 0.007771 CAT1795 TRUE 
G029150 -1.72605 -3.39836 0.219192 MIR1302-10 TRUE 
G029156 -1.56768 0.278262 0.033168 WASIR2 TRUE 
G029543 1.014125 1.452777 0.05825   TRUE 
G029836 3.45029 0.089496 0.010351 RP11-65J21.4 TRUE 
G030045 3.471665 -3.42146 0.298081 RP11-429K17.1 FALSE 
G030443 2.946707 -1.68009 0.250879 ESAT93 TRUE 
G030445 2.224184 -0.50135 0.180222   TRUE 
G031234 0.551103 5.242305 0.503294 MT1X,DPPA2P4 TRUE 
G031345 2.527321 -3.48937 0.17547 CRAT4 TRUE 
G031570 -1.04742 0.727521 0.082053   FALSE 
G031811 1.273835 6.310542 0.039968 ZFHX3 TRUE 
G031940 1.626879 -1.48317 0.441982   TRUE 
G032033 2.345185 0.803853 0.122124 PRCAT47, ARlnc1 TRUE 
G032157 4.281667 0.584181 0.042052 KCCAT592 TRUE 
G032161 2.338742 -1.90459 0.644724 KCCAT103 TRUE 
G032162 4.097745 -2.91283 0.459008   TRUE 
G032200 -1.43318 -2.86358 0.302731   FALSE 
G033025 -3.87994 -3.86784 0.029689 LINC00675 TRUE 
G033054 1.332873 3.876648 0.088487 ZNF18,RPL21P122 TRUE 
G033966 2.897175 -2.71539 0.244139 AC015849.12 TRUE 
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G034483 0.18823 2.366982 0.868899 MEAT128 FALSE 
G035180 1.009611 6.100407 0.063386 VMP1 TRUE 
G035181 1.186456 -0.73564 0.098795 CAT1958 FALSE 
G035267 -0.40137 0.294888 0.703085   FALSE 
G035370 -1.36513 -0.42872 0.05856   FALSE 
G035430 2.52264 -0.99598 0.153784   FALSE 
G035432 2.367083 -4.24796 0.381265   FALSE 
G036007 0.786606 6.303478 0.057621 RP11-353N14.5,TBC1D16 TRUE 
G036055 -2.07652 -2.76204 0.121124 CTD-2561B21.3 TRUE 
G036065 -2.80834 -4.19604 0.151915   TRUE 
G036093 -2.33215 -3.37839 0.117876 THCAT107 TRUE 
G036240 -1.39938 2.118313 0.055144 LACAT117 TRUE 
G036242 2.474863 -2.18838 0.150307   TRUE 
G036277 -1.86196 -2.92347 0.094757 RP11-14P20.1 TRUE 
G036290 -1.06489 3.576236 0.022244   FALSE 
G036314 -3.15727 -3.28551 0.127509 LINC00470,RP11-288C17.1 TRUE 
G036657 -1.19448 2.681492 0.04639 RP11-861E21.1 FALSE 
G036676 -1.47541 -1.37018 0.147752   TRUE 
G036767 3.442996 -3.27553 0.106789 MEAT86 TRUE 
G036901 -1.13203 -0.85951 0.205868 RP11-621L6.3 TRUE 
G036953 5.085424 -1.76239 0.019978 AQP4-AS1 TRUE 
G036958 4.50091 -2.77922 0.368466 AQP4-AS1 TRUE 
G037652 2.803241 -3.5241 0.33847   FALSE 
G037664 1.710822 5.437217 0.003608 RP11-108P20.1,MALT1 TRUE 
G037684 1.926495 0.43449 0.209754   TRUE 
G037920 -1.26768 0.437091 0.056127 DSEL,CTD-2541J13.1 FALSE 
G038047 6.965749 -2.06305 0.014509 RP11-126K15.1 TRUE 
G038054 2.877181 -3.36277 0.505406   TRUE 
G038563 -2.03726 -3.30387 0.370064   TRUE 
G038694 -0.95685 1.410002 0.059143 KCCAT275 FALSE 
G039235 -1.43563 -2.0681 0.373277 CTD-2192J16.11 FALSE 
G039445 3.168078 0.166061 0.309987   FALSE 
G039681 -2.00896 -3.4696 0.22499   TRUE 
G039774 -1.48687 -0.95995 0.295909   FALSE 
G040328 -1.62976 -2.83756 0.094471   FALSE 
G040376 3.069986 -3.29013 0.098239   TRUE 
G040593 -0.89947 4.930078 0.08749 LRFN1,CTC-246B18.8 FALSE 
G040635 0.733791 6.497617 0.086089 ZNF546,PSMC4,CTC-471F3.6 FALSE 
G040900 -1.08781 0.817244 0.159522 RP11-15A1.2 FALSE 
G041027 -0.13484 0.689709 0.866395 CAT2113 TRUE 
G041349 1.336208 9.323637 0.280006 CTD-2568A17.1 TRUE 
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G041363 -3.05623 -3.44812 0.267831 CTB-147C22.8 FALSE 
G041739 2.133448 -1.78797 0.140128   TRUE 
G041868 0.719199 -3.57458 0.680448 CTC-444N24.13 TRUE 
G041938 -1.50138 -2.54004 0.288694 CTD-2619J13.19 FALSE 
G042070 -2.07643 -2.07349 0.097847 AC018685.1 FALSE 
G042286 2.230012 0.578907 0.022556   FALSE 
G042341 -1.53572 1.046452 0.194136 CAT207 TRUE 
G042418 -0.19303 -3.23738 0.935638   TRUE 
G042532 2.875899 -3.44589 0.368418 PRCAT126 TRUE 
G042596 -1.40339 -1.03225 0.075586 AC079145.4 FALSE 
G042696 2.075451 -2.968 0.226001 BRCAT387 FALSE 
G042906 2.934558 -3.05154 0.273422   TRUE 
G043040 -2.10741 -3.45717 0.204801 AC020594.5 FALSE 
G043304 -1.75332 0.809875 0.052496 KHCAT367 TRUE 
G043436 3.05746 -3.71492 0.232877   FALSE 
G044809 -1.48959 -1.46217 0.150655 KCCAT298 FALSE 
G044873 -2.45026 -3.67847 0.210015   TRUE 
G045024 -2.62353 -3.26382 0.142153   TRUE 
G045282 3.615251 -1.96762 0.087628 CRAT41 TRUE 
G045317 -1.41141 1.836644 0.07871 CAT288 TRUE 
G045585 -1.22959 -2.52117 0.499405 HICLINC62 FALSE 
G045881 2.865413 -3.00706 0.435629 OVAT98 TRUE 
G045939 1.981531 0.862341 0.010671 AC018804.3 FALSE 
G045973 2.422984 -1.26897 0.081595   TRUE 
G045991 2.85109 -3.22869 0.12512   FALSE 
G046013 1.976443 -0.64193 0.05982   TRUE 
G046046 -1.49022 -1.903 0.393657 RP11-725P16.2 FALSE 
G046160 -1.4184 -0.6794 0.099678   FALSE 
G046325 3.055415 -4.01242 0.241941   FALSE 
G046493 -2.15339 -2.53194 0.598985 AC061961.2 FALSE 
G046726 -1.58491 0.370166 0.06561 PRCAT52 TRUE 
G046755 2.128283 -3.07751 0.175375   FALSE 
G046789 -2.23952 -0.47632 0.315622   TRUE 
G046869 4.20075 2.896508 0.212228 PRCAT44 TRUE 
G047119 -2.12767 -3.57564 0.537926   FALSE 
G047196 0.672998 -3.38796 0.71702 RP11-438L19.1 FALSE 
G047232 -2.19318 -4.02178 0.281674 AC007966.1,AC008174.3 FALSE 
G047342 -2.26832 -3.47495 0.058665 HNCAT25 FALSE 
G047447 3.014398 -2.5332 0.388046   TRUE 
G047809 1.431345 2.275725 0.091021 CCNYL1 TRUE 
G047838 1.475707 8.779537 0.021354 IDH1,AC016697.2 FALSE 
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G048220 3.123402 -4.45069 0.237742   TRUE 
G048744 -2.03864 -2.59131 0.150333   FALSE 
G048958 -1.56019 -2.28737 0.090733 AC114730.5 FALSE 
G049118 -2.48271 -3.04456 0.035821   FALSE 
G049125 2.021664 -2.75568 0.120513   TRUE 
G049439 -3.31715 -2.24029 0.357632 RP11-157E14.1 FALSE 
G049641 -2.1155 -3.78793 0.160757 ESAT110 FALSE 
G049678 3.583105 -2.4339 0.285866 LGAT90 FALSE 
G049687 4.695585 -2.83402 0.054085   TRUE 
G050039 -1.52393 -0.32925 0.185747 OVAT22 FALSE 
G050719 -1.95044 -2.85918 0.096711   FALSE 
G051083 2.823898 -0.54529 0.292117 CAT2184 TRUE 
G051095 4.115547 -3.04448 0.224061   TRUE 
G051142 -3.86036 -2.7866 0.110614 OVAT151 FALSE 
G051303 -2.79881 -1.26763 0.15726   FALSE 
G051309 -2.00204 -1.35536 0.065133 RP11-93B14.5 TRUE 
G051383 -1.13174 2.85313 0.093204   TRUE 
G051436 0.670692 6.898255 0.08565   TRUE 
G051610 -1.18213 4.322191 0.099994 LINC00478 TRUE 
G052017 -2.68284 -3.05531 0.160349 HUNK-AS1 TRUE 
G052077 2.060642 -0.97585 0.240257 IL10RB-AS1 TRUE 
G052134 5.596326 -2.93806 0.09666 LINC00160 TRUE 
G052135 3.170495 -3.91367 0.274146 CAT2206 FALSE 
G052222 3.065809 -3.68781 0.276546   TRUE 
G052331 2.865746 -2.2517 0.199216 PRCAT17 TRUE 
G052333 5.320418 2.821257 0.03574 PRCAT38 TRUE 
G052334 6.057732 0.667845 0.085387 PRCAT23 FALSE 
G052336 1.490611 -0.14263 0.063174 PRCAT82 TRUE 
G052447 -1.85491 -1.87343 0.072066   FALSE 
G052460 -2.05228 -2.84222 0.045093   FALSE 
G052516 -1.69753 -0.43256 0.05663   FALSE 
G052527 -1.34068 0.612529 0.063419 AL773604.8 TRUE 
G052551 -1.80575 -1.43595 0.088799 KCCAT638 TRUE 
G052610 -0.82027 2.094316 0.089199 MCM3AP-AS1 TRUE 
G052613 -1.09912 3.297382 0.033729 MCM3AP-AS1 FALSE 
G052646 2.67517 -4.00997 0.431947 POTEH-AS1 FALSE 
G052797 -1.5264 -0.60521 0.061651 CAT2223 TRUE 
G052848 -0.23056 -1.76755 0.91422   FALSE 
G052853 -2.07322 -2.98275 0.212562 LINC00896 FALSE 
G052925 4.004657 -3.69051 0.419482 KB-1592A4.15,AL117485 FALSE 
G053066 -1.17104 -0.4974 0.084177   FALSE 
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G053485 3.940381 -1.82414 0.131197 RP1-127L4.10 TRUE 
G053486 3.95116 -2.57176 0.348021   FALSE 
G053607 -1.9879 -2.00466 0.062271   TRUE 
G053674 -1.35937 2.732232 0.063884 ELFN2,DQ594725 FALSE 
G053708 0.897047 4.523936 0.066046 ANKRD54 TRUE 
G053961 -2.00003 -1.8589 0.059894 CTA-126B4.7 FALSE 
G054033 -1.00494 0.609311 0.091656 KHCAT97 FALSE 
G054063 2.020559 -2.36774 0.069587   TRUE 
G054130 3.601571 0.372222 0.058199   TRUE 
G054131 3.742133 1.48255 0.048349   FALSE 
G054133 3.088103 -0.00383 0.103218 LOC730668 FALSE 
G054434 -1.30771 3.073655 0.070977 RP11-97C16.1 FALSE 
G054452 -1.23101 0.308185 0.054907 ITPR1-AS1 TRUE 
G054486 2.114731 -5.00623 0.514695   FALSE 
G054811 -1.47875 -0.72716 0.049432 CAT389 FALSE 
G055301 2.193166 1.035908 0.077851 AC097359.1 FALSE 
G055447 2.18231 -0.22069 0.348492   TRUE 
G055462 -1.48253 -1.52168 0.084232 CAT400 FALSE 
G055480 -2.09565 -3.05617 0.082517   FALSE 
G055896 -2.24116 -2.82255 0.156149 CAT410 FALSE 
G055988 -2.02702 0.291157 0.412161   TRUE 
G056035 2.86229 -3.84176 0.338026 KCCAT260 TRUE 
G056292 4.627277 -2.40154 0.239468 LVCAT46 FALSE 
G056935 1.595333 4.487098 0.015232 LINC00883 TRUE 
G057053 -3.32119 -1.23167 0.250988 RP11-90K6.1 TRUE 
G057062 -2.24683 -1.09445 0.195453 RP11-572C15.6 TRUE 
G057244 -2.22401 -3.28893 0.079555   FALSE 
G057283 3.118228 -2.36212 0.294381   FALSE 
G057284 4.159438 -2.31583 0.165573   FALSE 
G057398 -2.02956 2.014061 0.156957 RP11-379B18.5 TRUE 
G057514 0.823954 8.416813 0.084521 RPN1,POU5F1P6 FALSE 
G057557 0.551371 5.91327 0.071874 ,RPL32P3,BX641154 TRUE 
G057593 -1.15646 3.523208 0.049336 LACAT17 FALSE 
G057924 3.748474 1.53674 0.353552 CHST2 FALSE 
G058210 -2.38522 -3.00162 0.040887 RP11-529G21.2 TRUE 
G058215 -3.18849 -4.94246 0.173549 KCCAT39 FALSE 
G058256 1.876028 -0.73964 0.280904 ESAT16 TRUE 
G058489 -2.23338 4.948063 0.148988 SI,RP11-747D18.1 FALSE 
G058547 -1.98705 -1.53175 0.224061   TRUE 
G058643 -1.55068 -3.27553 0.189117 RP11-185E8.1 FALSE 
G058722 -2.42901 -1.17365 0.164835 PRCAT24 TRUE 
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G059025 0.327163 -2.93106 0.803086   TRUE 
G059106 -2.55484 -3.71656 0.341642 RP11-48F14.2 TRUE 
G059324 -0.41752 -4.03768 0.849696   FALSE 
G059369 -1.32567 -1.29151 0.081806   FALSE 
G059439 1.576466 0.487942 0.159315 LINC00969 FALSE 
G059452 2.243055 2.435608 0.10459 KCCAT630 FALSE 
G059663 -0.4025 2.673994 0.574967 LGAT106 TRUE 
G059668 0.199979 5.311342 0.780097 KPCAT2 TRUE 
G059676 3.116358 4.254516 0.005154 HV535487 TRUE 
G059677 2.854194 1.876596 0.004898 CTBP1-AS FALSE 
G059682 -0.57075 -0.90487 0.570524   TRUE 
G059745 -2.01705 -2.99935 0.096561   FALSE 
G059823 -0.92646 2.304127 0.429881 AC226119.5 TRUE 
G059855 2.776496 -2.95286 0.15434   TRUE 
G059857 3.009263 0.351528 0.121889   TRUE 
G059864 -2.62442 -1.71271 0.044566   FALSE 
G059867 -2.04011 -3.5985 0.151226   TRUE 
G059984 -1.63372 -1.84546 0.06796 HNCAT68 TRUE 
G060068 1.156664 7.851356 0.057055 RP11-448G15.3 TRUE 
G060215 -1.10908 1.672588 0.068804 TAPT1-AS1 TRUE 
G060776 -0.22363 -2.37947 0.851793   FALSE 
G061287 -2.35391 -2.29708 0.404143 RP11-725D20.1 TRUE 
G061455 -2.13087 -1.86799 0.245056   TRUE 
G061709 -2.06254 -3.4082 0.154557 CAT561 FALSE 
G061721 2.432969 -2.11548 0.10743 AC107072.2 FALSE 
G062022 2.070118 -3.44744 0.324685 RN7SKP244,7SK TRUE 
G062025 1.99341 0.323828 0.045208 FAM13A-AS1 FALSE 
G062041 -1.24791 2.163784 0.043887 RP11-115D19.1 TRUE 
G062057 -2.4536 -0.79629 0.032556   FALSE 
G062116 3.224245 -3.74087 0.165206 CAT574 TRUE 
G062224 -3.09171 -2.29607 0.161628   FALSE 
G062381 -2.99751 -3.69894 0.240354   FALSE 
G063265 4.238715 -3.76134 0.222735 PRCAT187 TRUE 
G063348 2.462588 -3.80905 0.429552 CAT594 TRUE 
G063514 -2.00217 -3.12989 0.045588 CAT600 FALSE 
G063530 -1.12901 5.420321 0.06987 CVAT11 TRUE 
G063618 -1.23932 0.083001 0.067538 RP11-218F10.3 FALSE 
G063845 3.060114 4.933645 0.276964 RP11-440I14.2,HPGD FALSE 
G063846 2.607233 -1.14629 0.318449 RP11-440I14.3 FALSE 
G064103 1.482696 1.036643 0.062366 RP11-714G18.1,SNX25 FALSE 
G064346 2.365893 -4.13703 0.347141   TRUE 
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G064797 2.500019 4.989899 0.023953 CTD-2165H16.3 TRUE 
G064843 -1.86622 -1.24572 0.097121 RP11-260E18.1 FALSE 
G065393 -2.86536 -1.69694 0.069894 CTD-2116N24.1 FALSE 
G065410 1.232887 2.298507 0.09064 LIFR-AS1 TRUE 
G065433 -2.36333 -4.52847 0.439482   FALSE 
G065553 1.230315 2.505369 0.098879 CAT655 TRUE 
G065780 -2.57794 -2.46459 0.048062   FALSE 
G065803 2.674788 -2.26336 0.161225   TRUE 
G065808 -1.64159 -0.19811 0.075878 CTD-2031P19.3 TRUE 
G065880 -2.25392 -2.65758 0.141745 LOC101928569 TRUE 
G066769 1.867301 -1.61259 0.191932   TRUE 
G066890 2.247371 -4.06804 0.588654   FALSE 
G067016 0.673261 6.650198 0.093223 PJA2,CTD-2587M2.1 TRUE 
G067899 0.212064 -3.79722 0.914224   FALSE 
G068067 2.661636 -2.58203 0.06163   TRUE 
G068470 -2.90086 -1.77043 0.068239 CTC-340A15.2 TRUE 
G068471 -3.49602 -3.62172 0.020237   TRUE 
G068966 -2.1948 -3.21672 0.138541   TRUE 
G069047 3.723394 -3.41632 0.054125 CAT756 TRUE 
G069069 -1.04491 1.427673 0.065648 CTC-338M12.5 TRUE 
G069122 -2.09052 -2.77542 0.170315 LACAT77 TRUE 
G069259 1.355817 -1.39144 0.091775   FALSE 
G069472 2.082248 -4.04617 0.409378   TRUE 
G070137 -2.18119 -3.50696 0.142715 HCG14 TRUE 
G070488 1.302193 0.171372 0.082339 HCG25 TRUE 
G070556 -2.07182 -3.51849 0.147742   TRUE 
G070610 6.29957 -2.30556 0.485713 CAT795 TRUE 
G070612 4.554682 9.215672 0.002644 FKBP5,LOC285847 TRUE 
G070619 4.344905 -1.84839 0.105973   TRUE 
G070798 -3.45864 -2.94729 0.023295 HNCAT211 FALSE 
G070801 -2.21155 -2.71656 0.133769   TRUE 
G070950 2.271519 -3.18429 0.182763   TRUE 
G070968 3.197496 0.030825 0.046615   FALSE 
G071242 1.159907 3.212114 0.036001 OVAT19 TRUE 
G071271 4.587036 -3.60996 0.029314 LSCAT162 TRUE 
G071600 -0.48331 -2.32494 0.875622   FALSE 
G072429 -1.60635 -1.44244 0.057898   TRUE 
G072446 3.689979 -4.08736 0.169976   TRUE 
G072863 3.135769 -2.24069 0.077282 BRCAT246 FALSE 
G072921 -0.07872 -3.29345 0.97268   FALSE 
G073186 1.701079 -0.69226 0.259209 RP11-356I2.4 TRUE 
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G073824 3.121558 -1.8858 0.205041   TRUE 
G074015 -2.34359 -3.14536 0.411657   FALSE 
G074101 2.902999 -0.20088 0.032725   TRUE 
G074104 2.235417 -2.53504 0.417475   FALSE 
G074149 -1.58188 0.801403 0.032755 RP1-266L20.4 FALSE 
G074385 2.817504 -4.57984 0.357059 KHCAT361 FALSE 
G074407 -2.30898 -4.2499 0.471235 PNAT3 FALSE 
G074494 -2.11097 -2.58359 0.049824   FALSE 
G074539 -1.40895 -0.16751 0.076914   TRUE 
G074968 2.010818 -1.18126 0.410168 PRCAT161 TRUE 
G075017 2.281212 -0.78629 0.180889 HNCAT223 TRUE 
G075063 -2.50601 -4.47707 0.288189 AC004947.2 TRUE 
G075089 -2.01154 0.153998 0.683709 HOTTIP TRUE 
G075092 -2.61906 -1.954 0.223106 RP1-170O19.17,EVX1-AS FALSE 
G075097 -4.60832 -0.3503 0.029346   TRUE 
G075676 -2.42862 -4.53335 0.264144   TRUE 
G076097 -1.89262 -1.50227 0.249581   FALSE 
G076184 -1.85953 -0.64316 0.021942   TRUE 
G076242 -0.73731 2.600749 0.077485 LOC441242 TRUE 
G076645 -2.88207 -1.82329 0.107078 PRCAT177 TRUE 
G076860 7.604254 3.444154 0.06407 CTB-167B5.2,STEAP4 TRUE 
G077087 -2.22722 -3.44423 0.174488   FALSE 
G077380 -2.65683 -3.4608 0.071783   FALSE 
G077505 -0.2167 -2.74062 0.85187 SLC26A4-AS1 TRUE 
G077510 1.765936 0.129628 0.04568 AC002467.7 TRUE 
G077512 1.745997 0.68737 0.031341 AC002467.7 TRUE 
G077737 -2.60346 -0.66291 0.031509 ST7-AS1 FALSE 
G077739 -2.31591 -1.56796 0.163094 ST7-AS1 FALSE 
G077742 -2.3044 -3.58705 0.135025   FALSE 
G077982 -2.30111 -4.26111 0.306287 AC000124.1 FALSE 
G078277 -2.44813 -1.8145 0.016501 AC015987.1,AC015987.2 TRUE 
G078281 -2.71091 -0.30828 0.019327 AC015987.1 TRUE 
G078444 -1.02459 0.858999 0.069018 WEE2-AS1 TRUE 
G078504 2.664191 -2.2404 0.164717   TRUE 
G078673 -0.76416 5.310495 0.074907 ZNF783,RP4-800G7.2 TRUE 
G078770 -2.37024 -1.39958 0.052013   TRUE 
G079054 4.063248 -3.99732 0.202558 HICLINC181 TRUE 
G079125 -1.57549 0.454829 0.036431   FALSE 
G079134 -2.07412 -1.20131 0.064847 FAM87A FALSE 
G079148 -2.01396 -0.42951 0.040909 ERICH1-AS1 TRUE 
G079291 4.130739 -3.8813 0.103485 SMAT11 TRUE 
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G079502 1.390094 -0.01851 0.040702 LSCAT125 FALSE 
G079556 2.371455 -3.10437 0.196563   TRUE 
G079682 -1.96913 0.410999 0.030334 RP11-156K13.1 TRUE 
G079833 -2.0032 -1.00896 0.073681 RP11-582J16.4 FALSE 
G079868 0.642972 4.433418 0.078996 RP11-1149O23.4 FALSE 
G079946 0.994022 4.798586 0.017807 RP11-395I14.2,GNRH1 TRUE 
G080409 2.444153 -2.29417 0.046735 PRCAT118 TRUE 
G080725 3.143953 -1.93841 0.032343   TRUE 
G080834 -0.26278 -3.77161 0.907039 RP11-162D9.3 TRUE 
G081325 -1.66755 1.666923 0.07067 LACAT125 TRUE 
G081326 -2.24103 -2.20557 0.179672   TRUE 
G081606 1.413406 1.052917 0.083179 RP11-26J3.1,HEY1 TRUE 
G081615 3.120709 -1.20545 0.085584   TRUE 
G081661 -1.1029 -2.38219 0.736892 PRCAT127 TRUE 
G082010 -1.08956 -0.79801 0.099943 RP11-267M23.4 TRUE 
G082011 -1.9448 -3.3781 0.172501   FALSE 
G082227 0.984013 4.15626 0.044342 CAT1073 TRUE 
G082546 -2.17156 -3.61628 0.127186   FALSE 
G082839 2.039805 -2.97772 0.593665 LINC00964,LOC157381 TRUE 
G082910 -1.17115 1.593753 0.094349 PCAT1,CAT1096 TRUE 
G082921 -3.32178 -3.42433 0.016738   TRUE 
G082926 -1.44712 0.122449 0.064395 CAT1099 TRUE 
G083069 1.969502 -3.42333 0.505536 CAT1104 FALSE 
G083070 3.486336 -1.44583 0.180817   TRUE 
G083076 6.968643 -1.26333 0.036874 CAT1105 TRUE 
G083255 -0.27999 -3.24986 0.904926 RP11-128L5.1 FALSE 
G083270 -1.77936 -1.86731 0.06661 CAT1110 TRUE 
G083427 -1.48611 -0.68523 0.035188 AC087793.1 FALSE 
G083488 2.561124 -0.89171 0.11312   FALSE 
G083537 -2.10185 -3.36337 0.3318 AF186192.5,AF186192.6 FALSE 
G083581 1.070449 -2.04374 0.655781 RP11-143M1.3,FOXD4 FALSE 
G083669 -1.19217 3.558728 0.017932 CVAT7 TRUE 
G084112 2.404886 0.009819 0.225408   TRUE 
G084143 -3.39449 -2.50829 0.121207   TRUE 
G084146 -2.50645 -2.8591 0.290954   FALSE 
G084326 -2.0569 -2.95487 0.078675   FALSE 
G084916 3.548148 -4.44986 0.188249 CAT1147 FALSE 
G084971 2.645704 -1.32517 0.342742 THCAT527 TRUE 
G085024 -2.18213 -0.68974 0.382319 PRCAT102 TRUE 
G085136 5.214157 -3.22853 0.054979 CAT1155 TRUE 
G085294 -2.2938 -5.23099 0.358887   TRUE 
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G085431 2.840642 -3.20847 0.213208   TRUE 
G085534 1.135815 -0.23603 0.088984 PRCAT135 TRUE 
G085566 -2.18521 -3.20428 0.341135   TRUE 
G086306 -1.00567 4.120839 0.175835 THCAT63 FALSE 
G086466 2.662952 -1.30707 0.334593   TRUE 
G086627 -1.19919 -2.29797 0.496586 RP11-175D17.3 TRUE 
G087016 4.472483 -3.7218 0.025129 SNOU13 TRUE 
G087078 0.276445 -3.15884 0.845186 HNCAT22 TRUE 
G087152 -2.70803 -5.48883 0.278044 CAT1209 TRUE 
G087245 -1.26703 0.033701 0.092819   TRUE 
G087273 2.027331 -3.02711 0.239193   TRUE 
G087778 2.395636 -2.00543 0.053774   FALSE 
G088325 -2.13257 -2.73048 0.102258 ZNF630-AS1 FALSE 
G088623 -0.94804 0.098651 0.088277   FALSE 
G088721 -2.18126 -3.73679 0.189908   TRUE 
G088897 -4.41195 -4.24177 0.151531 XIST FALSE 
G089246 -2.32242 -3.34185 0.398295   FALSE 
G089267 -2.28821 -4.83273 0.414308 PNAT116 FALSE 
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Functions and therapeutic potential of long non-coding RNA ARLNC1 
in prostate cancer1 
 
Abstract 
Through a top-down bioinformatic analysis, we have identified AR-regulated long non-
coding RNA-1 (ARLNC1).  In this chapter, we assess the clinical relevance and therapeutic 
potential of ARLNC1, beyond our initial nomination of this lncRNA via its prostate 
lineage- and prostate cancer-specific expression in patient samples. We discovered an 
association of ARLNC1 levels with accentuated AR signaling and luminal epithelial 
differentiation in patient tumors, both of which are important clinical considerations for 
anti-androgen treatment. Using loss-of-function experiments in vitro and in vivo, we 
confirmed that ARLNC1 is critical for AR-positive prostate cancer cell growth. 
Interestingly, AR signaling is identified as one of the pathways regulated by ARLNC1, 
indicating the existence of a feedforward loop. These results suggest that ARLNC1 is a 
                                                          
1 This chapter was previously published as part of the following manuscript: Zhang, Y., et al., Analysis of 
the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer 
progression. Nat Genet, 2018. 50(6): p. 814-824. 
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lncRNA that contribute to prostate cancer development, at least in part through 
preservation of AR signaling.  
 
Introduction 
The androgen receptor signaling is the critical driver of all stages of prostate cancer. In the 
most lethal, metastatic castration resistant prostate cancer (mCRPC), persistent AR activity 
in spite of ADT and the second-generation AR-targeting agents is achieved by direct 
alteration to the AR signaling axis. Aberrations of AR signaling axis exist in 71.3% of 
mCRPC cases, with the majority being direct alterations affecting AR (amplification and 
mutation). As such, a better understanding of players in the AR signaling pathway may 
provide novel therapeutic opportunities to disrupt persistent AR activity. 
 
In the previous chapter, we discovered lncRNAs responsive to DHT stimulation from cells, 
and prioritized ARLNC1 with suggestive oncogenic roles. The objective of this chapter is 
to carry out in vitro and in vivo studies to investigate functions and evaluate therapeutic 
potential of ARLNC1 in prostate cancer.  
 
Results 
Prevalence of ARLNC1 in normal and cancer tissues 
Expression of ARLNC1 was interrogated across cancer and normal tissue RNA-Seq 
samples from TCGA and the Genotype-Tissue Expression (GTEx) project[1, 2], 
respectively. In the TCGA cohort, ARLNC1 exhibited a highly prostate cancer specific 
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expression pattern, with little to no expression in other tumor types (Figure 3.1A). 
Similarly, in the GTEx normal tissue cohort, its expression was limited to the prostate 
(Figure 3.1B).  
 
Among prostate samples, ARLNC1 expression was significantly higher in localized and 
metastatic prostate cancers compared to benign tissues, as assessed by RNA-Seq (Figure 
3.1C) and in situ hybridization (Figure 3.1D). In an extensive differential expression 
analysis using MiTranscriptome, ARLNC1 was found to be among the top 1% of 
transcripts most upregulated in prostate cancer and specific to the prostate lineage, with no 
significant associations in other tissues (Figure 3.2A). Moreover, the protein-coding genes 
that were most correlated with ARLNC1 were found to be associated with prostate cancer 
progression in ONCOMINE concept analyses performed on multiple clinical data sets[3] 
(Figure 3.2B).  
 
Furthermore, we compared the top- and bottom-quartiles of prostate cancer samples based 
on ARLNC1 expression, and as expected, found that the top-samples were characterized 
by elevated expression of “Androgen Receptor Signaling Targets” genes and an expression 
profile consistent with luminal epithelial prostate cancer, which was also reflected in the 
down-regulation of genes associated with the epithelial-to-mesenchymal transition (Figure 
3.2E-G). We verified that these differences were not due to tumor purity (Figure 3.2D). 
Overall, these results strongly suggest the association of ARLNC1 levels with AR signaling 
and luminal epithelial differentiation in patient tumors, which are important clinical 
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considerations for administering anti-androgen therapy. Additionally, we evaluated 
association between ARLNC1 level and Gleason score, the grading system used to 
determine prostate cancer aggressiveness. No significant association between ARLNC1 
expression and disease grade was observed (Figure 3.2C).  
 
Taken together, these results confirm that ARLNC1 expression is restricted to the prostate 
lineage, elevated in prostate cancer and associated with AR signaling throughout prostate 
cancer progression. 
 
Characterization of ARLNC1  
To functionally characterize ARLNC1, we first identified appropriate prostate cancer cell 
lines with moderate to high levels of ARLNC1 expression using in house RNA-Seq data 
(Figure 3.3A). Supporting the association of AR with ARLNC1, ARLNC1 expression was 
highly enriched in AR-positive cell lines, with the highest expression in MDA-PCa-2b and 
LNCaP cells. In addition, quantitative PCR (qPCR) analysis for the ARLNC1 transcript 
also demonstrated that this gene was expressed at the highest level in the MDA-PCa-2b 
and LNCaP cell lines (Figure 3.3B).  
 
As existing annotations of ARLNC1 (located on chromosome 16) predict the presence of 
several transcript isoforms that differ in exon and TSS usage, we determined the exact 
structure in MDA-PCa-2b and LNCaP cells, by random amplification of cDNA ends 
(RACE) (Figure 3.3D). A common TSS for ARLNC1 was found in both cell lines, and the 
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~2.8 kilobase (kb) transcript isoform was further confirmed by northern blot analysis 
(Figure 3.3C). Single molecule fluorescent ISH (smFISH) revealed that approximately 
100 molecules of ARLNC1 transcripts existed per MDA-PCa-2b cell (Figure 3.4A-B). 
Using smFISH and qPCR, we also found that ARLNC1 molecules were distributed equally 
between the nuclear and cytoplasmic cellular compartments (Figure 3.4C-D). 
 
Phenotypic effect of ARLNC1 loss in vitro 
Knockdown of ARLNC1 had a significant effect on the proliferation of AR-dependent 
MDA-PCa-2b, LNCaP, and LNCaP-AR cells, but had no effect on AR-negative DU145 
and PC3 cells (Figure 3.5A-D). Knockdown of ARLNC1 also resulted in increased 
apoptosis in AR-positive prostate cancer cells (Figure 3.5E-F). Although we were not able 
to generate single cell-derived clones harboring ARLNC1 knockout (by CRISPR-Cas9) in 
AR-positive MDA-PCa-2b or LNCaP cells, we observed a growth defect of the cell 
population with ARLNC1 deficiency (Figure 3.6). Furthermore, we designed antisense 
oligonucleotides (ASOs) targeting the ARLNC1 transcript (Figure 3.7A). Transfection of 
ASOs exhibited strong knockdown efficiency (Figure 3.7B). AR-positive cells transfected 
with ARLNC1 ASOs exhibited retarded growth, similar to those treated with siRNAs 
(Figure 3.7C). 
 
To elucidate ARLNC1 regulated genes in these processes, we performed gene expression 
profiling of wild-type and ARLNC1-knockdown MDA-PCa-2b cells (Figure 3.8A). We 
found that ASO-mediated knockdown resulted in similar effects on gene expression 
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profiling to siRNA (Figure 3.8B-C). Gene ontology (GO) pathway enrichment analysis of 
the differentially expressed genes revealed deregulation of four main biological activities: 
apoptosis, cell proliferation, DNA damage response and androgen signaling (Figure 3.8A). 
A significant decrease in AR target gene expression is particularly interesting (Figure 
3.8D-E) given the fact that ARLNC1 expression is stimulated by AR, suggesting a positive 
feedback loop between ARLNC1 and AR signaling. 
 
Phenotypic effect of ARLNC1 loss in vivo 
Since modulation of ARLNC1 expression levels resulted in a striking proliferation 
phenotype, we hypothesized that ARLNC1 inhibition could be used therapeutically for the 
treatment of prostate cancer. Cells expressing shRNA targeting ARLNC1 formed smaller 
tumors in mice when compared to cells expressing non-targeting shRNA (Figure 3.9A), 
thus suggesting that ARLNC1 is an important survival factor for AR-dependent prostate 
cancer in vivo. 
 
ASOs have been shown to be effective in targeting RNAs in vivo[4-6]. To evaluate the 
therapeutic potential of ARLNC1 ASOs, we first assessed the cellular free-uptake 
efficiency of ARLNC1 ASOs, a prerequisite for ASO therapeutic use. Importantly, several 
ASOs significantly reduced ARLNC1 levels through free uptake (Figure 3.7D). Free 
uptake of ARLNC1 ASOs led to a significant decrease in the proliferation capacity of 
MDA-PCa-2b cells in both normal cell culture and three-dimensional sphere conditions 
(Figure 3.7E, 3.9B-C). Treatment of mice bearing MDA-PCa-2b xenografts with 
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ARLNC1-targeting ASOs led to significant decreases in tumor growth compared to control 
ASO (Figure 3.9D-I). Taken together, these data, along with the association of ARLNC1 
with aggressive androgen signaling, suggest that ARLNC1 plays a critical role in the 




In this Chapter, we interrogated basic cell functions affected by ARLNC1, using a series 
of loss-of-functions assays (RNA interference, CRISPR-mediated knockout, and ASO-
mediated knockdown). As a novel non-coding regulator of AR signaling, ARLNC1 has the 
potential to be not only a mechanistic biomarker, but also a therapeutic target for advanced 
prostate cancer. Specific antisense nucleotides targeting ARLNC1, which we demonstrate 
to be specifically expressed in the prostate, could circumvent undesirable side effects that 
occur in other tissues with exposure to androgen synthesis inhibitors or anti-androgens. 
The application of ASOs has ushered in an exciting era that makes it possible to target 
previously ‘undruggable’ molecules directly at the transcript level, such as ARLNC1, 
which is likely to yield promising opportunities in cancer treatment. 
 
Materials and Methods 
Oncomine concept analysis of the ARLNC1 signature 
Genes with expression levels significantly correlated with ARLNC1 were separated into 
positively and negatively correlated gene lists. These two lists were then imported into 
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Oncomine as custom concepts and queried for association with other prostate cancer 
concepts housed in Oncomine. All of the prostate cancer concepts with odds ratio > 2.0 
and P value < 1 × 10 were selected. Top concepts (based on odds ratios) were selected for 
representation. We exported these results as the nodes and edges of a concept association 
network and visualized the network using Cytoscape version 3.3.0. Node positions were 
computed using the edge-weighted force directed layout in Cytoscape using the odds ratio 
as the edge weight. Node positions were subtly altered manually to enable better 
visualization of Mode labels[7]. 
 
RNA ISH on tissue microarray 
ISH assays were performed on tissue microarray sections from Advanced Cell Diagnostics, 
Inc. as described previously[8]. In total, 133 tissue samples were included (11 from benign 
prostate, 85 from localized prostate cancer and 37 from metastatic prostate cancer). 
ARLNC1 ISH signals were examined in morphologically intact cells and scored manually 
by a study pathologist, using a previously described expression value scoring system[9]. 
For each tissue sample, the ARLNC1 product score was averaged across evaluable TMA 
tissue cores. Mean ARLNC1 product scores were plotted in Figure 3.1C. 
 
RACE 
5ˈ and 3ˈ RACE were performed to determine the transcriptional start and termination sites 





Northern blot analysis 
NorthernMax-Gly Kit (Ambion) was used for ARLNC1 detection following the 
manufacturer’s protocol. Briefly, 20 μg of total RNA was resolved on a 1% agarose glyoxal 
gel and then transferred to nylon membrane (Roche), crosslinked to the membrane (UV 
Stratalinker 1800; Stratagene) and the membrane was prehybridized. Overnight 
hybridization was performed with a ARLNC1-specific P - labeled RNA probe. Membranes 
were exposed to HyBlot CL autoradiography film (Denville Scientific). The primer 








RNA isolation and cDNA synthesis 
Total RNA from cell lines was isolated using QIAzol Lysis reagent (QIAGEN) and 
miRNeasy kit (QIAGEN) with DNase digestion according to the manufacturer’s 





qRT–PCR analysis  
Relative RNA levels determined by qRT–PCR were measured on an Applied Biosystems 
7900HT Real-Time PCR System, using Power SYBR Green MasterMix (Applied 
Biosystems). All of the primers were obtained from Integrated DNA Technologies, and 
gene-specific sequences are listed in Table 3.1. GAPDH, HMBS and ACTB were used as 
internal controls for quantification of gene targets. The relative expression of RNAs was 
calculated using the ΔΔCt method. 
 
Cytoplasmic and nuclear RNA purification 
Cell fractionation was performed using the NE-PER nuclear extraction kit (Thermo 
Scientific) according to the manufacturer’s instructions. RNA was extracted using the 
previously mentioned protocol. 
 
siRNA-mediated knockdown 
Transfections with siRNA (50 nM) were performed with Lipofectamine RNAiMAX 
according to the manufacturer’s instructions. RNA and protein were harvested for analysis 
72 h after transfection. 
 
ASO-mediated knockdown 
ASOs targeting ARLNC1 were obtained from Ionis Pharmaceuticals. Transfections with 
ASOs (50 nM) were performed with Lipofectamine RNAiMAX according to the 
manufacturer’s instructions. RNA and protein were harvested for analysis 72 h after 
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transfectionufacturer’s instructions. RNA and protein were harvested for analysis 72 h after 
transfection. 
 
Gene expression profiling 
Total RNA was extracted following the aforementioned protocol. RNA integrity was 
assessed using the Agilent Bioanalyzer. Microarray analysis was carried out on the Agilent 
Whole Human Oligo Microarray platform, according to the manufacturer’s protocol. 
siRNA-mediated knockdown experiments were run in triplicates, comparing knockdown 
samples treated with two independent ARLNC1 siRNAs to samples treated with non-
targeting control siRNA. ASO-mediated knockdown experiments were run in replicates, 
comparing knockdown samples treated with two ARLNC1 ASOs to samples treated with 
non-targeting control. An AR signature was generated using MDA-PCa-2b cells treated 
with 10 nM DHT in triplicates. 
 
Analysis of Agilent 44k microarrays was carried out using limma[10] and included 
background subtraction (bc.method = ‘half’, offset = 100) and within-array normalization 
(method = ‘loess’). Between-array quantile normalization of average expression levels (but 
not log-fold changes) was performed using the function normalizeBetweenArrays (method 
= ‘Aquantile’). Control probes and probes with missing values were excluded from further 
analyses. Probes were annotated to Gencode v22 genes using the mapping downloaded 
from Ensembl (efg_agilent_wholegenome_4 × 44k_v2). Probes originally annotated as 
85 
 
AK093002 were used to detect ARLNC1. Differentially expressed genes following 
ARLNC1 knockdown in MDA-PCA-2b cells were identified from triplicate biological 
repeats using adjusted P value < 0.1 and absolute log fold-change > 0.6 cutoffs. Consensus 
targets of ARLNC1 knockdown using siRNA and ASOs were identified using a merged 
linear model (all 10 samples treated replicates) and a P value < 0.001 cutoff. 
 
Cell proliferation assay 
Cells treated with siRNAs or ASOs were seeded into 24-well plates and allowed to attach. 
Cell proliferation was recorded by IncuCyte live-cell imaging system (Essen Biosciences), 
following the manufacturer’s instructions. 
 
Apoptosis analysis 
Cells were grown in 6-well plates and transfected with nonspecific siRNA or siRNAs 
targeting ARLNC1. Apoptosis analysis was performed 48 h after transfection, using the 




Cells were lysed in RIPA lysis and extraction buffer (Thermo Scientific no. 89900) 
supplemented with protease inhibitor cocktail (ROCHE no. 11836170001). Protein 
concentrations were quantified using the DC protein assay (BIO-RAD), and protein lysates 
were boiled in sample buffer. Protein extracts were then loaded and separated on SDS–
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PAGE gels. Blotting analysis was performed with standard protocols using polyvinylidene 
difluoride membrane (GE Healthcare). Membranes were blocked for 60 min in blocking 
buffer (5% milk in a solution of 0.1% Tween-20 in Tris-buffered saline (TBS-T)) and then 
incubated overnight at 4 °C with primary antibody. After three washes with TBS-T, 
membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary 
antibody. Signals were visualized with an enhanced chemiluminescence system as 
described by the manufacturer (Thermo Scientific Pierce ECL Western Blotting Substrate). 
Primary antibodies used were: androgen receptor (1:1000 dilution, Millipore, no. 06-680, 
rabbit), GAPDH (1:5000 dilution, Cell Signaling, no. 3683, rabbit), PSA (KLK3)(1:5000 
dilution, Dako, no. A0562, rabbit) and cleaved PARP (1:1,000 dilution, Cell Signaling, no. 
9542, rabbit). 
 
In vivo experiments 
All experiments were approved by the University of Michigan Institutional Animal Care 
and Use Committee. For tumor generation with shRNA-mediated knockdown, shRNA 
targeting ARLNC1 was cloned in pSIH1-H1-copGFP-T2A-Puro (System Biosciences). 
Lentiviral particles were generated at the University of Michigan Vector Core. LNCaP-AR 
cells were infected with lentivirus expressing ARLNC1 shRNA for 48 h. Knockdown of 
ARLNC1 was confirmed by qPCR analysis. Male athymic nude mice were randomized 
into two groups at six to eight weeks of age. Five million cells expressing sh-ARLNC1 or 
sh-vector were injected into bilateral flanks of mice. Caliper measurements were taken in 
two dimensions twice a week by an investigator blinded to the study objective and used to 
87 
 
calculate tumor volume. The study was terminated when the tumor volume reached 1,000 
mm. For ASO treatment in vivo, six- to eight-week-old male athymic nude mice were 
inoculated subcutaneously with MDA-PCa-2b cells suspended in a Matrigel scaffold in the 
posterior dorsal flank region (5 million cells per site, two sites per animal). When the mean 
tumor volume reached approximately 150 mm3, mice were randomized into two groups, 
and respectively treated with ARLNC1-specific or control ASO. ASOs, dosed at 50 mg/kg, 
were subcutaneously injected between the scapulae once daily for three periods of five 
days on/two days off. Tumor size was measured twice per week using a digital caliper by 
a researcher blinded to the study design. Mouse body weights were monitored throughout 
the dosing period. When the average tumor size in the control group reached 1,500 mm3, 
mice were euthanized and the primary tumors were excised for weight determination. One 
third of the resected specimen was placed in 10% formalin buffer, and the remaining tissue 
was snap-frozen. For in vivo experiments, power analysis (GPOWER software) performed 
for each tumor type tested to date indicates that the sample size we chose yields a statistical 
power >90% for detection of tumor size reduction of 40%. Sample sizes were not pre-
determined for all other assays. For in vivo experiments, animals were randomized. 










Figure 3.1 Expression of ARLNC1 across lineages and within prostate cancer 
(A) Relative expression (FPKM) of ARLNC1 across different cancer types in the TCGA cohort.  
(B) Relative expression (FPKM) of ARLNC1 across a panel of normal tissues in the GTEx normal 
tissue RNA-seq cohort (n = 9,435 samples) (http://www.gtexportal.org/). Box-plot definitions: 
center, median; box limits, 1st and 3rd quartiles; whiskers follow the 1.5 rule. 
(C) relative expression (FPKM) of ARLNC1 across benign prostate (n = 52 samples), localized 
prostate cancer (n = 500 samples) and metastatic prostate cancer (n = 100 samples). PCa versus 
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Normal: ****P < 2.2 × 10−16; Mets versus Normal: ****P = 2.6 × 10−7 (two-sided t test). Box-plot 
definitions: the center line depicts the median, the box shows the first and third quartiles, 
and the whiskers follow the 1.5 rule. 
(D) ISH of ARLNC1 transcript in a human prostate cancer tissue microarray. Representative 
ARLNC1 staining is shown for benign prostate and localized and metastatic prostate cancer tissue. 
The bar plot represents mean ARLNC1 expression scores across benign prostate (n = 11), localized 
prostate cancer (n = 85) and metastatic prostate cancer (n = 37) tissues, with vertical bars indicating 
the bootstrapped 95% confidence interval of the means. Significance was calculated by a Kruskal–























Figure 3.2 ARLNC1 related signatures in prostate cancer 
(A) Tissue- and cancer-specific expression of ARLNC1 according to MiTranscriptome. The SSEA 
test (total n = 7,256 samples) was used to determine whether each gene was significantly associated 
with a set of samples (e.g., prostate cancer) or cancer progression in a given lineage (e.g., prostate 
normal to prostate cancer). The genes were ranked according to their strength of 
association. Shown is the percentile rank for ARLNC1 (enrichment-positive, depletion-negative) 
across the tested sample sets/comparisons.   
(B) Oncomine concepts analysis of genes positively or negatively (bottom) correlated with 
ARLNC1. The network was visualized using the force-directed layout algorithm in the Cytoscape 
tool, with node sizes representing the number of genes in each molecular concept and node names 
indicating the author of the primary study. 
(C) ARLNC1 expression levels are not associated with Gleason score. AURKA expression levels 
are significantly associated with Gleason score. Based on n = 500 samples from TCGA. 
Significance was determined by two-sided t test. Box-plot definitions: center, median; box limits, 
1st and 3rd quartiles; whiskers follow the 1.5 rule. 
(D) Tumor content estimated from whole exome sequencing is compared between high (top 
quartile) and low (bottom quartile) ARLNC1 expression in mCRPC samples (n = 100). Box-plot 
definitions: center, median; box limits, 1st and 3rd quartiles; whiskers follow the 1.5 rule. 
(E) Signatures associated with prostate cancer and luminal differentiation were selected from 
MSigDB and contrasted between the ARLNC1-high (top quartile) and ARLNC1-low (bottom 
quartile) mCRPC samples (n = 100). The z score represents the effect-size and direction for the 
relative signature enrichment. For each signature ‘Up’ signifies that a signature is expected to be 
upregulated in the tested condition; conversely, ‘Dn’ signifies that a signature is expected to be 
downregulated. 
(F) Curated pathway signature analysis between ARLNC1-high (top-quartile) and ARLNC1-low 
(bottom-quartile) mCRPC samples (n = 100). The z score represents the effect size and direction 
for the relative signature enrichment. 
(G) Cancer hallmark signature analysis between ARLNC1-high-expression (top quartile) and 
ARLNC1-low-expression (bottom quartile) mCRPC samples (n = 100 samples). The z score 
represents the effect size and direction for the relative signature enrichment, determined by two-














Figure 3.3 Characterization of ARLNC1 transcript 
(A) Relative expression of ARLNC1 (FPKM) across 14 prostate cancer cell lines.  
(B) qPCR analysis of ARLNC1 expression in nine prostate cancer cell lines. Expression levels of 
several known prostate cancer-associated lncRNAs are also shown. Mean ± s.e.m. values are 
graphed, n = 3. 
(C) Left, representative image of ARLNC1 gene structure in AR-positive prostate cancer cells. 
Annotations of ARLNC1 in Ensembl and the Encyclopedia of DNA Elements (ENCODE) are also 
shown. Inset, expression of ARLNC1 transcripts in MDA-PCa-2b cells, validated by northern blot. 
ARLNC1-negative DU145 cells serve as a negative control.  
(D) 5’ RACE and 3’ RACE results in MDA-PCa-2b cells and LNCaP cells. Experiments were 










Figure 3.4 Cellular localization of ARLNC1 
(A) smFISH images depicting localization of ARLNC1 transcripts in a panel of prostate cancer cell 
lines. Representative pseudocolored images are shown of MDAPCa-2b, LNCaP, VCaP, 22Rv1, 
PC3, RWPE, and DU145 cells probed for ARLNC1 (gray) or GAPDH (gray, control). The nucleus 
is stained with DAPI (blue). Scale bar, 5 μm; n = 3 independent experiments for each cell line.  
(B) Scatterplot representing the average number of ARLNC1 transcripts per cell in a panel of 
prostate cancer cell lines, including MDA-PCa-2b, LNCaP, VCaP, 22Rv1, PC3, RWPE, and 
DU145. The black line and whiskers depict the mean and s.e.m., respectively (n = 50 cells for each 
cell line aggregated from three independent experiments). 
(C) Percentage of nuclear/cytoplasmic RNA levels of ARLNC1, ACTB, and U1, measured by 
qRT–PCR after subcellular fractionation of MDA-PCa-2b and LNCaP cells. U1 serves as a positive 
control for nuclear gene expression, while ACTB RNA serves as a positive control for cytoplasmic 
gene expression. The graphs show the mean ± s.e.m., n = 3 independent experiments for each cell 
line. 
(D) Representative grayscale images of MDA-PCa-2b cells stained for DAPI (nucleus, blue) and 
ARLNC1, AR, or GAPDH transcripts (smFISH, gray). Scale bar, 10 μm. Quantification of the 
number of molecules per cell and the nucleo-cytoplasmic distribution of each transcript are also 
represented (n = 60 cells for each sample aggregated from three independent experiments). The 





Figure 3.5 Changes on basic cell functions following siRNA-mediated ARLNC1 loss  
(A) siRNA-mediated knockdown of ARLNC1 in vitro in AR-positive prostate cancer cell lines 
(MDA-PCa-2b and LNCaP) inhibits cell proliferation. Mean ± s.d. values are shown, n = 6 
independent cell cultures per group, **P (adjusted) = 0.0001 compared to si-NT-treated cells, by 
one-way ANOVA with Dunnett’s multiple-comparisons test. 
(B) Loss of ARLNC1 does not affect cell growth in AR-negative prostate cell lines DU145 and 
PC3. P value not significant (NS) compared to si-NT-treated cells, by one-way ANOVA. 
(C) Top: siRNA knockdown of ARLNC1 in LNCaP-AR cells inhibits cell proliferation. Mean ± 
s.e.m. are shown, n = 4, **Adjusted P < 0.001 compared to siNT treated cells, by one-way ANOVA 
analysis. Bottom: Knockdown efficacy of siRNAs targeting ARLNC1 in LNCaP-AR cells. Mean 
± s.e.m. are shown, n = 3. **P < 0.001 compared to siNT group by two-tailed Student’s t-test. 
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(D) Knockdown efficacy of three independent siRNAs targeting ARLNC1 in MDA-PCa-2b cells. 
Mean ± s.e.m. values are shown, n = 3. ***P = 0.0001 determined by ANOVA with Dunnett 
correction. 
(E) ARLNC1 loss leads to increased apoptosis as shown by western blot analysis of PARP and 
cleaved PARP in LNCaP cells following ARLNC1 knockdown. The experiment was repeated 
independently three times with similar results. 
(F) Increased apoptosis observed in MDA-PCa-2b and LNCaP cells 48 h after transfection with 
ARLNC1 siRNAs. ARLNC1-negative PNT2 cells serve as a negative control. Fold change of 
apoptosis was calculated relative to si-NT-treated samples. n = 3 independent cell cultures. Mean 






















Figure 3.6 Effect of ARLNC1 loss generated by CRISPR-Cas9 
(A, B) In HEK-293T cells (A) and PC3 cells (B), genomic PCR indicates loss of ARLNC1 genomic 
region. Proliferation curve indicates same proliferation rate between WT clone and ARLNC1 
knockout clone. 
(C, D) Pool of MDA-PCa-2b cells (C) or LNCaP cells (D) were treated with guide RNA pairs 
targeting ARLNC1, and monitored for 5 passages. Genomic PCR analysis of ARLNC1 genomic 
region and qPCR analysis of ARLNC1 transcript indicate a diminishing population with ARLNC1 














Figure 3.7 Changes on basic cell functions following ASO-mediated ARLNC1 knockdown 
(A) The positions of ARLNC1 ASO-targeting sites (1-6) are indicated on the schematic 
representation of the ARLNC1 transcript.  
(B) MDA-PCa-2b cells were transfected with six independent ASOs targeting ARLNC1. 
Knockdown efficacy was evaluated by qPCR analysis. Mean ± s.e.m. values are shown, n = 3. ***P 
= 0.0001 determined by ANOVA. 
(C) Transfection of ASOs targeting ARLNC1 in AR-positive MDA-PCa-2b cells inhibits cell 
proliferation. The AR-negative prostate cell line PNT2 serves as a negative control. Mean ± s.e.m. 
values are shown, n = 6 independent cell cultures per treatment group. *P (adjusted) = 0.0112, **P 
(adjusted) = 0.0065, NS: not significant; compared to the control-ASO group by one-way ANOVA 
with Dunnett correction for multiple comparisons. 
(D) The free-uptake efficacy of ARLNC1 ASOs was examined in MDA-PCa-2B cells 72h after 
ASO addition to the culture medium (10 μM). ARLNC1 expression was evaluated by qPCR 
analysis. Mean ± s.e.m. values are shown, n = 3. ***P = 0.0001, **P = 0.0032; determined by 
ANOVA with Dunnett correction. 
(E) Free-uptake treatment with ASOs targeting ARLNC1 resulted in retarded growth of MDA-
PCa-2b cells in vitro. ARLNC1-negative prostate cell line PNT2 served as a negative control. Mean 





Figure 3.8 Transcriptome changes induced by ARLNC1 silencing 
(A) Gene expression profiling for ARLNC1 knockdown in MDA-PCa-2b cells (n = 3 biologically 
independent cell cultures for each siRNA). The chart presents the top enriched pathways following 
ARLNC1 knockdown, identified using GO enrichment analysis (RandomSet test). 
(B) Gene expression profiling for siRNA-mediated or ASO-mediated ARLNC1 knockdown in 
MDA-PCa-2b cells. The numbers above the heat map represent the specific microarray replicates. 
(C) Correlation analysis of siRNA-mediated knockdown and ASO-mediated knockdown of 
ARLNC1 among replicated microarray experiments in MDA-PCa-2b cells (n = 2 biological 
replicates per ASO treatment group and n = 3 biological replicates per siRNA treatment group). 
(D) qRT–PCR analysis of ARLNC1, AR, KLK2, KLK3, and STEAP2, in MDA-PCa-2b cells 
transfected with siRNAs against ARLNC1, AR, EZH2, or non-specific control. siRNA against AR 
serves as a positive control for inhibited AR signaling, while siRNA against EZH2 serves as a 
negative control. Mean ± s.e.m. values are shown, n = 3. ***P < 0.001; ns, not significant, 
determined by ANOVA. 
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(E) qRT–PCR analysis of ARLNC1, AR and AR targets (KLK2, KLK3, FKBP5 and STEAP2) in 
MDA-PCa-2b cells transfected with ASOs against ARLNC1. Data were normalized to a 
housekeeping gene, and the levels in control ASO-treated cells were set to 1. Mean ± s.e.m. values 
are shown, n = 3. Adjusted P values were determined by one-way ANOVA with Dunnett correction 
















































Figure 3.9 Phenotypic effect following ARLNC1 silencing in cell line derived xenograft.  
(A) Tumor growth of LNCaP-AR cells expressing shRNA targeting ARLNC1 or shRNA vector. 
Mean ± s.e.m. values are shown. n = 10 independent tumors, ***P < 0.0001, **P = 0.0007, as 
determined by two-tailed Student’s t test. 
(B-C) ARLNC1 ASOs inhibit MDA-PCa-2b cell proliferation in the 3D sphere models. Cells were 
harvested at the end of the experiment, and ARLNC1 expression was evaluated by qPCR analysis. 
Mean ± s.d. values are shown, n = 6. ***P < 0.0001 compared to control-ASO-treated cells, by 
two-tailed Student’s t test. 
(D) Effect of ASO treatment on the growth of MDA-PCa-2b xenografts in male athymic nude mice, 
with control ASO (n = 15) or ARLNC1 ASO (n = 13) treatment subcutaneously at 50 mg per kg 
body weight, five times per week for 3 weeks. Tumors were measured by caliper biweekly and 
tumor weights were measured at the end point. Mean ± s.d. values are shown. *P = 0.0251, ***P 
< 0.0001; compared to control ASO by two-tailed Student’s t test. 
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(E) Percentage change in mouse body weight over the time of ASO treatment in MDA-PCa-2b 
xenografts treated with control ASO (n = 15) or ASO targeting ARLNC1 (n = 13). Mean ± s.e.m. 
values are shown. Significance was determined by two-tailed Student’s t test. 
(F) Representative image of in situ hybridization for ARLNC1 in MDA-PCa-2b cell line–derived 
xenograft. H&E staining is shown for tumor tissue and murine kidney. 
(G) qRT–PCR analysis of ARLNC1, NKX3-1, and AR in MDA-PCa-2b xenografts treated with 
control ASO (n = 15) or ASO targeting ARLNC1 (n = 13). Data were normalized to a housekeeping 
gene (GAPDH), and the average expression level in the control ASO group was set to 1. Mean ± 
s.e.m. values are shown. *P = 0.0483, ***P = 0.0004; compared to control group by two-tailed 
Student’s t test. 
(H) Left, immunoblots of AR and GAPDH in MDA-PCa-2b xenografts treated with control ASO 
(n = 15) or ASO targeting ARLNC1 (n = 13). Right, the relative intensity of the bands was 
quantified using ImageJ. Mean ± s.e.m. values are shown. **P < 0.005; ns, not significant; 
compared to the control-ASO-treated group by two-tailed Student’s t test.  
(I) Left, immunohistochemistry staining for Ki67 in MDA-PCa-2b xenograft treated with control 
ASO or ASO against ARLNC1. Right, summary of Ki67 tumor staining for control (n = 15) or 
ARLNC1-ASO-treated tumors (n = 13) shows significant difference in Ki67 staining intensity. 
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ARLNC1, a lineage-specific long-noncoding RNA that regulates 
Androgen Receptor signaling axis1 
 
Abstract 
Having characterized the basic transcript features and functional phenotypes of ARLNC1, 
we went on to investigate the mechanisms that drive ARLNC1 expression, and explore 
how ARLNC1 regulates the AR-signaling axis. In this Chapter, we identified the 
transcription factors that drive ARLNC1 expression in a lineage-specific manner, each of 
which have been previously reported to interact with AR, and therefore underscores AR as 
the major regulator. In addition, we have dissected the cellular mechanism of ARLNC1-
mediated modulation of AR transcripts, and find that the lncRNA affects the cytoplasmic 
level of the AR transcripts. ARLNC1 regulates AR mRNA post-transcriptionally via 
specific RNA-RNA associations in situ. our results now robustly demonstrate a 
feedforward loop in AR signaling axis, where AR, in concert with other lineage specific 
                                                          
1 This chapter was previously published as part of the following manuscript: Zhang, Y., et al., Analysis of 
the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer 
progression. Nat Genet, 2018. 50(6): p. 814-824. 
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factors, transcriptionally regulates ARLNC1, and that ARLNC1 regulates its master 
regulator (AR) post-transcriptionally. 
 
Introduction 
Recently, out group identified a prostate lineage-specific, pro-oncogenic lncRNA named 
ARLNC1 that is overexpressed in prostate cancers. Subsequent studies found that 
ARLNC1 possesses diagnostic potential for both primary and metastatic prostate cancer. 
Phenotypically, ARLNC1 silencing inhibits cell proliferation and induces apoptosis. 
Interestingly, analysis of ARLNC1-regulated transcriptome revealed enrichment of AR 
targets. ARLNC1 loss resulted in attenuated global AR signaling.  
 
However, several questions remain regarding ARLNC1 expression pattern and functions: 
(1) What are the transcription factors that determine its prostate lineage-specific expression 
pattern? (2) What is the mechanistic nature of ARLNC1 regulation of AR signaling? Is it 
mediated by RNA-chromatin, RNA-RNA, or RNA-protein interactions? 
 
Results 
ARLNC1 is directly regulated by AR and FOXA1 
Since ARLNC1 was identified as an AR-regulated lncRNA, we asked the question whether 
ARLNC1 is directly or indirectly regulated by AR. We thus inspected the ARLNC1 
promoter region for AR occupancy in AR ChIP-Seq data from both DHT-stimulated VCaP 
and LNCaP cells (Figure 4.1A). An androgen-induced AR peak was identified in both cell 
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lines. Importantly, this AR-binding site was also observed in prostate tissue samples and 
contained a canonical androgen response element[1] (Figure 4.1A). These observations 
were corroborated by ChIP–qPCR in MDA-PCa-2b cells, which showed the highest level 
of ARLNC1 expression (Figure 4.1B). Considering the observation that ARLNC1 
expression is prostate tissue-specific, while AR expression is not as much, we searched for 
additional regulators (transcription factors and epigenetic modifiers) of this gene (Figure 
4.2). Motif analysis of the ARLNC1 promoter region identified several transcription factor 
binding sites, including a FOXA1 response element. To further validate ARLNC1 gene 
regulation by AR and FOXA1, we evaluated ARLNC1 transcript levels following AR or 
FOXA1 knockdown. AR or FOXA1 loss resulted in decreased expression of ARLNC1, 
along with other canonical AR target genes that served as positive controls (Figure 4.1C, 
Figure 4.3A). ChIP-Seq and ChIP–PCR analysis additionally confirmed the putative 
FOXA1-binding motif on the ARLNC1 promoter (Figure 4.3B). Together, these 
observations suggest that ARLNC1 is directly regulated by AR and modestly regulated by 
FOXA1, which partially explains the tissue-specific expression pattern of ARLNC1, as 
expression of these two factors overlaps nearly exclusively in prostate tissue[2, 3] (Figure 
4.3C). 
 
ARLNC1 affects AR signaling 
In the previous chapter, we performed gene expression profiling of wild-type and 
ARLNC1-knockdown MDA-PCa-2b cells (Figure 3.8A). Gene ontology (GO) pathway 
enrichment analysis of the differentially expressed genes revealed deregulation of 
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androgen signaling, and this finding was corroborated by qPCR analysis (Figure 3.8D, E). 
To confirm this observation, we generated an AR target gene signature from MDA-PCa-
2b cells stimulated with DHT and performed gene set enrichment analysis (GSEA) using 
this gene signature (Figure 4.4A-B). Knockdown of ARLNC1 led to suppression of genes 
positively regulated by AR and upregulation of genes negatively regulated by AR (Figure 
4.4A, C). This was further confirmed by an AR reporter activity assay (Figure 4.4G-H). 
Interestingly, ARLNC1 knockdown also had a significant effect on the messenger RNA 
and protein levels of AR (Figure 4.4E-F), suggesting direct regulation of AR by ARLNC1. 
However, we found that ARLNC1 overexpression did not affect AR and its signaling 
cascade (Figure 4.4I). 
 
RNA-RNA interaction between ARLNC1 and AR in vitro and in situ 
Non-coding RNAs have been shown to target mRNAs via direct or indirect RNA–RNA 
interaction[4-8]. To identify target mRNAs that could interact with ARLNC1, we 
performed an unbiased prediction of RNA–RNA interactions using IntraRNA[9, 10]. 
Interestingly, the 3’ UTR of the AR transcript was identified as a target of ARLNC1 
(Figure 4.5A-B). An in vitro RNA–RNA interaction assay between the 3’ UTR of AR and 
full-length ARLNC1 confirmed this in silico prediction (Figure 4.5C). To evaluate this 
interaction in the context of the cellular environment, multiplexed smFISH for AR and 
ARLNC1 transcripts was performed in MDA-PCa-2b cells. On co-staining MDA-PCa-2b 
cells with either AR and a panel of lncRNAs, or ARLNC1 and a panel of mRNAs, we 
observed specific co-localization between AR and ARLNC1 transcripts in the nucleus 
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within foci that were typically larger than individual molecules (Figure 4.5D, H). The 
extent of colocalization was much higher than that expected from co-incidental co-
localization with an abundant transcript, such as MALAT1 or GAPDH (Figure 4.5E-F). 
More specifically, co-localization typically occurred at a stoichiometry of 2:1 
ARLNC1/AR, which accounted for ~10–20% of all AR and ARLNC1 transcripts in the 
cell (Figure 4.5G). Furthermore, AR–ARLNC1 co-localization was observed in 
ARLNC1-positive prostate cancer tissues (Figure 4.6).  
 
Domain on ARLNC1 that mediates its interaction with AR  
Using an in vitro RNA–RNA binding assay, we identified nucleotides (nt) 700–1300 of 
ARLNC1 to be critical for binding to the AR 3ˈ UTR (Figure 4.7A-B). To confirm this 
observation within the cellular context, we ectopically overexpressed different fragments 
of ARLNC1 together with AR in U2OS osteosarcoma cells. In this exogenous system, co-
localization between AR and ARLNC1 was once again demonstrated, wherein co-
localization was dependent on the presence of nt 700–1300 of ARLNC1 (Figure 4.7C-D). 
Furthermore, incubation with a pool of antisense oligonucleotides (ASOs) that blocked the 
interaction sites led to a significant reduction in ARLNC1-AR interaction in vitro and in 
situ (Figure 4.8A-E). Decreased AR signaling was also observed following blocking of 
this interaction (Figure 4.8F-G). 
 
ARLNC1 regulates the cytoplasmic levels of AR transcripts. 
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We then sought to delineate the mechanism of ARLNC1-mediated AR regulation. We first 
monitored the stability of these two transcripts and found that AR and ARLNC1 have 
similar half-lives of ~9 h (Figure 4.9A). As ARLNC1 depletion resulted in a striking 
reduction of AR protein levels, much more than could be explained by AR transcript 
reduction, we hypothesized that ARLNC1 could affect AR post-transcriptionally. To test 
this hypothesis, we tracked subcellular localization of AR transcripts using smFISH after 
depleting ARLNC1. We confirmed successful in situ knockdown of ARLNC1 using 
siRNAs, antisense oligonucleotide (ASO) and the blocking oligonucleotides that targeted 
ARLNC1-AR interaction (ASO-blocking) in MDA-PCa-2b cells (Figure 4.9B-C). 
 
Quantification of the subcellular distribution of ARLNC1 suggested that the nuclear 
fraction of ARLNC1 was enriched only in the ARLNC1 siRNA (si-ARLNC1) condition 
(Figure 4.9E), a result that was expected for siRNAs that are typically more functional in 
the cytosol[11]. Surprisingly, ARLNC1 knockdown or obstruction of the AR-ARLNC1 
interaction increased the nuclear AR fraction by dramatically decreasing cytoplasmic 
levels of the AR transcript (Figure 4.9F-G). This observation was further supported by 
BrU-Seq and BrUChase-Seq, two high-throughput tools that monitor transcript synthesis 
and stability. On ARLNC1 knockdown, the synthesis rate of the AR transcript remained 
the same, while the stability of the transcript decreased, particularly through the 3’ UTR 
region (Figure 4.9D). Taken together, our data suggest that ARLNC1 regulates the 
cytoplasmic levels of AR transcripts. Furthermore, the transcriptional coupling between 
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Our results now robustly demonstrate that AR, together with other lineage specific 
cofactors, transcriptionally regulates ARLNC1, and that ARLNC1 regulates its master 
regulator (AR) post-transcriptionally via co-localizing to AR mRNA (Figure 4.10). While 
lncRNAs are commonly shown to stabilize mRNAs via genomically anti-sense 
mechanisms, we found that two transcripts from distinct chromosomal loci could associate 
inside cells to regulate mRNA abundance. The mechanism we identified echoes previous 
studies on lncRNAs: 1/2-sbsRNAs[6], BACE1-AS[5] and TINCR[8], which highlights the 
role of lncRNA in increasing or decreasing RNA stability. Moreover, acting upstream of 
AR signaling presents the possibility that targeting ARLNC1 may afford an additional 
option to patients that have de novo or acquired resistance to therapies targeting AR itself 
(enzalutamide or abiraterone, etc).  
 
Materials and Methods 
ChIP–qPCR assay 
AR, FOXA1 or NKX3-1 ChIP was performed following our previous protocol[12]. 
(Antibodies: AR, Millipore cat. no. 06-680; FOXA1, Thermo Fisher cat. no. PA5-27157; 
NKX3-1, CST cat. no. 83700S.) Primers targeting the CYP2B7 promoter were purchased 




ChIP-Seq data analysis 
ChIP-Seq data from published external and in-house data sets, GSE56288 and GSE55064, 
were reanalyzed using a standard pipeline. Briefly, groomed reads (vendor QC, adapter 
removal) were aligned to the GRCh38 reference genome using STAR settings that disable 
spliced alignment: outFilterMismatchNoverLmax: 0.05, outFilterMatchNmin: 16, 
outFilterScoreMinOverLread: 0, outFilterMatchNminOverLread: 0, alignIntronMax: 1. 
Improperly paired alignments and non-primary alignments were discarded. Peaks were 
called using MACS2 (callpeak --broad --qvalue 0.05 --broad-cutoff 0.05 and callpeak –
callsummits --qvalue 0.05)[13] and Q (-n 100000)[14]. ChIP enrichment plots were 
computed from alignment coverage files (BigWig)[15] as trimmed (trim = 0.05) smooth 
splines (spar = 0.05). The baseline (non-specific) ChIP signal was estimated from genomic 
windows furthest from the center of the queried region (peak summit, TSS) and subtracted 
from each signal before plotting. 
 
siRNA-mediated knockdown 
siRNA oligonucleotides targeting ARLNC1, AR, FOXA1, BRD4, NKX3-1, LSD1, IRF1, 
POU1F1 or EZH2 and a non-targeting siRNA were purchased from Dharmacon. (si-AR-
pool, cat. no. L-003400-00-0005; si-FOXA1, cat. no. LU-010319-00-0005; si-BRD4, cat. 
no. LU-004937-00-0002; si-NKX3-1, cat. no. LU-015422-00-0005; si-LSD1, cat. no. LU-
009223-00-0002; si-IRF1, cat. no. LU-011704-00-0005; si-POU1F1, cat. no. LU-012546-
00-0005; si-EZH2, cat. no. L-004218-00-0005; si-NT, cat. no. D-001810-01-05.) For AR 
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knockdown, two more siRNAs were purchased from Life Technologies (no. HSS179972 
and no. HSS179973). Transfections with siRNA (50 nM) were performed with 
Lipofectamine RNAiMAX according to the manufacturer’s instructions. RNA and protein 
were harvested for analysis 72 h after transfection. 
 
Gene Set Enrichment Analysis 
Enrichment analyses for custom and experimentally derived signatures (that is, AR targets, 
genes upregulated and downregulated following DHT treatment) were carried out using 
the non-parametric GSEA software with all default settings. For GO term enrichment, we 
applied the parametric randomSet enrichment statistic to voom–limma-estimated fold-
changes (see Method from the last Chapter). 
 
Androgen receptor reporter gene assay 
Dual luciferase reporter assays were performed using the Cignal Androgen Receptor 
Reporter Kit (Qiagen) according to the manufacturer’s instructions. Briefly, cells were co-
transfected with siRNAs (nonspecific, targeting AR or ARLNC1) and reporter vectors 
(negative control or AR reporter), using Lipofectamine 2000 transfection reagent (Thermo 
Fisher Scientific). Forty hours after transfection, DHT (or ethanol vehicle control) was 
added to induce AR signaling. The Dual Luciferase assay was conducted 8 h after DHT 
stimulation, using the Dual Luciferase Reporter Assay System from Promega (cat no. 
1910). Reporter activity was analyzed on the basis of the ratio of Firefly/Renilla to 




Overexpression of ARLNC1 
Full-length ARLNC1 was amplified from MDA-PCa-2b cells and cloned into the pCDH 
clone and expression vector (System Biosciences). Insert sequences were validated by 
Sanger sequencing at the University of Michigan Sequencing Core.  
 
RNA in vitro transcription 
Linearized DNA templates for full-length ARLNC1, ARLNC1 fragments, ARLNC1 
deletion, antisense ARLNC1, LacZ, SCHLAP1-AS, THOR and AR-3’ UTR-1-980 were 
synthesized using T7-containing primers (Table 4.1). In vitro transcription assays were 
performed with T7 RNA polymerase (Promega) according to the manufacturer’s 
instructions. For BrU-labeled RNA synthesis, 5-bromo-UTP was added to the transcription 
mix. At the end of transcription, DNA templates were removed by Turbo DNase 
(ThermoFisher), and RNA was recovered using RNA Clean and Concentrator Kit 
(Promega). RNA size and quality was further confirmed by the Agilent Bioanalyzer.  
 
RNA–RNA in vitro interaction assay 
Twenty-five microlitres of Protein A/G Magnetic Beads were washed twice with RIP wash 
buffer (Millipore, cat. no. CS203177) before incubating with BrU antibody for 1 h at room 
temperature. After antibody conjugation, beads were washed twice with RIP wash buffer 
and then resuspended in incubation buffer containing RIP wash buffer, 17.5 mM EDTA 
(Millipore, cat. no. CS203175) and RNase Inhibitor (Millipore, cat. no. CS203219). Equal 
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amounts (5 pmol) of BrU-labeled RNAs (ARLNC1, ARLNC1-AS, ARLNC1-1-1300, 
ARLNC1-1301-2786, ARLNC1-1-700, ARLNC1-701-1300, ARLNC1-del-701-1300, 
LacZ, SCHLAP1-AS, THOR) were incubated with beads in Incubation Buffer for 2 h at 4 
°C. Following incubation, 2.5 pmol of the AR 3ˈ UTR-1–980 RNA fragment was added 
into individual tubes and incubated overnight at 4 °C. After incubation, beads were washed 
six times with RIP Wash Buffer. To recover RNA, beads were digested with proteinase K 
buffer containing RIP Wash Buffer, 1% SDS (Millipore, cat. no.CS203174), and 1.2 μg/μl 
proteinase K (Millipore, cat. no. CS203218) at 55 °C for 30 min with shaking. After 
digestion, RNA was extracted from supernatant using the miRNeasy kit (QIAGEN), and 
reverse transcription was performed using the Superscript III system (Invitrogen). The 
amount of AR 3’ UTR-1–980 recovered in each interaction assay was quantified by qPCR 
analysis. Data were normalized to the ARLNC1-AS control, using the ΔCt method. We 
designed ASOs blocking the AR–ARLNC1 interaction sites (ASO-blocking, Ionis 
Pharmaceuticals) and used them in the in vitro interaction assays. Data were normalized to 
the control ASO, using the ΔCt method. 
 
RNA stability assay 
LNCaP cells were treated with 5 μg/ml of actinomycin D for various times as indicated. 
RNA was extracted and qRT–PCR was carried out as described above. RNA half-life was 





smFISH and image analysis were performed as described previously[16, 17]. Probe 
sequences targeting ARLNC1, PCAT1, DANCR, AR, EZH2 and FOXA1 were designed 
using the probe design software in https://www.biosearchtech.com/stellaris-designer and 
are listed in Table 4.2. TERRA probes were designed as described previously[18]. Other 
probes were purchased directly from the LGC-Biosearch. U2-OS cells were seeded in 6-
well dishes and transfected with ARLNC1-expression vector alone, or in combination with 
AR expression vector, using Fugene-HD (Promega) according to the manufacturer’s 
protocol. Cells were incubated for 24 h, reseeded into 8-well chambered coverglasses, and 
were formaldehyde-fixed for smFISH (as described above) after 24 h. 
 
BrU-Seq and BrUChase-seq 
BrU-Seq and BrUChase-Seq assays were performed as previously described[19, 20], with 
MDA-PCa-2b cells treated with either si-NT or si-ARLNC1. BrU-labeling was performed 






Figure 4.1 ARLNC1 is directly regulated by AR 
(A) AR ChIP–seq in prostate cancer cell lines and tissues. Normalized ChIP–seq enrichment is 
shown. Top, AR or control (IgG) ChIP–seq results across the ARLNC1 locus in LNCaP and VCaP 
cells with vehicle (ethanol) or DHT treatment. Bottom, AR ChIP–seq in benign prostate and 
clinically localized prostate cancer tissue. ARE, androgen response element. 
(B) ChIP–qPCR in MDA-PCa-2b cells showing AR or IgG enrichment (ChIP/input) over the 
ARLNC1 promoter region (primer 1) or a control region (primer 2). Data are shown as the mean ± 
s.e.m. (n = 3 biologically independent samples). ***P (adjusted) < 0.0001, NS (not significant): P 
= 0.5746, compared to the control region (primer 2) by ANOVA with Sidak correction for multiple 
comparisons. Top, schematic of the amplicon locations for ChIP–qPCR validation. 
(C) Expression of AR and AR target genes (ARLNC1, TMPRSS2, SLC45A3 and KLK3) in MDA-
PCa-2b cells transfected with control siRNA (si-NT) or siRNAs against AR (si-AR-pool, si-AR-1, 
si-AR-2). Mean ± s.e.m. values are shown, n = 3 biologically independent samples. ***P = 0.0001, 







Figure 4.2 Predicted transcriptional regulation at ARLNC1 promoter 
ChIP–seq peaks of H3K4me1, MED1, BRD4, FOXA1, and NKX3-1 from LNCaP cells at the 
ARLNC1 promoter region. AR ChIP–seq tracks from normal prostate and prostate cancer are also 
shown. Motif analysis results are summarized at the bottom, suggesting possible binding of AR, 










Figure 4.3 Lineage specific expression of ARLNC1 is driven by AR and FOXA1 
(A) Top, qPCR analysis of ARLNC1 expression in LNCaP cells, following treatment with siRNAs 
targeting AR, FOXA1, NKX3-1, BRD4, EZH2, LSD1, IRF1, and POU1F1.  Mean ± s.e.m. values 
are shown, n = 3. *Adjusted P = 0.0436, **adjusted P = 0.0264, ****adjusted P = 0.0001, compared 
to control siRNA (si-NT) by ANOVA with Dunnett correction. Bottom, the on-target effect of 
siRNAs was evaluated by qPCR analysis. Mean ± s.e.m. values are shown, n = 3. **P = 0.006, 
***P < 0.001, compared to control siRNA (si-NT) by two-tailed Student’s t test.  
(A) ChIP-PCR analysis in MDA-PCa-2b cells showing relative enrichment (ChIP/input) of AR, 
FOXA1, NKX3-1, or IgG over ARLNC1 promoter region or control region. Error bars represent 
mean ± s.e.m. (n = 3). ***Adjusted P = 0.0001 compared to negative control, by ANOVA with 
Dunnett correction for multiple comparisons.  
 (C) Relative expression (TPM) of AR (left) and FOXA1 (right) across a panel of normal tissues in 
the GTEx normal tissue RNA-seq cohort (n = 8,745 samples). Box-plot definition: center, median; 













Figure 4.4 A positive feedback loop between ARLNC1 and AR signaling 
(A) GSEA showing significant enrichment of the ARLNC1-regulated gene set with respect to the 
AR target gene sets (n = 3 independent gene expression profiles). Shown are enrichment plots for 
gene sets consisting of genes positively regulated by AR (top) and genes negatively regulated by 
AR (bottom). 
(B) Reproducibility of expression profiling following 10 nM DHT treatment in MDA-PCa-2b cells. 
The most significant AR targets were used to derive a gene signature of the AR response. 
(C) Comparison of ARLNC1-regulated and AR target genes based on RNA–seq following 
knockdown of AR and ARLNC1. Significant genes and their log-transformed fold changes in either 
of the conditions are shown (n = 2 independent cell cultures per-condition). Combined significance 
levels, determined by a limma-moderated t test (across both knockdowns), are indicated by circle 
size. 
(D) Overlap between genes differentially expressed upon AR knockdown and ARLNC1 
knockdown in MDA-PCa-2B cells. 
(E) qRT–PCR analysis of ARLNC1 and AR in MDA-PCa-2b cells transfected with siRNAs against 
ARLNC1, AR, EZH2 or non-specific control (NT). siRNA against AR serves as a positive control 
for inhibition of AR signaling, while siRNA against EZH2 serves as a negative control. Mean ± 
s.e.m. values are shown, n = 3. **P < 0.01, ***P = 0.0001, determined by ANOVA with Dunnett 
correction. 
(F) Immunoblots of AR, PSA and GAPDH in MDA-PCa-2b cells transfected with siRNAs 
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against ARLNC1, AR, EZH2 or non-specific control (NT). The experiments were repeated three 
times independently with similar results. 
(G) siRNA knockdown of ARLNC1 in MDA-PCa-2b cells impairs AR signaling as determined by 
AR reporter gene assay. siRNA against AR serves as a positive control for inhibition of AR 
signaling. Mean ± s.e.m. values are shown, n = 3 biologically independent cell cultures. **P < 0.01, 
***P = 0.0001, determined by ANOVA with Dunnett correction.  
(H) siRNA knockdown of ARLNC1 in LNCaP cells impaired AR signaling by AR reporter gene 
assay. siRNA against AR served as a positive control for AR signaling inhibition. Mean ± s.e.m. 
values are shown, n = 3. *P = 0.0233; ns, not significant. P values determined by two-tailed 
Student’s t test. Veh, vehicle control. 
(I) qPCR analysis of ARLNC1 and AR signaling genes in LNCaP cells (left) and MDA-PCa-2b 
cells (right) transfected with ARLNC1-expressing vector or control vector. Mean ± s.d. values are 









































Figure 4.5 Co-localization of AR mRNA and ARLNC1 in vitro and in prostate cancer cells 
(A) In silico prediction of ARLNC1 RNA-binding partners, with the y axis representing log2 
transformed absolute RNA-binding energy between ARLNC1 and various RNA species while the 
x axis depicts log2-transformed average expression levels of these RNAs in prostate cancer. 
(B) Schematic of the predicted RNA-RNA interaction between ARLNC1 and the 3′ UTR of AR. 
(C) ARLNC1 interacts with the AR 3′ UTR in an in vitro RNA–RNA interaction assay. Compared 
to a panel of control RNAs (ARLNC1 antisense, LacZ, SChLAP1-AS, THOR), ARLNC1 binds to 
AR 3′ UTR-1–980 with high affinity. The binding affinity was quantified by qPCR analysis of the 
AR 3′ UTR. Data were normalized to the ARLNC1-AS control. Mean ± s.e.m. are shown, n = 3. 
**P < 0.001, by two-tailed Student’s t test. 
(D-F) smFISH depiction of AR–ARLNC1 colocalization in situ. (D), Representative 
pseudocolored images of MDA-PCa-2b cell nuclei stained for the appropriate endogenous (endo) 
transcripts (green, red) and with DAPI (nucleus, blue). Scale bar, 5 μm. The orange circles represent 
regions of colocalization. (E-F), Quantification of the percentage of AR or ARLNC1 molecules 
colocalizing with a panel of lncRNAs (E) or mRNAs (F). The center line and whiskers depict the 
median and range, respectively, and the box extends from the 25th to the 75th percentile (n = 50 
cells for each sample aggregated from 3 independent experiments). ***P < 0.0001, by two-tailed 
Student’s t test. 
(G) Stoichiometry of ARLNC1:AR colocalization. The dotted line represents a 1:1 stoichiometry, 
whereas the bold dotted line represents 2:1 stoichiometry. Each dot represents the number of 
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molecules when AR and ARLNC1 colocalize in any given cell (n = 1,000 colocalized spots from 
nine independent samples). 
(H) Representative pseudocolored images of U2-OS cells ectopically expressing ARLNC1 alone 
(green, left and right) or both ARLNC1 and AR (red, middle) and stained for the appropriate 
transcripts and DAPI (blue). Scale bar, 10 μm. The inset depicts a zoomed-in view of the orange 











































Figure 4.6 Co-localization of AR mRNA and ARLNC1 in prostate cancer tissues 
(A) Representative pseudocolored images of ARLNC1-positive prostate cancer tissues stained with 
DAPI (nucleus, blue) and for AR (green), HMBS or ARLNC1 transcripts (smFISH). Inset, 5.5 × 
5.5 μ m2 zoomed-in view of the box within the main panel.   
(B) Quantification of the percentage of AR molecules colocalizing with HMBS transcripts or 
ARLNC1. The center line and whiskers depict the median and range, respectively, and the box 
extends from the 25th to the 75th percentile (n = 15 field-of-views for each sample aggregated from 




























Figure 4.7 Identification of the ARLNC1 fragment mediating RNA–RNA interaction with 
AR mRNA 
(A) In vitro RNA–RNA interaction assay identifies nucleotides 700-1300 on ARLNC1 as critical 
binding site to AR 3′ UTR-1-980. ARLNC1 fragments covering nucleotides 700–1300 display 
comparable or higher AR 3′ UTR binding affinity than ARLNC1-S, with ARLNC1-700-1300 
exhibiting the highest binding affinity. Data were normalized to the ARLNC1-AS control. Mean ± 
s.e.m. values are shown, n = 3. ***P (adjusted) = 0.0001, determined by ANOVA with Dunnett’s 
multiple-comparisons test. 
(B) Deletion ofnucleotides 700–1300 on ARLNC1 results in impaired binding to the AR 3′ UTR, 
as shown by in vitro RNA–RNA interaction assay. Data were normalized to the ARLNC1-AS 
control. Mean ± s.e.m. values are shown, n = 3. ***P = 0.0001, **P = 0.0003, by two-tailed 
Student’s t test. 
(C-D) smFISH shows that nucleotides 700–1300 in ARLNC1 are important for colocalization in 
situ. (C) Representative pseudocolored images of U2OS cells stained with DAPI (nucleus, blue) 
and for ARLNC1 (green) and AR transcripts. Inset, 10 × 10 μ m2 zoomed-in view of the orange 
box in the main image. (D) Quantification of the percentage of AR molecules colocalizing with 
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various ARLNC1 fragments. The center line and whiskers depict the median and range, 
respectively, and the box extends from the 25th to the 75th percentile (n = 50 cells for each sample 


















































Figure 4.8 Disrupting RNA-RNA interaction between ARLNC1 and AR by antisense 
oligonucleotides 
(A) ASOs targeting nucleotides 700–1300 on the ARLNC1 transcript (ASO-blocking pool) inhibit 
ARLNC1 interaction with the AR 3′ UTR. In vitro RNA–RNA interaction assays were performed 
using ARLNC1 and the AR 3′ UTR, with the addition of the blocking ASO pool or control ASO. 
Data were normalized to the control ASO. Mean ± s.e.m. values are shown, n = 3. P = 0.0014, by 
two-tailed Student’s t test. 
(B-C) Representative pseudocolored images of MDA-PCa-2b cells stained for DAPI (nucleus, 
blue) and ARLNC1 (green) and AR transcripts, following treatment of blocking ASOs targeting 
the ARLNC1:AR 3’ UTR interaction. Quantifications of colocalization are depicted in (C). Center 
line and whiskers depict the median and range, respectively, and the box extends from the 25th to 
75th percentiles (n = 60 cells for each sample aggregated from three independent experiments). P 
value was computed by two-tailed Student’s t test. 
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(D-E) Representative pseudocolored images of U2-OS cells stained for DAPI (nucleus, blue) and 
ARLNC1 (green) and AR transcripts, following treatment of blocking ASOs targeting the 
ARLNC1:AR 3’ UTR interaction. U2-OS cells were transfected with ARLNC1 and AR expression 
vector prior to blocking ASO treatment. Scale bar, 10 μm. Quantifications of colocalization in U2-
OS cells are depicted in (E) as a box plot. Center line and whiskers depict the median and range, 
respectively, and the box extends from the 25th to 75th percentiles (n = 60 cells for each sample 
aggregated from three independent experiments). P value was computed by two-tailed Student’s t 
test. 
(F-G) qPCR analysis of ARLNC1, AR and AR signaling genes (KLK2, KLK3, NKX3-1, 
TMPRSS2 and FKBP5) in MDA-PCa-2b cells (F) or LNCaP cells (G) transfected with control or 
blocking ASOs targeting the interaction site between ARLNC1 and the AR 3′ UTR. Mean ± s.e.m. 























Figure 4.9 ARLNC1 regulates the cytoplasmic level of the AR transcript 
(A) Half-life of GAPDH, AR, ARLNC1, and MYC RNA transcripts in LNCaP cells. Cells were 
incubated with actinomycin D for the indicated times, and target RNA quantities were evaluated 
by qPCR. RNA halflife was calculated by linear regression analysis. n = 3. At different time points, 
mean ± s.d. values are shown. 
(B) Quantification of ARLNC1 levels, as measured by smFISH, after treatment of MDA-PCa-2b 
cells with siRNA against AR (si-AR), siRNA against ARLNC1 (si-ARLNC1-3), ASO against 
ARLNC1 (ASO-ARLNC1-1), or blocking ASO against the AR–ARLNC1 colocalizing segment 
(ASOblocking). Data were normalized to si-NT (Left) or ASO-Control (Right). Mean ± s.e.m. 
values are shown, n = 3 independent experiments and 60 cells analyzed for each sample. P values 
were computed by two-tailed Student’s t test. 
(C) Quantification of AR transcript levels, as measured by smFISH, after treatment of MDA-PCa-
2b cells with siRNA against AR (si-AR), siRNA against ARLNC1 (si-ARLNC1-3), ASO against 
ARLNC1 (ASOARLNC1-1), or blocking ASO against the AR–ARLNC1 colocalizing segment 
(ASO-Blocking). Data were normalized to si-NT (Left) or ASO-Control (Right). Mean ± s.e.m. 
values are shown, n = 3 independent experiments and 60 cells analyzed for each sample. P values 
were computed by two-tailed Student’s t test. 
(D) BrU-seq alignment track (Top) and BrUChase-seq alignment track (Bottom) at the AR gene 




(E) Nucleo-cytoplasmic distribution of ARLNC1 after appropriate treatment of MDA-PCa-2b cells 
with siRNA against AR (si-AR), siRNA against ARLNC1 (si-ARLNC1-3), ASO against ARLNC1 
(ASO-ARLNC1-1), or blocking ASO against the AR–ARLNC1 colocalizing segment (ASO-
Blocking). Mean ± s.e.m. values are shown, n = 3 independent experiments and 60 cells analyzed 
for each sample. P values were computed by comparing to si-NT- or ASO-Control-treated cells, by 
two-tailed Student’s t test. 
(F) ARLNC1 regulates AR post-transcriptionally by specifically affecting cytoplasmic AR mRNA. 
Representative pseudocolored images are shown of MDA-PCa-2b cells stained for DAPI (nucleus, 
blue) and AR (gray) after treatment with siRNA against AR (si-AR), siRNA against ARLNC1 (si-
ARLNC1-3), ASO against ARLNC1 (ASO-ARLNC1-1) or blocking ASO against 
the AR–ARLNC1 colocalizing segment (ASO-blocking).  
(G) Fractional column plots depicting the nucleo-cytoplasmic distribution of AR mRNA after the 
various treatment conditions in (F), as computed using smFISH. Mean ± s.e.m. values are shown, 
n = 3 independent experiments and 60 cells analyzed for each sample. The P values were computed 





































































Table 4.2 smFISH probes used in Chapter 4 
Name smFISH probe sequence (5'-3') 
ARLNC1 (31 probes) ctagaaccttctattcattc 
  gaacaacaacagaagccaga 
  catggaaccagcacctgaaa 
  tggagtttccttattttcgg 
  gaacgagttccagtggacaa 
  taaccttgggggccatgaag 
  gtgctgaagttctagatgga 
  agcagctatatgaattagga 
  gtttagctctgcgggaagtg 
  ggtctttatttcatatctgt 
  caaccagagcaactgctgtc 
  atgtcttacttccctcacag 
  cttctaaagtggggctctga 
  tcattatctagccagttcac 
  cactgctatagcagcgttag 
  aactgaaaacccatcacctc 
  gggtattgatgtttgaggtc 
  taaaggagggactctgttcc 
  tgccatctcattctttctaa 
  tcactttgcctgtttcattg 
  tcaggaatggctgagtgatg 
  ttctagttgcctgttttaca 
  gtctccaaatacttcaagct 
  caggaatgatgcagtcctta 
  tacatacagtgtttcggagc 
  aacttccttaattccctgag 
  gcctttatgaacactgtgtt 
  aacatctctgaccttgtctc 
  catcctttattctccattat 
  tgtttgtctactctggatgt 
  gcacagaagcagtacacact 
    
AR (62 probes) aaagctcctcggtaggtctt 
  cacgctctggaacagattct 
  tgaaggttgctgttcctcat 
  cagcagggacaacgtggatg 
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  tgcttaagccggggaaagtg 
  aggatgtctttaaggtcagc 
  aagtgccccctaagtaattg 
  ttggcgttgtcagaaatggt 
  cgacactgccttacacaact 
  aaaagtggggcgtacatgca 
  caatggggcacaaggagtgg 
  agcagagaacctttgcattc 
  cagtatcttcagtgctcttg 
  cccttgaaaggggaatactc 
  ttctagccctttggtgtaac 
  tagacggcagttcaagtgtc 
  ccggacttgtagagagacag 
  gtagtcgcgactctggtacg 
  ccagagccagtggaaagttg 
  ttgatgcgagcgtggggatg 
  aagagagtgtgccaggatga 
  catacaactggccttcttcg 
  acacatcaggtgcggtgaag 
  gactgggatagggcactctg 
  ccatttcgcttttgacacaa 
  taaggtccggagtagctatc 
  caatgggcaaaacatggtcc 
  cttctggggtggaaagtaat 
  catctccacagatcaggcag 
  tccatagtgacacccagaag 
  tcagcggctcttttgaagaa 
  caagtttcttcagcttccgg 
  tcctcctgtagtttcagatt 
  tgtgacactgtcagcttctg 
  ctgacattcatagccttcaa 
  gcttccaggacattcagaaa 
  acacactacacctggctcaa 
  caaggctgcaaaggagtcgg 
  ccagttcattgaggctagag 
  cacttgaccacgtgtacaag 
  cacgtgtaagttgcggaagc 
  aggagtactgaatgacagcc 
  catggcaaacaccatgagcc 
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  cattggtgaaggatcgccag 
  aagtagagcatcctggagtt 
  attgaaaaccagatcagggg 
  ctgtacatccgggacttgtg 
  ttgagagaggtgcctcattc 
  tgatttggagccatccaaac 
  tcatgcacaggaattcctgg 
  atgctgaagagtagcagtgc 
  tttttgatttttcagcccat 
  ccttgatgtagttcattcga 
  gcatgcaatgatacgatcga 
  agcaggatgtgggatttttt 
  ttggtgagctggtagaagcg 
  aagtgaactgatgcagctct 
  ccatgtgtgacttgattagc 
  atcatttccggaaagtccac 
  cttgcacagagatgatctct 
  tttcccagaaaggatcttgg 
  ggtgtggaaatagatgggct 
    
PCAT1 (29 probes) gcctatgcagatatccaata 
  aagggtacagatgctttctc 
  gacctgtgggaattcataca 
  agaggttcctttcttcatta 
  taggtagctctttgtactca 
  gctatgcatcttatatcctt 
  tctttaattgctcaggttcc 
  caagtgccagttaagtgtga 
  ggccttattaagatgggatc 
  cttatccattggtgtttctg 
  cacttagaggcacatgggaa 
  ttaaagtccagttaggttcc 
  tttctcttctcacttctagt 
  ttatcttgggaggttccaat 
  catggtcttatgtatctgcg 
  caaaggcgttggtgatgttg 
  gtctttgtcgacttccaatg 
  gcttcaatgattcctctcaa 
  atggtcaacattgcgttctt 
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  cacccacttatcaagttttt 
  tttggatttttgctgagctc 
  ggttattgttgttgcgtaga 
  cccaaatccacttttcattg 
  attgctggttgccatatata 
  gctcattgatttgttgagca 
  aacttttgaagcgctgcttg 
  aactatgtagcccaatttgt 
  ttggaaagcgtgttctgcat 
  gtgcgtcaggattcgacaaa 
    
DANCR (30 probes) cgggaagactctgggcaagg 
  cgggcgcacaaaccagagag 
  gcaactccagctgacaaaga 
  cgaaacccgctacatagtgg 
  aactcctggagctcaaggtc 
  acttccgcagacgtaagaga 
  tgcgctaagaactgaggcag 
  ataccagcaacaggacattc 
  gggatagttggcttaagtca 
  ggcactttcctattgtaact 
  cacgtggttgctacaagtta 
  cagcattgtcactgctctag 
  aacatgaagcacctgctaca 
  acagcgtgaaacttgtagag 
  gcttttgtaggttcatgact 
  gctgagcatcttcaaagatt 
  ggtcttggagaaatttcaga 
  gcatgatcctgttttgttca 
  tgcagcttgggtgtgtattc 
  gccaaaccaaaatagggcta 
  tgtggctgaagatctcatgg 
  ggaagatttttatctcctgc 
  acttgcagctgatgaaagct 
  tcggttttctcaaatagcca 
  gtcacccacagaatccaatt 
  tgatgtgcaaagcggtcatc 
  gaaggtaaggatgataccca 
  tttgactggcacaaaaggtt 
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  ggtgatgacatatcaagagc 
  agccaagacaagtggcaatt 
    
EZH2 (34 probes) ccaacaaactggtcccttct 
  gtactctgattttacacgct 
  aacctcttgagctgtctcag 
  ctttacttcatcagctcgtc 
  cttcgctgtttccattcttg 
  aagtcactggtcaccgaaca 
  atgggatgacttgtgttgga 
  agcaactgcattcagagtct 
  ataaaattctgctgtagggg 
  ctgttcggtgagttctttat 
  gtacattcaggaggaagtgc 
  catcgcctacagaaaagcgt 
  gcacttacgatgtaggaagc 
  gttgggtgttgcatgaaaag 
  ctgtgttcttccgcttataa 
  aaggtttgttgtctagagct 
  aatgctggtaacactgtggt 
  gtgagagcagcagcaaactc 
  tgctactgttattgggaagc 
  ttccagcacattaatggtgg 
  ttggtgtttgacaccgagaa 
  ggactctaaacattgaggct 
  taacctagcaatggcacaga 
  ctgtctacatgttttggtcc 
  ctggagctatgatgctagat 
  ctgtatctttctgcagtgtg 
  aaacatggttagaggagccg 
  tggatgatcacagggttgat 
  atcacacaagggcacgaact 
  agatggtgccagcaatagat 
  tgataaaaatcccccagcct 
  tctccacagtattctgagat 
  gatggctctcttggcaaaaa 
  aaaaacagctcttcgccagt 
    
FOXA1 (47 probes) tgcccaatacaaccatccag 
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  catcttcacagttcctaaca 
  tgtctgcgtagtagctgttc 
  aggtgttcatggagttcatg 
  tcgtagtcatggtgttcatg 
  gttggcataggacatgttga 
  cgcagtcatgctgttcatgg 
  tagctgcgcttgaacgtctt 
  gagatgtacgagtagggcgg 
  ctggatggccatggtgatga 
  atgatccactggtagatctc 
  tgccggtaataggggaagag 
  agccgttctcgaacatgttg 
  tgcttctcgcacttgaagcg 
  ctggagtcttcaactccgag 
  aacgggtggttgaaggagta 
  ggacatgaggttgttgatgg 
  ttgaagtccagcttatgctg 
  tattgcagtgcctgttcgta 
  caacgtagagccgtaaggcg 
  atacacaccttggtagtacg 
  aagtgtttaggacgggtctg 
  ttgcactgggggaaaggttg 
  aaattggtttggggttgtct 
  ggatcattaaacttcgcagg 
  gtagggggtcaggtaaggag 
  attgccacagacctgtaaac 
  cttttaagagcctctagtgt 
  agcaaatggctctgatgttt 
  gcatgtgcataattaagtcc 
  acggaggatgtctacacatc 
  gcaactcttgagaatgtatc 
  ttggggtccttgtaactttc 
  attcctgaggaattgattcc 
  agaagcagagttcttgaggg 
  atgacatgaccatggcactc 
  ctctcctccaacattgtaat 
  aaatccagctccctataact 
  ttgaatcttggaccacgttt 
  atggccactatcaataggat 
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  agcacacgatggcaatgatt 
  tccaactgtggaaagtgcat 
  gtctggctatactaacacca 
  gaacattttccacggcttaa 
  gtccttaactgcaaatgatc 
  aaacacagaaggcttaagcc 
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Circular RNAs as a novel class of non-coding transcripts with 
diagnostic potential in prostate cancer1 
 
Abstract 
Circular RNAs (circRNAs) are an intriguing class of non-coding RNA due to their 
covalently closed structure, higher stability compared to linear counterparts, and implicated 
roles in gene regulation. Recently, our lab used an exome capture RNA sequencing 
protocol to characterize circRNA landscape across >2,000 cancer samples. When 
compared against Ribo-Zero sequencing, capture sequencing significantly enhanced the 
enrichment of circRNAs and preserved accurate circular-to-linear ratios. Using capture 
sequencing, we built the most comprehensive catalog of circRNA species to date: 
MiOncoCirc, the first database to be composed primarily of circRNAs directly detected in 
tumor tissues. MiOncoCirc serves as a valuable guide for the development of circRNAs as 
diagnostic or therapeutic targets across cancer types. 
 
                                                          
1 This chapter was previously published as part of the following manuscript:  Vo, J.N., et al., The Landscape 
of Circular RNA in Cancer. Cell, 2019. 176(4): p. 869-881 e13. 
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In this chapter, we performed validation of circRNA species nominated from MiOncoCirc. 
We confirmed that circRNAs are resistant to treatment of RNaseR, a 3’ to 5’ 
exoribonuclease that digests all linear RNAs except lariat or circular RNA structures. 
Furthermore, we confirmed existence of a novel class of circular transcripts, termed read-
through circRNAs (rt-circRNAs), that involve exons originating from different genes. In 
prostate cancer, we identified a group of circRNAs that are specifically enriched in 
Neuroendocrine Prostate Cancer (NEPC). In addition, we showed that circRNAs have 
potential to serve as non-invasive biomarkers. They are more stable than linear RNAs 
incubated in plasma, and some circRNAs were detectable in urine.  
 
Introduction 
Out lab has developed a poly(A)-independent, exome-capture based RNA-Seq protocol to 
profile circular RNAs[1]. This method is able to consistently detect more circular RNA 
species compared to the previously used Ribo-Zero sequencing protocol, while 
maintaining comparable circular-to-linear fractions to sequencing results before.  
 
Using exome-capture RNA-Seq protocol, we have constructed a bioinformatics pipeline to 
generate MiOncoCirc compendium[1], consisting circRNA species detected from clinical 
cancer samples, cancer cell lines, and pooled normal tissues (Figure 5.1). Published 
circRNA bioinformatics tool, CIRCexplorer[2], as well as in-house computational pipeline 
CODAC[3], were adapted to discover backspliced circular RNA reads originated from one 
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gene (circRNA), or more than one genes (read-through circular RNAs, rt-circRNA, 
typically from adjacent genes).  
 
Characterization of circular RNAs in MiOncoCirc revealed several features and properties 
associated with circRNA expression (Figure 5.2): (1) More than 99% of circRNAs harbor 
circular junction boundaries flanked by the canonical splicing motif AG-GT, supporting 
the theory that circRNAs are produced from back-splicing events. (2) CircRNAs generated 
from single gene could form several isoforms. The number of circRNA isoforms increases 
proportionally with number of exons per gene (Figure 5.2A). (3) Regarding abundance, 
baseline expression of the linear gene counterpart is not a reliable predictor of the 
corresponding levels of circRNAs originated from it (Figure 5.2B). Rather than driven 
solely by abundance of linear gene counterparts, circular RNAs expression are more likely 
to be a result from diverse regulatory splicing mechanisms. (4) There is a small subset of 
circRNAs that are consistently detectable in more than 90% of samples, with more than 5-
fold higher expression levels than median abundance of all circRNAs. This is possibly due 
to their gnomic structures which support transcript back-splicing and circularization 
(Figure 5.2C). (5) The majority of circRNA species exist ubiquitously across different 
tissues, or with limited lineage-specificity (Figure 5.2D). A small set of circRNAs with 
high tissue-restricted expression (895 circRNAs from MiOncoCirc) could be explained by 
the tissue specificity of the parental genes that circRNAs originate from. This set of 





Identification and validation of read-through circRNAs (rt-circRNA) 
circRNAs produced from exons originating from different genes were previously reported 
to be products of gene fusions, in which each fusion partner donated their exons for 
backsplicing, and were named f-circRNAs[4]. We recently developed a novel annotation 
pipeline, CODAC, that could annotate backsplicing events involving two genes. Since 
pairs of homologous or paralogous genes can give rise to mapping ambiguities and false 
positives, we performed preliminary filtering, as well as indicated pairs with high degrees 
of similarity. Although we did not detect any f-circRNAs in MiOncoCirc resulting from 
chromosomal translocations and deletions, we discovered a novel class of circular 
transcripts that involved exons originating from two adjacent genes on the same strand: the 
rt-circRNA. Without the genomic information from matched whole-genome sequencing 
(WGS) and whole-exome sequencing acquired through our integrative clinical sequencing 
approach[5], rt-circRNAs would have appeared deceptively similar to linear transcripts 
resulting from tandem duplications in RNA-seq (Figure 5.3A). In general, rt-circRNAs 
comprised a small portion of all circRNAs in each sample (average 2.5%) and were 
detected at lower abundance (average 3.13 lower) than most other circRNAs from a single 
gene [1]. 
 
Some of these backspliced reads involving two genes were commonly found across 
different cancer types (Figure 5.3B) and were even detected in normal tissues or in samples 
with normal copy number (diploid) of the parent genes, which further suggested that they 
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were true common transcriptomic processes rather than rare genomic events. To further 
experimentally validate by quantitative reverse transcriptase PCR (qRT-PCR) that this 
class of read-through transcript was circularized, we searched for transcripts that were 
expressed in cell lines and selected a backspliced event spanning two adjacent genes, 
TTTY15 and USP9Y, which were less than 9 kb apart on chromosome Y and detected in 
several prostate cancer tissue samples (Figure 5.3C). The product of outward-facing 
primers involving exon 3 of TTTY15 and exon 3 of USP9Y were detected via qRT-PCR 
in LNCaP prostate cancer cells, as well as the product of inward-facing primers involving 
the same pair of exons. However, only the product of out-ward-facing amplification was 
resistant to RNase R degradation (Figure 5.3C), and the backspliced exon-exon junctions 
of USP9Y and TTTY15 were validated by Sanger sequencing (Figure 5.3E), confirming 
that the target was a circular molecule. 
 
Finally, even though read-through circularization was largely widespread across cancer 
types (Figure 5.3B), we were able to nominate a small set of select rt-circRNAs that were 
tissue specific in the MiOncoCirc compendium (Figure 5.3D). Their tissue specificity 
could be explained by the tissue-specific expression. of the genes involved in the 
generation of the corresponding rt-circRNAs. 
 
Differentially expressed circRNAs in Neuroendocrine Prostate Cancer 
Because circRNAs are “spliced out” from mRNAs, any cellular process or transformation 
that has a profound impact on the transcriptome should likewise alter the circRNA 
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landscape of the cell. Thus, we characterized the circRNA landscape of prostate cancers 
undergoing neuroendocrine differentiation. Neuroendocrine prostate cancer (NEPC) is a 
rare, aggressive subtype of prostate cancer that can arise from post-hormonal therapy for 
PRAD[6] and has a poor prognosis[7]. In our cohort, pathologists diagnosed eight NEPC 
cases based on cell morphology.  
 
We then performed differential circRNA expression analyses (Figure 5.4A) and uncovered 
34 upregulated and 48 downregulated circRNAs with statistical significance (p < 0.01). In 
NEPC, the most significantly upregulated and downregulated circRNAs were circ-
AURKA and circ-AMACR, respectively (Figure 5.4B). This finding is consistent with the 
change in parental gene expression of AURKA and AMACR. We carried out qRT-PCR in 
RNase R-treated NCI-H660, a neuroendocrine cell line, and confirmed that circ-AURKA 
was generated from exon 6 backspliced to exon 3 (Figure 5.4C, E). Finally, we confirmed 
that circ-AURKA was expressed more highly in the NEPC cell line NCI-H660 than in the 
non-NEPC prostate cell lines, LNCaP and VCaP, a result that was consistent with the 
expression of its parent gene (Figure 5.4D). 
 
CircRNAs Are More Stable Than Cognate Linear Transcripts 
Due to their lack of open ends, circRNAs are resistant to exoribonuclease (RNase R 
treatment) and are potentially more stable than their cognate linear transcripts, thus making 
them ideal candidates for biomarker development. To evaluate the stability of circRNAs 
identified in MiOncoCirc, total RNA was first isolated from LNCaP prostate cancer cells 
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and incubated with RNase R for 30 min. The ratio of circular-to-linear RNA species was 
then quantified by qRT-PCR. All circRNA species tested showed resistance to 
exoribonuclease and were thus significantly more stable than their linear counterparts 
(Figure 5.5A). In an orthogonal method to assess the stability of circRNAs, we compared 
concentrations of circular and linear transcripts in LNCaP cells that were treated with 
actinomycin D, a transcription inhibitor, over time. In LNCaP cells harvested at 0, 2, 4, 8, 
and 24 h after actinomycin D treatment, relative circRNA levels increased whereas relative 
mRNA levels decreased (Figure 5.5B), thus demonstrating the relatively higher stability 
of circular transcripts. Identification of biomarker species that are resistant to degradation 
is desirable for clinical settings. To determine whether circRNAs are more stable than their 
cognate linear RNAs in biospecimens, we analyzed the stability of circRNA in human 
blood plasma. VCaP RNAs were incubated in the plasma to simulate an environment of 
circulating RNAs. Indeed, as assessed by the ratio of circular-to-linear transcripts of select 
candidates, circRNAs were more stable than linear RNA in plasma after incubation (Figure 
5.5C). 
 
Detection of circRNAs in urine from prostate cancer patients 
Because noninvasive methods of detection are more ideal for screening assays in the clinic, 
we assessed whether circRNAs could be reliably detected in urine samples. We generated 
three libraries with exome capture RNA-seq and detected 1,092 circRNAs in urine samples 
from prostate cancer patients that completely overlapped with circRNAs identified in 
PRAD tissue samples from the MiOncoCirc compendium (Figure 5.6A). Furthermore, 
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analysis of circRNAs by qRT-PCR showed that circRNA species could be detected in urine 
from prostate cancer patients (Figure 5.6B). Furthermore, these data demonstrate that, 
even with low starting amounts of RNA (50 ng), exome capture RNA-seq of urine samples 




Read-through chimeric transcripts are widespread phenomena and may represent a 
mechanism for the evolution of protein complexes[8], which may explain the detection of 
some rt-circRNA at high frequency in our consortium. Circularized read-through events 
may have several important implications. First, whether the process of circularization 
(“backsplicing”) is a co-transcriptional or post-transcriptional process has remained an 
ongoing debate[9-14]. However, recent evidence provided by Liang et al. (2017) shows 
that depleting CPSF3, a 3’ end processing endonuclease, could increase the intergenic read-
through as well as circularization at one specific locus. Further, the formation of rt-
circRNAs confirms that in some pairs of genes, circularization must occur prior to cleavage 
and polyadenylation. Our data, therefore, contribute to clarifying the timing of the 
circularization process and provides evidence for the co-transcriptional model. Second, the 
backspliced reads from those resulting from RNA circularization, genomic tandem 
duplications, or some structural rearrangements in RNA-seq appear identical (Figure 
5.3A). Indeed, one of our most commonly detected backspliced events, from exon 3 of 
USP9Y to exon 3 of TTTY15, was previously proposed to be a “fusion” or “translocation” 
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in prostate cancer[15]. Our validation via RNase R treatment and Sanger sequencing 
(Figure 5.3C, E), however, proved that it is a rt-circRNA. The MiOncoCirc resource will 
thus serve as a highly valuable tool for cancer genomic researchers who wish to filter out 
rt-circRNA transcripts from a list of potential structural rearrangement candidates. 
 
In conclusion, we have performed validation for selected circRNA species catalogued in 
MiOncoCirc. The database serves as an important resource for scientists who wish to 
explore the lineage-specific and expression patterns of circRNAs in cancer, as well as the 
intriguing mechanisms of read-through splicing. Such studies may shed light into the 
function of circRNAs and help develop the use of circRNAs in diagnostic medicine. 
 
Materials and Methods 
Cell lines 
LNCaP, VCaP, 22Rv1 (male, prostate adenocarcinoma), and NCI-H660 (male, prostate 
epithelial neuroendocrine) cell lines were obtained from the American Type Culture 
Collection (ATCC). LNCaP and 22Rv1 cells were cultured in ATCC-formulated 
RPMI1640 medium supplemented with 10% fetal bovine serum (FBS; Invitrogen). VCaP 
cells were maintained in ATCC-formulated Dulbecco’s Modified Eagle’s Medium 
supplemented with 1% penicillin/streptomycin (Invitrogen) and 10% FBS (Invitrogen). 
NCIH660 cells were maintained in ATCC-formulated RPMI-1640 medium, supplemented 
with 0.005 mg/mL insulin, 0.01 mg/mL transferrin, 30 nM sodium selenite, 10 nM 
hydrocortisone, 10 nM beta-estradiol, 2 mM L-glutamine, and 5% FBS. All cell lines were 
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genotyped to confirm their identity at the University of Michigan Sequencing Core. We 
maintained cell lines at 37C in a 5% CO2 cell culture incubator and tested all cell lines 
routinely for Mycoplasma contamination. 
 
RNase R treatment 
Total RNA was isolated by TRIZOL lysis followed by purification using the miRNeasy 
Mini Kit (QIAGEN) with DNase digestion step. 2 mg of total RNA was either treated with 
0 units (control) or 20 units of RNase R (Lucigen) in reaction buffer consisting 20 mM 
Tris-HCl (pH 8.0), 100 mM KCl, and 0.1 mM MgCl2, respectively. Treatment was 
conducted at 37 °C for 1 hour, followed by RNase R inactivation at 65°C for 20 min. RNA 
was then extracted using miRNeasy Mini Kit (QIAGEN) and eluted in 15 ml of water. 
Reverse transcription was performed using SuperScript III Reverse Transcriptase 
(Invitrogen) and random primers (Invitrogen) following manufacturer’s standard protocol. 
 
RT-qPCR and validation of circRNA 
To assess relative expression of circRNA candidates, quantitative Real-time PCR (qRT 
PCR) assays were performed using Power SYBR Green Master Mix (Applied Biosystems) 
and were carried out with the StepOne Real-Time PCR System (Applied Biosystems). 
Sequences of oligonucleotide primers were included in Table 5.1, with the following 
abbreviations used- li: linear RNAs; circ: circular RNAs; in: inward facing direction; out: 
outward facing direction; F: forward; R: reverse. Linear version of a housekeeping gene, 
GAPDH, were amplified as control. Expression of targets were calculated relative to the 
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housekeeping gene. Fold changes following RNase R treatment were calculated relative to 
the control untreated samples. The genomic sequence of qPCR products from the circRNA 
backspliced junction was further validated with Sanger Sequencing at the University of 
Michigan Sequencing Core. 
 
Actinomycin D treatment 
To validate the stability of RNAs, LNCaP cells were plated in 6-well plates and incubated 
for 12 hours. After incubation, cells were treated with 2.5 mg/mL of actinomycin D 
(Sigma) for 0-24 hours. Cells were harvested in Qiazol at 0, 2, 4, 8, and 24 hours post-
treatment. RNA was isolated using the miRNeasy mini kit (QIAGEN). RNA was 
quantified, and 1 mg of RNA was used to make cDNA using SuperScript III First-Strand 
Synthesis System for RT-qPCR (Invitrogen) using random primers. We then performed 
RT-qPCR and analyzed data with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
used as a normalization control. 
 
RNA stability in blood plasma 
To check the stability of various linear and circular transcripts in plasma, we first isolated 
the blood plasma from fresh blood taken from healthy individual (male, age 30). In short, 
a total of 15 mL blood was collected in a vacutainer tube containing EDTA as the 
anticoagulant and mixed well before centrifugation at 2,000 rcf for 20 min at room 
temperature. The plasma layer was then carefully aspirated and stored at –80°C in 
cryovials. Next, we incubated 1 mg of VCaP RNA with 100 mL of plasma for 0, 15, 30, 
153 
 
45, 60, and 75 min. After incubation, total RNA was isolated and various linear and circular 
transcripts were quantified using qRT-PCR. The expression of transcripts at the zero-
minute time point was considered as the control. Relative levels of circular and linear 
transcripts were calculated and shown. 
 
Urine RNA extraction for RNA-seq and qRT-PCR 
Post-digital rectal examination (Post-DRE) urine was collected from 13 prostate cancer 
patients presenting for diagnostic prostate biopsy using standardized protocols at 
University of Michigan Rogel Cancer Center. Urine was collected in an equal volume of 
RNA Protection Reagent and then frozen at 80°C until extraction of RNA was performed. 
Urine RNA was isolated by MagMAX mirVana Total RNA Isolation Kit (Invitrogen), 
which allows for recovery of total RNA (both intra- and extracellular) in urine. Capture 
sequencing was performed on three urine samples (Figure 5.6A), and qRT-PCR was 







Figure 5.1 Overview of the MiOncoCirc Compendium 
(A) Summary of high-depth, paired-end RNA-seq samples from previously published datasets, cell 
line panels, and normal tissues.  
(B) Exome capture RNA-seq protocol and the bioinformatics pipeline for creation of MiOncoCirc. 
The unmapped reads from chimeric aligner (STAR) were annotated against the exon junctions. 
CIRCexplorer was used to call circRNA transcripts, and CODAC was used to annotate circRNAs 
involving two genes. FeatureCounts was used to quantify gene expression. 
(C) MiOncoCirc, an online database that enables querying and downloading of circRNAs 






Figure 5.2 Properties and prevalence of circRNAs in MiOncoCirc 
(A) Genes can form multiple circRNA transcripts. The number of circular transcripts increased 
proportionally with the number of exons per gene. 
(B) Average expression of circRNA abundance (in normalized backspliced reads) versus average 
expression of parental expression (in FPKM). Parent gene expression was grouped into bins of 50. 
Overall, there was no difference in the mean of the bins (ANOVA p = 0.12), indicating that the 
correlation was weak (Spearman’s r = 0.12). 
(C) Circular RNA abundance (in normalized backspliced reads) versus sample fraction (%). There 
was a small portion of circRNAs (<2% of all circRNAs, generated from 589 genes, marked as 
“high”) that were detected in more than 90% of all samples. They also had higher expression 
compared to the median of all circRNAs. 
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(D) Tissue-specific heatmap of genes that can generate circRNAs, as demonstrated in 17 cancer 
cohorts from the MiOncoCirc compendium. A gene was considered to be consistently detected if 






Figure 5.3 Existence of novel circularized, read-through transcripts involving two genes 
(A) Schematic showing that genomic tandem duplications and circRNAs involving two genes can 
appear similar in paired-end RNA-seq. Specifically, when mates of a paired-end read were aligned 
in divergent orientation to exons of two adjacent genes, the result could be interpreted as either a 
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duplication of a group of exons from two genes (Scenario 1) or a circularization from the 
downstream gene back to the upstream gene (Scenario 2). 
(B) The frequency and distribution of the top 30 most abundant back-spliced events involved 
neighboring genes in miOncoCirc compendium. 
(C) The circular read-through event involving exon 3 of TTTY15 and exon 3 of USP9Y was chosen 
for validation in LNCaP cells. Post-RNase R treatment, only the qRT-PCR product of outward-
facing primers was resistant to exoribonuclease degradation. 
(D) The tissue specificity heatmap of rt-circRNAs. The rt-circRNAs specific to liver and prostate 
cancer are labeled. 
(E) Schematic depicting the circular read-through event that generated circTTTY15e3-USP9Ye3 
transcript detected in the MiOncoCirc compendium. The Sanger sequencing result of circTTTY15-
USP9Y RT-qPCR product showed the correct sequence spanning the backsplice exon-exon 











Figure 5.4 Circular RNAs enriched in Neuroendocrine Prostate Cancer 
(A) The heatmap of 34 upregulated and 48 downregulated circRNAs with statistical significance 
(p < 0.01) in NEPC compared to CRPC cases. 
(B) Comparing NEPC to CRPC, the most significantly upregulated circRNA was circ-AURKA 
(Mann–Whitney U test p < 0.001); the most significantly downregulated circRNA was circ-
AMACR (Mann–Whitney U test p = 0.002). 
(C) qRT-PCR of outward-facing primers of AURKA (backspliced from exon 6 to exon 3) in RNase 
R-treated NCI-H660, a NEPC cell line, confirmed the circular structure of this molecule. p < 0.0001 
calculated from one-way ANOVA. Error bars show mean ± SD for triplicates. 
(D) qRT-PCR of circular and linear AURKA in prostate cancer cell lines. Both circ-AURKA and 
linear-AURKA were expressed higher in NCI-H660 than in two non-NEPC cell lines, LNCaP and 
VCaP. Error bars show mean ± SD for triplicates. 
(E) Schematic depicting the circular RNA generated from AURKA transcript detected in the 
MiOncoCirc compendium. Bottom: The Sanger sequencing result of circAURKA RT-qPCR 




Figure 5.5 Stability of circular RNAs compared to linear counterparts 
(A) Compared to their linear counterparts, circRNAs were resistant to RNase R degradation. Linear 
transcripts were detected by inward-facing qRT-PCR primers, while circular transcripts were 
detected by outward-facing qRT-PCR primers (**p < 0.0001, calculated from Student’s t test). 
Error bars show mean ± SD for triplicates. 
(B) After transcription inhibition by actinomycin D in LNCaP cells, linear transcripts (Linear) 
degraded faster than their corresponding circular transcripts (Circular). Samples were harvested at 
0, 2, 4, 8, and 24 h post-treatment. GAPDH was used as the control. The fold changes were 
calculated relative to the starting time point. circHIPK2 was selected to represent ‘‘high’’ class 
circRNAs. circLUZP2 represented “low” class circRNAs but with elevated expression in prostate 
cancer compared to normal. 
(C) After incubating VCaP RNAs in plasma, the circular-to-linear ratio of circRNAs increased over 






Figure 5.6 Detectable circRNAs in urine samples 
(A) circRNAs were detected by exome capture RNA-seq of three urine samples from prostate 
cancer patients. These circRNAs greatly overlapped with circRNAs identified in prostate cancer 
tissues from the MiOncoCirc cohorts.  
(B) The relative expression of circRNAs detected in urine from 10 prostate cancer patients. Linear 
GAPDH expression was used for normalization, and KLK3 was included as a positive control. 












Table 5.1 Primers used in Chapter 5 
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Concluding remarks and future directions for investigating  
non-coding RNAs in cancer 
 
Summary of this study 
For many years, researchers have been searching for oncogenes and tumor suppressors that 
contribute to cancer development. Most of these are protein-coding genes, which only 
consist of ~2% of human genome. During the last decade, advances in next-generation 
sequencing enabled the discovery of non-coding transcripts, a new category of molecules 
that function in a spatiotemporal manner in normal tissue development and oncogenesis 
process. Through interactions with chromatin, RNA, and protein, long non-coding RNAs 
mediate diverse cellular functions, including epigenetic regulation, RNA transcription, 
post-transcriptional regulation, and translation control. Under the context of cancer, the 
lncRNA expression landscape has been comprehensively profiled by several studies, but 
their clinical utilities, functioning mechanisms, and therapeutic potential remain largely 
unknown.  
 
In prostate cancer, malfunction of Androgen Receptor (AR) signaling has been shown to 
drive prostate cancer progression. However, nearly all of the genes identified in this 
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pathway are protein-coding targets. To systematically identify lncRNAs regulated by AR 
signaling, we analyzed RNA-seq data from AR-positive prostate cancer cell lines before 
and after DHT stimulation. To prioritize lncRNAs that contribute to prostate cancer 
progression, we intersected the lncRNAs identified above with a list of lncRNAs that 
exhibit differential abundance between benign prostate and primary/metastatic prostate 
cancer tissues. Through this analysis, we discovered a lncRNA, ARLNC1, that is strongly 
induced by AR and has elevated expression in localized and metastatic prostate cancer.  
 
We further characterized the transcript structure, cellular localization, and expression 
pattern of this lncRNA. We found that ARLNC1 expression is largely confined to the 
prostate lineage, and this pattern is dictated by the direct regulation of AR and cofactors 
(FOXA1) at ARLNC1 promoter region. Loss-of-function studies using RNAi-, ASO-, and 
CRISPR-based technologies demonstrated that ARLNC1 silencing inhibits cell 
proliferation and induces apoptosis in vitro and in vivo. Interestingly, we also observed 
attenuated AR signaling following ARLNC1 loss. We further dissected the cellular 
mechanism of ARLNC1-mediated modulation of AR signaling and found that it regulates 
AR mRNA post-transcriptionally via specific RNA-RNA associations in cells. These 
results echo previous observations, where lncRNAs serve as pathway regulators in a 
feedforward loop (Figure 6.1). These results have shed light on ARLNC1’s mechanism of 




This study also suggested the clinical relevance of ARLNC1 expression: (1) ARLNC1 has 
potential to serve as a diagnostic biomarker. It could be readily detected using RNA in-situ 
hybridization (RNA-ISH) on formalin-fixed paraffin-embedded (FFPE) tissue samples, 
with expression significantly higher in localized and metastatic prostate cancer tissues 
compared to benign prostate. (2) Orthogonal targeting of the lncRNA specifically 
modulates AR and its aberrant signaling in tumors. This could be achieved using antisense 
technologies in several models in vitro and in vivo.  
 
Finally, we investigated another class of non-coding transcript, circular RNAs. We 
confirmed the existence of a novel class of circRNA, read-though circRNAs. Stability of 
circRNAs is higher compared to their linear counterparts, and circRNAs with high 
abundancy can be detected in urine. The existence of circRNA in cell-free specimens, plus 
their increased stability compared to linear RNAs, make circular RNAs another attractive 
pool for biomarker exploitation.  
 
Unexplored areas of this study 
We have shown that AR transcriptionally regulates ARLNC1 and that ARLNC1 regulates 
its master regulator (AR) post-transcriptionally. The co-localization between ARLNC1-
AR was supported by multilayered in vitro and in situ evidences from RNA-RNA 
interaction assays and RNA in situ hybridization. However, it remains a question whether 
this interaction is facilitated by protein binding partners, and how exactly does ARLNC1 
affect AR mRNA stability. Future studies on the ARLNC1 interactome and ARLNC1-
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bound miRNAs may shed light on these questions. Furthermore, the clinical relevance of 
ARLNC1 as a diagnostic marker can be further evaluated on a large cohort of FFPE or 
urine samples. Perhaps ARLNC1 can join a panel of established biomarkers to provide 
improved sensitivity and specificity for prostate cancer detection.  
 
ARLNC1 interactome 
Since lncRNAs rarely function alone with no protein co-factors, it is very likely that RNA-
binding proteins are involved in the mechanistic function of a lncRNA. We have performed 
preliminary experiments to dissect the ARLNC1 interactome. In order to identify the 
protein binding-partners of ARLNC1, we carried out a RiboTrap assay followed by mass 
spectrometry analysis (Figure 6.2A). We used synthesized BrU-labeled lncRNA to 
incubate with cell lysate from the nucleus or cytoplasm of MDA-PCa-2B cells. In both cell 
nucleus and cytoplasm, we identified two proteins that strongly interact with ARLNC1: 
HuR(ELAV1) and TIAR. Both HuR and TIAR are known to bind to AU-rich elements and 
regulate the stability of messenger RNAs, including AR mRNA[1-5]. It is thus worth 
investigating whether the lncRNA-protein binding indeed exists in the cell, and whether 
these proteins play a role in ARLNC1-mediated functions, especially in the context of AR 
signaling. 
 
By using RNA-immunoprecipitation (antibodies against HuR and TIAR) followed by 
qPCR analysis, we validated ARLNC1-binding with protein partners HuR and TIAR from 
cells (Figure 6.2B). Interestingly, HuR (not TIAR) also binds strongly with AR mRNA, 
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which is in accord with published results[5]. In order to investigate the functional 
significance of the interaction between ARLNC1 and HuR, we performed gene expression 
profiling following siRNA-mediated knockdown of ARLNC1 or HuR. We observed a 
significant overlap of genes regulated in each setting (Figure 6.2C), indicating that these 
two molecules might be involved in common RNA regulating processes. Furthermore, 
using the AR signature previously defined in MDA-PCa-2B cells, gene set enrichment 
analysis detected enrichment of AR-regulated gene set following HuR depletion (Figure 
6.2D). This result confirms the regulatory effect by HuR on AR signaling, while suggesting 
a phenotypically-relevant link between HuR and ARLNC1. Additionally, HuR depletion 
resulted in a decreased level of AR protein (Figure 6.2E), an effect resembling the 
observation following ARLNC1 knockdown.  
 
Now that we have established the direct binding between HuR and ARLNC1, and the 
phenotypic effect of HuR on AR signaling, we can test the hypothesis whether ARLNC1 
sustains AR mRNA level by recruiting HuR protein to AR 3’UTR. Moreover, given the 
significant overlap between the HuR- and AR-regulated transcriptomes, it is worth 
investigating whether ARLNC1 facilitates HuR-mediated RNA stabilization of a group of 
mRNA targets.  
 
Involvement of miRNA in ARLNC1 functions 
Our current model suggests that mechanistic ARLNC1 function is at least partially driven 
by lncRNA-mRNA interaction via the sequence information encoded in the RNA 
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molecules. This base pair matching resembles the well-established miRNA-RNA binding 
in principle. MicroRNAs have been studied as key modulators of mRNA stability, while 
many lncRNAs have proposed roles of miRNA sponging/decoy. In some cases, lncRNAs 
act as microRNA decoys, causing sequestration of microRNAs favoring expression of 
repressed target mRNAs[6]. For instance, lnc-MD1 “sponges” both miR-133 and miR-135 
to stabilize MAML1 and MEF2C. Both of them are transcription factors that control 
muscle differentiation by activating muscle-specific gene expression[7]. lncRNA H19 
“sponges” the let-7 family of microRNAs via canonical and non-canonical binding sites, 
thus playing a key role in cell differentiation and cancer metabolism[8]. lncRNA-ROR 
“sponges” miR-145 to stabilize ZEB2, thus promoting invasion and metastasis in 
hepatocellular carcinoma[9]. In other cases, lncRNAs stabilize mRNA by competing with 
miRNAs for shared target mRNAs. For example, lncRNA BACE1-AS competes with miR-
485-5p for binding to BACE1 mRNAs, leading to elevated expression level of BACE1, a 
critical enzyme in Alzheimer’s disease pathophysiology[10].  
 
As for AR mRNA, multiple miRNAs have been reported to bind with its 3’UTR region 
and modulate transcript abundance[11]. Based on our results so far, one hypothesis could 
be that ARLNC1 competes with miRNAs for binding with the 3’UTR region in AR mRNA. 
This hypothesis could be first tested in silico, by predicting binding sites involved in 
miRNA-lncRNA-mRNA interplay. The specific binding domains on AR 3’UTR and 
ARLNC1 could then by validated by binding assays, and the effect of miRNAs could be 




Clinical Significance of ARLNC1  
Through RNA-seq analysis, we observed elevated ARLNC1 expression in prostate cancers 
compared to benign tissues, thus indicating that it may serve as a useful diagnostic marker. 
As expected, the ROC analysis to differentiate cancers from normal showed an AUC of 
0.819, which was only slightly lower than PCA3, a well-known diagnostic marker of 
prostate cancer that currently being clinically utilized (Figure 6.3). In addition, we 
confirmed the differential expression of ARLNC1 using in situ hybridization (ISH)-based 
screening of prostate tissues. As expected, expression of ARLNC1 was high in both 
localized and metastatic prostate cancer cells, and low in normal prostate cells. 
Furthermore, we discovered an association of ARLNC1 levels with accentuated AR 
signaling and luminal epithelial differentiation in patient tumors, both of which are 
important clinical considerations for anti-androgen treatment.  
 
Our results call for a more thorough assessment of clinical utility of ARLNC1 as a 
prognostic or diagnostic biomarker. Comprehensive analyses to interrogate ARLNC1 
expression with prognosis and treatment resistance could be conducted using Affemetrix 
Human Exon ST 1.0 microarray data generated from clinical cohorts after radical 
prostatectomy. The ARLNC1 RNA-ISH assay developed here could be applied to larger 
cohorts of formalin-fixed paraffin-embedded tissues represented on tissue microarrays [12] 
to determine the correlation between ARLNC1 abundance with the progression of prostate 
cancer stages. In addition, expression of ARLNC1 can be further assessed in whole urine 
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samples collected after digital rectal examination and analyzed with clinical-grade 
transcription-mediated amplification assays[13, 14]. Association between ARLNC1 levels 
and clinicopathological variables can be evaluated to determine whether ARLNC1 levels 
serve as indicators for clinical aggressiveness or treatment responses. If proved useful, 
ARLNC1 could be further tested in a multi-gene biomarker panel that serves as a part of 
clinical decision-making algorithms for routine patient care.  
 
Future directions of non-coding RNA research in cancer 
Correct annotations of non-coding RNAs  
While we appreciate the contribution of next-generation sequencing in nominating 
genomic alterations and transcriptome aberrations, intrinsic limitations in library 
preparation and defects in sequencing analysis pipelines have resulted in incorrect 
annotations of transcriptomic structures. In our recent work to profile circRNAs, we have 
found that some back-spliced read-through circRNAs were previously annotated as gene-
rearrangements. For instance, the circRNA ESR1-CCDC170 was reported as gene 
rearrangement in an aggressive subset of estrogen-receptor positive breast cancers[15]. It 
is thus of pivotal importance to revisit gene alteration datasets and update the annotations 
with our latest understanding of RNA species.  
 
Differentiation of functional long non-coding RNAs from transcription by-product  
Although lncRNA species have been comprehensively profiled in normal lineages of 
tissues, as well as in cancer tissues, only a handful of lncRNAs have been characterized 
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with clear functions to play oncogenic roles in cancer. The huge knowledge gap calls for 
scalable functional investigation methods towards identifying lncRNAs with bona fide 
roles contributing to cancer progression.  
 
CRISPR screens provide novel opportunities to address this challenge. The CRISPR-Cas9 
system for genome editing is a powerful tool for functional screens in vitro and in vivo. 
Co-expressing Cas9 endonuclease and a single short guide RNA molecule (gRNA) is 
sufficient to generate double-stranded DNA breaks in eukaryotic cells. These double-
stranded DNA breaks are primarily repaired through the error-prone non-homologous end-
joining pathway, often generating small indels at the target site and introducing frame-shift 
alterations. Thus, the CRISPR-Cas9 system provides a simple way of disrupting the open 
reading frame of protein-coding genes to produce loss of function alleles. However, when 
it comes to the study of lncRNAs, these transcripts are generally insensitive to reading 
frame alterations. In order to knockout lncRNAs reliably, we need to generate deletions of 
larger fragments. 
 
Three types of CRISPR systems have been developed to fulfill this need. (a) CRISPR-Cas9 
system featured by paired guide RNAs [16]; (b) CRIPSRi-system that represses the 
transcription of any gene via the targeted recruitment of the nuclease-dead dCas9-KRAB 
repressor fusion protein to the transcriptional start site (TSS) by a guide RNA (sgRNA)[17-
20]; (c) CRISPR-Cas13d-system that directly targets mRNAs [21, 22]. The CRISPR-
Cas13d system possesses unique advantages over the first two systems, in that it acts 
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directly on RNA molecules without affecting chromatin structures and local DNA at the 
genomic region harboring lncRNA. Meanwhile, CasRx-mediated knockdown exhibits high 
efficiency and specificity compared to RNA interference across diverse endogenous 
transcripts [21, 22]. 
 
These CRIPSR systems can be applied to the study of lncRNAs that are either highly 
conserved between species, or specifically expressed in different lineages of cancer. Proof-
of-concept screens can be carried out in cancer cell line models. By recording the relative 
abundance of guide RNAs at different time points, we will be able to identify oncogenic 
lncRNAs that accelerate cancer cell growth and tumor-suppressive lncRNAs that delay 
cancer cell growth. Cellular location, regulated pathways, effected cell functions, as well 
as acting mechanisms of the identified functional lncRNAs could be further studied using 
loss-of-function and gain-of-function assays.  
 
Conclusion 
High-throughput sequencing technology has revolutionized our understanding of non-
coding transcriptome. A growing number of non-coding RNA species has been discovered 
in well-known and novel classes of non-coding RNAs, including microRNAs, long non-
coding RNAs, and circular RNAs. Despite functional relevance, their expression spectrum 
is largely specific to lineages, and deregulated in the processes of neoplasia growth, cancer 
progression, and drug response. Functional studies of non-coding RNAs have identified a 
small set of them as critical nodes in oncogenic or tumor suppressive regulation networks. 
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Through physical interactions with chromatin structures, DNA, RNA, or proteins, ncRNAs 
could either boost or suppress key pathways in cancer. Therefore, ncRNAs provide novel 
therapeutic and diagnostic opportunities for cancer management.   
  
My thesis work has examined the androgen-responsive lncRNAs as well as circular RNAs 
in prostate cancer. We defined the AR-regulated non-coding transciptome and 
characterized the pro-oncogenic role of a lineage-specific lncRNA, ARLNC1. The 
involvement of ARLNC1 in AR signaling regulation echoes the roles of some other 
lncRNAs that function through feedback loops. Our work also suggests that the RNA-
targeting antisense technology is likely to provide benefit for cancer types with oncogenic 
lncRNA expression. Additionally, the existence of circular RNAs species has been 
validated in prostate cancer. The disease-associated expression pattern of circular RNAs, 
plus their comparatively stable structures in cell-free bio-fluid, makes circular RNAs a new 
frontier in cancer biomarker development. Future directions of non-coding RNA research 
include curation of lncRNA annotations, development of large-scale screens to identify 













Figure 6.2 ARLNC1 interactome 
(A) RNA immunoprecipitation followed by Mass-Spectrometry to identify proteins binding with 
ARLNC1. 
(B) RNA immunoprecipitation (RIP) to validate the binding of ARLNC1 with candidate protein. 
Inset: Western blotting analysis of proteins pulled down by immunoprecipitation. 
(C) Venn Diagram indicating overlap between HuR-regulated genes ARLNC1-responsive targets 
identified from RNA-Seq analysis following HuR loss or ARLNC1 loss. 
(D) Gene Set Enrichment Analysis showing enrichment of AR-regulated gene set following HuR 
depletion.  
(E) Immunoblot assay showing relative protein levels of AR and GAPDH in MDA-PCa-2B cells 















Figure 6.3 Clinical significance of ARLNC1 
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